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Abstract 
Anti-apoptotic proteins play a fundamental role in cell survival. Under physiological conditions, 
such proteins trigger apoptosis in defective or damaged cells only; under pathological 
conditions, however, they can be dysregulated allowing the cells to survive despite being 
harmful. Considering the importance of anti-apoptotic proteins in many physio-pathological 
roles, their specific inhibition is an attractive strategy to develop safe therapeutics. 
This thesis describes the inhibition of two classes of anti-apoptotic proteins: 
1) Inhibition of the anti-apoptotic protein CK2 to develop novel anti-cancer molecules targeting 
pockets outside the well-conserved ATP-binding site: 
-Using a Fragment-Based-Drug-Discovery (FBDD) approach twelve small molecule inhibitors of 
CK2 were developed. The lead molecule, 3l, inhibited the catalytic activity of CK2α by binding in 
the cryptic αD pocket with a Kd of 4 μM. 3l stopped proliferation of colorectal cancer cells with a 
GI50 of 10 μM and presented improved drug-like properties and selectivity compared to 
previously reported inhibitors. Remarkably, 3l has the potential to be developed into a potent 
and selective anticancer drug.  
-Using a combination of rational-based approach and peptide stapling, twenty-two 
conformationally-constrained peptides were generated to target the protein-protein interaction 
(PPI) of CK2 and affect its function. The lead peptide, P7-F1C5, presented a novel, highly-
functionalised constraint that allowed the molecule to become cell-permeable, exert its anti-
proliferative activity in cancerous cells, and to become resistant to serum proteases. P7-F1C5 is 
the first macromolecule reported in the literature that binds to CK2α with sub-micromolar 
affinity (Kd 150 nM), and that can act as a chemical probe for targeting the PPI of CK2. 
2) Inhibition of the anti-apoptotic Bcl-2 proteins to dissect their role in platelet activation and 
apoptosis. 
Bcl-2 proteins regulate cell lifespan; however, their role in non-nucleated platelets is not fully 
understood. The elucidation of these pathways in platelets is crucial to the development of 
selective anti-platelet therapeutics.  
To this end, this thesis describes the development and the first application of twenty-seven BH3-
only peptides in human platelets highlighting how peptides can provide an alternative to 
conventional methodologies to study PPIs in platelets. The most promising peptide, P9-F5C5, 
engaged the anti-apoptotic protein Bcl-xL with 26 nM affinity and reviled a new role for the 
protein Bim in platelet activation.
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Until three decades ago, the high-throughput screening (HTS) of libraries of small organic 
molecules was the gold-standard approach used as a starting point in drug discovery. However, 
these multimillion-compound libraries were characterised by a high degree of structural 
similarity and included compounds targeted against known binding sites, hence limiting the 
chances of engaging previously unexplored biological space. When screened against well-
established targets, HTS libraries were particularly effective, but when screened against new or 
difficult biological systems, they provided very few hits and several false positives.1 In the last 
few decades, a deeper understanding of biotechnology and biology have expanded the number 
of ‘druggable’ targets and pushed medicinal chemists to employ new molecular entities beyond 
traditional small molecules as well as new approaches to discover life-changing medicines. 
Fragment-Based Drug Discovery (FBDD), for instance, has emerged as a complementary 
technique to discover new binding sites and new drugs more efficiently. The establishment of 
FBDD was made possible thanks to advances made in the field of biotechnology that allow 
detection of weak bindings such as those of fragments.2  
Advances in biology, on the other hand, have led to the realisation that the majority of 
medicinally-relevant biological systems can rarely be targeted with traditional small molecules. 
Consequently, pharmaceutical industries have expanded their pipelines to accommodate 
previously uncharted chemical entities – hereinafter referred to as new modalities.3 New 
modalities – e.g. peptides, antisense oligonucleotides, proteins, synthetic mRNA, proteolysis 
targeting chimeras (PROTACs) – feature nowadays at any stage of the drug discovery programs 
and clinical studies and they are soon-to-become the medicines of tomorrow, able to engage 
targets considered ‘undruggable’ until not long ago.  
For the purpose of this dissertation, an overview of recent advances on both FBDD and 
therapeutic peptides will be presented in this chapter, since other new modalities fall beyond 
the scope of the work being described.  
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1.1. Fragment-Based Drug Discovery 
FBDD is a structure-based approach that provides lead compounds to target biological systems.2 
FBDD allows the screening of fewer, low-molecular-weight molecules compared to other 
approaches employed to obtain chemical leads such as HTS.a There are several advantages to 
using smaller fragment-sized libraries:  
- the sampling of the chemical space is much more efficient due to the lower number of 
possible obtainable molecules; 
- being less complex than traditional small molecules, fragments make fewer interactions 
with the proteins but can bind to a greater number of pockets, on a greater number of 
targets, resulting in higher hit rates; 
- owing to their smaller size, libraries can be assembled and screened by small biotech 
companies and academic groups.1 
Although initial hits usually have lower potency, FBDD is considered to be more efficient in the 
optimisation phases of drug discovery, which are guided by the 3D information of fragment 
binding modes obtained by means of experimental techniques.2,4,5 
In a typical FBDD flow (Figure 1), firstly, a fragment library is assembled, and the fragments are 
then screened using biophysical techniques. Due to the low molecular weight and potency of the 
initial fragments, highly sensitive biophysical techniques are required for initial screening, such 
as Surface Plasmon Resonance (SPR), Isothermal Calorimetry (ITC), Thermal Shift (TS) and 
functional assays.6,7 X-ray or NMR techniques are used to investigate the binding modes of the 
fragment hits in the protein of interest and, therefore, to characterise the fragments.8–10 The 
third step in a FBDD approach is fragment elaboration. In this stage, the fragments to be 
progressed are selected according to different criteria such as potency, Ligand Efficiency (LE)b, 
Ligand Lipophilicity Efficiency (LLE)c and availability of X-ray or NMR structures.11–13 The more 
drug-like fragments showing an IC50 in the mM range and interesting binding modes to the 
target are selected to be optimised into leads (IC50 in nM range). Such elaboration is achieved via 
iterative cycles of synthesis, structural analysis, and computer-aided design.5 
                                                          
a FBDD screens thousands of compounds with a number of heavy atoms ≤ 20; HTS screens millions of compounds with ~ 30 heavy 
atoms each.1 
b The LE is defined as the Gibbs free energy of binding (KJ·mol-1 or Kcal·mol-1) divided by the number of non-hydrogen atoms.284 LE 
normalises the potency with respect to the number of heavy atoms, and it is of great importance when comparing the potency of 
compounds with a variety of formula weight (FW).12 At the fragment stage, an LE of approximately 0.3 or higher is preferred.11  
c The introduction of lipophilic groups can provide a quick mean of improving the potency of a fragment, but it often leads to 
problems such as non-specific binding and poor bioavailability.11 LLE (defined as pIC50 minus cLogP) is a parameter that can be used 
to ensure that the generated fragments do not gain an excessive hydrophobic character during the elaboration. An LLE of ~5 or 
higher is advisable.13  
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Figure 1 - Typical FBDD flow. The fragment hits generated by the screening of the library are further elaborated via 
linking, merging and/or growing strategies. The elaboration is the result of iterative cycles of chemical synthesis, 
biophysical assays and in silico design. 
The fragment elaboration typically occurs via linking, growing and/or merging strategies. The 
growing strategy consists in using a single vector to grow the fragments to engage in additional 
interactions (Figure 2a). The merging strategy sees, instead, the best features of the original 
fragments merged into what is predicted to be a more potent and drug-like molecule (Figure 
2b).11 Alternatively, in the linking strategy fragments binding in different parts of the same 
pocket or in two adjacent pockets are linked together via linkers (Figure 2c).5 The linking of 
fragments has been considered to be the most difficult of the three methods: a linker should be 
introduced to maintain the optimal binding configurations that have been adopted by the 
individual fragments, should establish additional interactions with the protein to prevent a loss 
in LE, and should be synthetically accessible.11,14 However, when successful, the linking strategy 
can provide boosts in potency as high as 300-fold compared to the single fragments.15 The 
significant enhancement in binding affinity can be explained with the concept of ‘super-
additivity’.14–17 Upon binding to the targeted protein, each fragment loses a significant part of its 
rigid body rotational and translational entropy resulting in an entropic penalty. The linked 
molecule would account for one entropic penalty only whilst two separate fragments would be 
affected by two unfavourable entropic terms.15 Consequently, the linked molecules can have a 
more favourable binding free energy (ΔG) than the sum of the ΔG values of the individual 
fragments.15 
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Figure 2 - Schematic representation of the different strategies that can be applied during fragment elaboration: (a) 
growing, (b) merging, (c) linking strategy. The protein is shown in light blue, fragments in red and yellow and the 
linker in black. 
FBDD has shown some advantages with respect to more conventional drug discovery 
approaches. In particular:  
1) Starting the optimisation with small compounds capable of making high-quality 
interactions with the protein means that the molecular weight, complexity and 
physicochemical properties of the molecule can be easily controlled during the 
elaboration.2 
2) The high binding energy per atom can be maintained during the optimisation from hit 
to lead.16,17 
3) The ligand Efficiency (LE) and the Veber ‘rule-of-three’d allow easy comparison of 
lead-likelihood of fragments of different sizes.2  
4) Compared to HTS, far fewer fragments are required in the initial screening to sample 
the chemical space (thousands vs millions of compounds).5 
On the other hand, there are few disadvantages related to FBDD. However, these drawbacks are 
biotechnology-dependent and can be overcome with further advances in the field. In particular: 
1) The low potency of the initial fragments requires the use of sensitive biophysical 
screening techniques and high fragment concentrations (up to 50 mM). Due to the high 
concentration, the fragments need to be highly soluble in the hydrophilic solvents used.5  
                                                          
d According to the Veber ‘rule of three’ a fragment to be elaborated into an oral bioavailable lead should satisfy the following criteria: 
FW < 300 g·mol-1, H-bond donor (HBD) ≤ 3; H-bond acceptor (HBA) ≤ 3, cLogP ≤ 3; Number of rotatable bonds (NRB) ≤ 3; Polar 
surface area (PSA) ≤ 60 Å2. 285,286 
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2) Due to low potency, the fragments are also unsuitable for cell screening and kinetic 
assays where high concentration will likely lead to false positives.5  
1.1.1. State of the art of FBDD 
FBDD is currently widely used both in industry and academia as a powerful and complementary 
drug discovery approach. FBDD has proved to be efficient in delivering drug candidates for 
targets that have been regarded as ‘undruggable’ in the past, such as protein-protein interactions 
(PPIs).5 Currently, around 40 new molecular entities at different clinical stages have been 
developed using FBDD for a variety of targets. Table 1 lists some of the drug candidates 
discovered using FBDD currently in phase II, III and approved.18 In addition, it is estimated that 
at least 20 molecules are currently undergoing phase I studies.  
Table 1 - List of selected drug candidates discovered using a FBDD approach currently in late-stage clinical studies. 
Drug Stage Company Target 
Vemurafenib Approved Plexxikon B-Raf 
Venetoclax Approved AbbVie/Genentech Bcl-2 
Asciminib Phase III Novartis Bcr-Abl 
Erdafitinib Phase III Astex FGFR1-4 
Lanabecestat Phase III AstraZeneca/Lilly/Astex BACE1 
PLX3397 Phase III Plexxikon CSF1R, KIT 
Verubecestat Phase III Merck BACE1 
AT7519 Phase II Astex CDK1,2,4,5,9 
AT9283 Phase II Astex Aurora, JAK2 
AUY-922 Phase II Novartis HSP90 
AZD5363 Phase II AstraZeneca/Astex/CRUK AKT 
CPI-0610 Phase II Constellation BET 
DG-051 Phase II deCODE LTA4H 
Eft508 Phase II eFFECTOR MNK1/2 
Indeglitazar Phase II Plexxikon Pan-PPAR 
LY2886721 Phase II Lilly BACE1 
LY517717 Phase II Lilly/Protherics FXa 
Novitaclax Phase II Abbott Bcl-2/Bcl-xL 
Onalespib Phase II Astex HSP90 
PF-06650833 Phase II Pfizer IRAK4 
PF-06835919 Phase II Pfizer KHK 
Highlighting the importance of FBDD in drug discovery, in 2011, the FDA approved the first 
fragment-based drug Vemurafenib (Zelboraf®) for the treatment of late-stage melanoma.19 
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Vemurafenib was developed from an azaindole derivative fragment (Scheme 1) and targets the 
ATP binding site of a mutant serine-threonine protein kinase B-Raf (V600E). Using a growing 
strategy, the initial fragment hit (IC50 100 μM) was elaborated into the 31 nM inhibitor 
Vemurafenib. 
 
Scheme 1 - Growing strategy applied to the development of Vemurafenib, the first drug developed using a FBDD 
approach. The parts of the molecule that represent the growth of the initial fragment are shown in blue. 
In 2015, Venetoclax (Venclexta®), a Bcl-2 antagonist, was approved for the treatment of chronic 
lymphocytic leukaemia, demonstrating the increasing success of the FBDD approach.20 
Venetoclax was developed adopting a linking strategy between two weakly binding fragments 
engaging two proximal pockets of Bcl-xL (Scheme 2). The fragment elaboration was guided by an 
‘SAR-by-NMR’ approach (Structure-Activity-Relationship guided by 2D protein-ligand NMR 
studies).21 Importantly, Venetoclax mimics the native BH3 domain of the pro-apoptotic Bcl-2 
proteins, thereby acting as one of the first small molecules targeting a difficult PPI.  
 
Scheme 2 - Chemical structures of Venetoclax and the initial fragments (blue and red) binding to two different binding 
sites. A linking strategy was adopted to link the two weakly binding fragments together via a sulfonamide (green). 
Despite the fact that FBDD emerged only 30 years ago, two drugs have already been approved by 
the FDA, and there are a great number of molecules currently undergoing clinical studies. This 
evidence altogether makes FBDD a promising and efficient alternative to discover new drugs, 
especially those interacting with difficult biological systems.1
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1.2. Therapeutic peptidese 
Small molecules (FW < 500 Da) have traditionally been used to target deep and well-defined 
pockets of biological targets (e.g. proteins, enzymes, receptors, ion-channels etc). Advances in 
biology, however, brought to light that 80% of the signalling pathways regulating important 
physio-pathological mechanisms are characterised by the interactions between proteins - often 
referred to as PPIs.22 Such interactions are characterised by the contacts between shallow and 
undefined pockets23,24,25 and, except for a few successful examples,26–31 the failed attempts to 
target PPIs with small molecules are still numerous. Peptides are an ideal alternative to small 
molecules: they mimic the endogenous portions of the interacting proteins; they show low 
immunogenicity since they are made of proteinogenic amino acids; they can be easily 
synthesised; and they have lower production costs compared to other biologics.32 However, the 
development of peptide therapeutics is limited by their poor pharmacokinetic (PK) properties.33 
In particular, peptides suffer from poor membrane permeability, poor stability to plasma 
proteases and high renal excretion often resulting in a short half-life.34 However, nature 
provides inspirational examples of a significant number of biologically-active peptides that 
validate their ability to interfere with both extra- and intra-cellular processes.35 These successful 
examples have inspired scientists to develop new methodologies aimed at overcoming the PK 
limitations of this class of molecules. 
1.2.1. Macrocyclised peptides  
Peptide cyclisation is probably the most widely adopted strategy to ameliorate the PK properties 
of peptides, with at least 125 macrocyclic peptides being reported as orally bioavailable.36 The 
macrocyclisation process on peptides, assuming it does not affect their secondary structure,36 is 
performed to lock the macromolecules in their binding conformation preserving their function 
and reducing entropic costs.37 Conversely, other methodologies applied to improve the PK 
properties of peptides, such as N-alkylation or the introduction of amide isosteres 
(peptidomimetics), may affect the peptide backbone resulting in changes that could compromise 
the peptide bioactivity. Peptide macrocyclisation can be achieved in different ways, and a 
schematic overview of the different techniques is shown in Figure 3. 
                                                          
e The text of this paragraph has been adapted from Iegre et al., Advanced Therapeutics, 2018.59 
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Figure 3 – Main classes of macrocyclisation techniques: head-to-tail, head-to-side chain, tail-to-side chain, side chain-to-
side chain that can be divided into 1C- and 2C-stapling. Peptide head (C-terminus) is shown as a blue carboxylic acid, tail 
(N-terminus) as a red amine. Side chains involved in macrocyclisation are presented as white spheres and the linker in 
black. 
The head-to-tail cyclisation generally involves the N-terminus and C-terminus of the peptide 
chain linked together via an amide bond; head-to-side chain and tail-to-side chain cross-link one 
of the terminus to a side chain of the peptide; side chain-to-side chain macrocyclisation, instead, 
involves the linkage of two side chains of the peptide sequence with or without the aid of a 
linker.37,38 The intramolecular reaction to cross-link two amino acids of the linear sequence is 
often referred to as one-component (1C) peptide stapling (PS).38 On the other hand, 
intermolecular coupling involving a staple (or linker) and two amino acid side chains is referred 
to as two-component (2C) PS.37,39–41 It should be noted that the term stapling often refers to 
macrocyclisations that produce α-helical peptides. When a cyclisation reaction results in a non-
helical peptide, the term constraining is generally accepted. In this dissertation, however, the 
terms stapling and constraining will be used interchangeably to describe macrocyclisations 
resulting in secondary structures beyond α-helices as well.  
In this dissertation, the stapling methodologies only will be presented in detail in the following 
paragraphs. 
1.2.1.1. One-component peptide macrocyclisation methodologies at a glance 
1C-PS is the oldest and simplest of the two classes of peptide stapling methodologies. Disulfide 
bridge formation between two Cys residues is a common constraining methodology often 
adopted by nature to stabilise peptides and proteins. Disulfide bonds, however, are susceptible 
to being reduced in certain environments, such as those found intracellularly;42 therefore, 
alternative 1C stapling techniques have emerged to overcome this limitation. The most used 1C 
stapling technique is the all-hydrocarbon (AH) chemistry which involves a Ring-Closing 
Metathesis (RCM) reaction between two unnatural amino acids bearing terminal alkenes on the 
side chains. First reported by Grubbs and Blackwell in the 1990s, the RCM has been widely 
adopted to stabilise several biologically active and cell-penetrating peptides into helical 
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structures.43,44 The RCM has been thoroughly optimised and, when the appropriate stapling 
position and amino acids are used, it proved to be successful in enhancing the helicity of 
peptides, improve the stability to proteases and impart cell-permeability to otherwise 
impermeable peptides.45–47 Another widely used 1C-PS chemistry is lactam formation. Reported 
for the first time in the late 1980s, lactam cyclisation provided peptides with superior bioactivity 
compared to the linear analogues.48 Lactam stapling has been mainly applied to peptides 
targeting extracellular or membrane-bound proteins, and its applicability to intracellular targets 
is yet to be determined.48,49 Even if more stable to proteolytic degradation than their linear 
counterparts, peptides stapled using this technique show inferior stability in respect to RCM-
stapled peptides.50 Since the advent of the pioneer 1C-PS methodologies, a plethora of 
alternative reactions have emerged in the literature, including: thiol-ene reactions between Cys 
and alkene amino acids,51 copper-catalysed azido-alkyne cycloaddition (CuAAC) between azido 
and alkyne groups,52–54 C-H activation reaction to cross-link aromatic side chains of natural 
amino acids,55 thioether formation,56 oxime formation,57 and UV-promoted cycloaddition58 
among others (Figure 4).  
 
Figure 4 - Overview of selected one-component peptide stapling chemistries using side chains of natural and unnatural 
amino acids. Amino acids are represented as grey spheres.  
General conclusions on the applicability of all the above-mentioned techniques to biologically-
relevant targets cannot be drawn considering that a limited number of comparative examples 
are available in the literature for all these emerging techniques.  
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The well-established 1C-PS techniques offer the advantage of being carried out on resin, thus 
saving purification steps. However, 1C-PS methodologies present one main disadvantage: any 
changes to the staple or the sequence required for peptide optimisation involve the re-synthesis 
of the amino acid used for stapling, synthesis of the linear peptide sequence, and re-stapling.59 
Significant optimisation may be required for each of these steps, including the insertion of the 
new amino acid in solid-phase peptide synthesis (SPPS) procedures. To overcome these 
limitations, research groups have focused on the development of 2C macrocyclisation 
methodologies.  
1.2.1.2. Two-component peptide macrocyclisation methodologies 
Unlike the 1C stapling techniques, the 2C-PS offers a considerable advantage: the staple or 
constraint is optimised independently from the peptide sequence, and it can be used to 
introduce cell-permeable motifs, fluorescent tags, functionalities useful for biological assays or 
to improve the PK properties of the overall peptides in a combinatorial manner.59 Most of the 
2C-PS techniques derive from the 1C counterparts and involve both natural and unnatural amino 
acids. Unlike the 1C macrocyclisations, 2C stapling is often not performed on-resin due to site-
isolation issues that penalise the desired intramolecular reaction in favour of the intermolecular 
reactions (Figure 5).50  
 
Figure 5 - Potential reaction pathways that can occur during the 2C-PS after the initial intermolecular coupling (a). 
Intramolecular coupling to give the desired product macrocycle (c), or a number of different undesired products due to 
multiple intermolecular coupling reactions (b, d). Taken from Iegre et al., Advanced Therapeutics, 2018.59 
The most reactive amino acid side chains are suitable for use in peptide macrocyclisation, with 
cysteine being the most used due to the high nucleophilicity of the sulfhydryl group. 60–63 With 
respect to their unnatural counterparts, natural amino acids are cheap, widely available and 
hence simplify the synthesis of the linear peptide. However, the use of natural amino acids could 
lead to orthogonality and chemo-selectivity problems. Thiol-ene, in both radical and conjugate 
Chapter 1: Current approaches in drug discovery – Peptides 
 
 
13 
addition, and SN2 reactions are the most commonly used reactions for the application of Cys to 
peptide stapling with a limited number of reports on SNAr.  
Greenbaum and Waters pioneered the field with the use of aryl-halide linkers to cross-link two 
Cys side chains, whilst Timmerman et al. have recently modified the aryl-halide linkers into 
water-soluble staples to access functionalised stapled peptides (Figure 6).64–66 Importantly, the 
cross-linking between aryl-halides and the thiol groups of Cys residues has been renamed as 
CLIPS (Chemical Ligation of Peptide into Scaffolds) technology, and it is currently used by start-
ups and pharmaceutical companies to access the so-called bicycle and tricycle peptides. Dawson 
et al. made use of 1,3-dichloroacetone to cross-link between Cys residues via an SN2 reaction 
followed by oxime linkage to introduce functionalities.67 Likewise, Cramer et al. exploited the 
SN2 reaction between diiodomethane and Cys residues to convert labile disulfide bridges into 
stable methylene thioacetals (Figure 6). Bernardes et al. have recently reported a biocompatible 
and chemo-selective methodology which exploits the reaction between cysteine and dibromo-
isobutylene to give cell-permeable grafted peptides.68 
Examples of thiol-ene reactions in peptide stapling are provided by Jiang et al. who used divinyl 
sulphonamides as linkers for 2C-PS with Cys.69 Similarly, Chou et al. reported of a light-mediated 
thiol-ene 2C stapling method utilising bis-alkene linkers.70 A similar method was developed by 
Keillor et al. using functionalised maleimides (Figure 6).71  
SNAr cysteine stapling chemistry has been reported by Pentelute et al. who exploited the 
reactivity of sulfhydryl groups towards perfluoroaryl compounds to access stabilised peptides,72 
whilst Derda et al. utilised decafluoro-diphenylsulfone to the same end.73 Remarkably, these 
stapling methodologies can be applied to Lys in addition to Cys residues (Figure 6).  
Cys-mediated peptide stapling reactions have also been used to generate reversible systems 
which efficiently pass between rigid and flexible states in a biorthogonal manner, with the aim of 
elucidating the relationship between binding, biological activity, and secondary structure. To 
this end, Wilson et al. utilised the nucleophilic substitution reaction between dibromo maleimide 
linkers and Cys (Figure 6).74 Similarly, Smith et al. employed an SNAr reaction to staple the 
peptide via 3,6-dichloro-1,2,4,5-tetrazine: under UV radiation such a linker would open and 
provide the uncyclised peptide bearing cyano groups on the cysteine residues.75 Treatment with 
an excess of cysteine would return the starting peptide (Figure 6). The 3,6-dichloro-1,2,4,5-
tetrazine linker was functionalised via a reverse-electron demand Diels Alder.75 
A limited number of examples see natural amino acids other than Cys in 2C-PS; namely Trp and 
Glu (Figure 6). Johannes et al. have developed a method in which two tryptophan residues were 
reacted with a para-substituted benzaldehyde in a condensation reaction to form 
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conformationally constrained model peptides with improved proteolytic stability towards 
proteases compared to the linear analogue.76 On the other hand, McDowell et al. reported an 
example of bis-lactamisation in peptide stapling utilising Glu amino acids that, after being 
protected, were reacted with diaminoalkanes to stabilise model helical peptides (Figure 6).77 
 
Figure 6 – Selected 2C-PS chemistries using Cys side (pink background), Trp (grey background), Lys (light blue 
background), and azido side chains (green background). Macrocycles obtained via thiol-ene reactions are shown in blue, 
in green stapling via SNAr and in black SN2. Stapled peptides obtained via CuAAC are shown in orange and lactamisation 
in brown. The yellow cloud indicates that various functionalities have been added to the staple/constraint. 
The only 2C-PS methodology that uses unnatural amino acids is the CuAAC (Figure 6), and it will 
be discussed in detail in the next paragraph. 
1.2.1.2.1. Spotlight on 2C CuAAC peptide chemistry 
Pioneer work carried out by Bong et al. reported  azido-alanine residues being introduced at an 
i,i+4 distance to each other and clicked with aliphatic and aromatic dialkyne linkers to stabilise a 
peptide based on a GCN4 leucine zipper.78 Inspired by this work, the Spring group expanded the 
2C-PS methodology to include stapling positions beyond i,i+4 and, importantly, to introduce 
functionalisation on the linker. The CuAAC 2C stapling reaction involves an intermolecular 
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coupling between two azido side chains of a linear peptide and a bis-alkynyl linker to give the 
cyclised peptide. The optimised macrocyclisation reaction is carried out in aqueous conditions, 
at low concentrations of peptide (1 mg/mL) and with one equivalent of the linker (Scheme 3).38 
 
Scheme 3 - Schematic representation of the CuAAC 2C-PS. The peptide is shown in orange, the core of the constraint as a 
green cloud. THPTA = Tris(3-hydroxypropyltriazolylmethyl)amine. n = 1 to 4. 
Among the disadvantages associated with the CuAAC 2C-PS technology there is the use of non-
proteinogenic amino acids containing azido side chains, the use of a copper(II) catalyst which 
leads to air-sensitivity of the catalytic copper-complex, requiring all solvents to be degassed, and 
the risk of toxicity arising from any residual copper in the final stapled peptides.38 On the other 
hand, there are a number of advantages that outbalance the drawbacks of this methodology. In 
particular, the use of azido side chains provides orthogonality with respect to the other amino 
acids, leading to the avoidance of chemo-selectivity issues. Furthermore, the azido amino acids 
can be readily synthesised in few steps, the conditions used in the stapling reaction are mild, and 
functionalisation of the linkers is relatively easy, allowing the quick and efficient generation of 
libraries of functionalised stapled peptides.38 Peptides constrained using the CuAAC 2C-PS 
methodology have proved to be stable to proteolytic degradation, cell-permeable, biologically 
active in cells, and have led to the creation of a toolbox of functionalised staples that found 
application in different targets.78–84 A list of selected peptides macrocyclised using the CuAAC 
2C-PS chemistry is shown in Table 2.  
Table 2 – List of selected biologically active macrocyclic peptides obtained using the CuAAC 2C-PS methodology. 
 
Position n Constraint Structure Sequence Ref 
i,i+4 
2  Extended 
TNKS 
REXGDGXE 
 
84 
3  Helix GNC4 Leucine Zipper 
RIKQLEEKIXGLGXKIEELEKK 
78 
i,i+6 3  Helix Cft4 
MDIXIDDILXELDKETTAV 
82 
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2 
 
Extended HNF1β 
TAMRA-Ahx-TXKKMRRXR 
83 
i,i+7 
2 
 
3 
 
Helix 
Model peptide 
AAEAWAXAEAAEAXEA 
 
Gsα 
RDIXQRNorLHLRXYELL 
 
81 
 
80 
3 
 
 
 
Helix 
 
 
 
 
p53 
LTFXHYWAQLSX 
 
 
 
 
p53 
ETFXDLWRLLXEN 
 
 
 
 
85 
 
81 
 
 
86 
 
 
2 
 
 
Helix 
GLP-1 
HAEGTFTSDVSSYXEGQAAKXFIAWLVKGR 
 
Exedin 
HGEGTFTSDLSKQXEEEAVRXFIEWLKNGGPSS
GAPPPS 
87 
= functionalities including biotin, PEGs, fluorescent tags, and cell-permeable motifs. 
Considering the variety of 2C-PS methodologies developed to date, it is clear that the decision of 
which one to use depends mainly on the structure of the peptide to be constrained and on the 
availability of the starting materials. The CuAAC 2C-PS methodology is among the most widely 
applied 2C-PS chemistries.78-87 It proved itself compatible with various amino acid sequences, 
enhanced the activity and proteolytic stability of several biologically active peptides, and it is 
applicable to both helical and non-helical peptides.79–84 Therefore, the CuAAC 2C-PS technique 
presents itself as a feasible stapling methodology to use when the priority is to functionalise the 
constrained peptides or study novel functionalised staples since the macrocyclisation reaction 
itself is well-validated. 
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1.2.1.3. Discovery of therapeutic macrocyclised peptides 
The strategies used to develop therapeutic macrocyclised peptides can be divided into three 
main groups: natural products, screening of peptide libraries, and target-based rational design 
(Figure 7). 
 
Figure 7 – Major approaches adopted by pharmaceutical industries and academic groups to discover cyclic peptides as 
therapeutics: a) Peptides derived from natural sources; b) biological and chemical peptide libraries; 1) mRNA encoded 
libraries expressed in vitro and cyclised using specific reagents; 2) phage-display libraries expressed by bacteriophages in 
host cells and cyclised after phage release either by disulfide bridge formation or by CLIPS technology; 3) genetically 
selected cyclic peptides expressed in bacteria, cyclised in cell using the SICLOPPS technology and tested in functional 
assays in cells (RTHS: reversed bacteria two-hybrid system); 4) chemical libraries of cyclic peptides synthesised in parallel 
or using combinatorial chemistry; c) Target-based rational design of cyclic peptides: a generic PPI is shown as pink and 
red surface, designed peptides as red helices, and staple in grey sticks. Taken from Iegre et al., Advanced Therapeutics, 
2018.59 
Natural and semi-synthetic cyclic peptides (Figure 7a) pioneered the use of this class of 
macromolecules as therapeutics; indeed, nine natural product cyclic peptides were approved by 
the FDA and EMA between 2005 and 2015.88 Examples of this class of molecules are 
fermentation products of microorganisms - Caspofungin,89,90 Cyclosporin A,91 Daptomycin,92 
Anidulafungin,93 Romidepsin,94 Linaclotide and Pasireotide95 among others - hormones and 
hormones derivatives - Vasopressin, Octreotide and Oxytocin.88 These peptides find application 
as antifungal agents, antibiotics, chemotherapeutics, treatments for hormonal disorders and 
offer the advantage of being highly selective and stable in vivo.  
Peptide libraries can be divided into biological and chemical libraries. Biological peptide 
libraries (Figure 7b) are synthesised with the aid of bacteriophages (phage-display) or using 
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cell-free display technologies (mRNA display) and cyclised using some of the methodologies 
listed herein: 
- cysteine amino acids are added to the phage-displayed peptide in a random manner to 
allow successive disulfide bridge formation.96–100 The “CLIPS” cyclisation technology is a 
variant of this methodology, and it generates bicyclic peptides via conjugation between 
three cysteine residues and a tris-(bromomethyl)benzene (TBMB) core.101 More 
recently, alternative trivalent thiol-reactive linkers have been used to provide bicyclic 
peptides characterised by diverse conformations and include N,N’,N’’-(benzene-1,3,5-
triyl)tris(2-bromoacetamide) (TBAB), N,N’,N’’-benzene-1,3,5-triyltrisprop-2-enamide 
(TAAB) and 1,3,5-triacryloyl-1,3,5-triazinane (TATA) (Figure 8a);102 
- head-to-tail cyclisation performed intracellularly exploiting the protein splicing 
capability of split inteins (the so-called SICLOPPS technology).103,104 This technology 
implements a reverse two-hybrid system to allow for functional and binding assays 
(Figure 8b); 
- mRNA encoded libraries of linear peptides are translated in vitro in a cell-free system. 
Cyclisation is then performed using reagents like disuccinimidyl glutarate to connect the 
N-terminus and a side chain of a Lys residue or via disulfide bridges across Cys residues 
(Figure 8c).105,106 
 
Figure 8 - Main types of cyclisation chemistries performed in the generation of biological libraries. a) CLIPS 
macrocyclisation used in phage display. The generic core is shown as a green cloud; b) Intein mediated SICLOPPS 
cyclisation; c) cyclisation done on mRNA encoded library. The DNA-RNA hybrid transcript is shown as blue and red 
helices, linkage of the peptide to the nucleic acid strand as a black, curved line. Generic amino acids are shown as white 
spheres. 
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Phage-display peptide libraries offer the advantage of providing highly diverse libraries. 
However, the peptides generated may have low affinity for the target and problems associated 
with the use of live cells and phages could arise. mRNA encoded libraries may overcome these 
limitations, therefore representing a valid alternative.107 New genetic technologies have recently 
emerged to allow the incorporation of unnatural amino acids into biological libraries, providing 
more flexibility in the composition of the peptide sequence.108–110 Of particular interest are the 
mRNA-encoded peptide libraries developed in the Suga group: thioether macrocyclic peptides 
are generated following spontaneous intramolecular reaction between Cys residues and the side 
chains of unnatural N-(chloroacetyl)-D-Trp or N-(chloroacetyl)-Tyr (Figure 9a).111,112 An 
alternative cyclisation has been achieved by the same group with the introduction of 5-
hydroxytryptamine and benzylamine amino acid derivatives followed by fluorogenic oxidative 
coupling between the two side-chains to afford fluorescent cyclic peptides (Figure 9b).113  
 
Figure 9 - Macrocyclisations performed using unnatural amino acids in peptide ribosomal synthesis. a) Macrocyclisation 
obtained using N-(chloro-acetyl) amino acid derivatives; b) Macrocyclisation performed using N-benzylamine and 
hydroxy tryptamine derivatives to obtain fluorescent cyclic peptides. The DNA-RNA hybrid transcript is shown as blue and 
red helices, linkage of the peptide to the nucleic acid strand as a black, curved line. Generic amino acids are shown as 
white spheres. 
Chemical libraries of cyclic peptides, on the other hand, are synthesised using parallel or 
combinatorial chemistry. Parallel synthesis is limited in the number of macrocycles that can be 
simultaneously generated, whilst combinatorial methods allow the generation of a greater 
number of compounds. Once assembled, the chemical peptide libraries can be screened against a 
selected target before or after cleavage from the resin support.114 
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The target-based rational design approach aims to develop cyclic peptides for well-validated 
targets for which structural information of the protein of interest is available. This approach 
does not require the synthesis of many biomolecules since the peptides designed feature amino 
acid sequences that resemble portions of the native protein that is being mimicked. This 
approach allows for more flexibility for peptide modification and the amount of product 
synthesised. Furthermore, a target-based rational design approach can be used to optimise hit 
peptides coming from library screenings.59  
In a typical example (Figure 7c), an X-ray crystal structure of the target protein and ideally of the 
native PPI is desired. In silico molecular modelling can guide the design of the peptide and 
identify suitable residues for cyclisation to happen.115 Further changes in the peptide sequence 
are aimed at replacing amino acids to increase the binding affinity and optimise PK properties. 
Subsequently, the designed peptides are synthesised and assessed in vitro. Iterative cycles of 
enzymatic, cellular, structural assays and synthesis are performed to build an SAR and guide 
further modifications until the optimal peptide is developed prior to in vivo testing. This 
approach offers the advantages of knowing the target in advance, and the synthesis of a smaller 
number of peptides is required to generate novel synthetic peptides with a high affinity for the 
desired target and improved PK properties. The main drawback of the target-based rational 
design approach is the need for detailed structural information of target and natural PPI 
sequence to guide the design.59 
1.2.1.4. Cyclised peptides in advanced stages of the pipeline 
Twenty-six cyclic peptide therapeutics have been approved by the FDA thus far.116 Of these, 
twenty were cyclised via intramolecular formation of disulfide bridges, four via intramolecular 
amide bonds and two via intramolecular formation of other types of chemical bonds (ester and 
carbamate).116 Vasopressin, the first cyclic peptide marketed, was approved in 1962 for the 
treatment of anti-diuretic hormone deficiency, and it is constrained via an intramolecular 
disulfide bridge. Macrocyclisation techniques besides disulfide bridging and lactamisation only 
became popular in the late 1990s, and it is therefore not surprising that the cyclic peptide drugs 
approved thus far do not feature more modern type of macrocycles, considering the long 
timelines of drug discovery and clinical studies. Noteworthily, most of the cyclic peptides with 
therapeutic applications approved to date derive from natural products. Thanks to the advances 
in biotechnology, the cyclic peptides that are currently undergoing clinical development feature 
both classic and modern cyclisation chemistries and have been discovered using directed-
evolution techniques, rather than being inspired by natural products.117 An overview of some 
notable cyclic pharmaceutical peptides with public structures available currently in clinical 
studies and approved drugs is shown in Figure 10. 
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Figure 10 - Overview of cyclic peptide drugs currently under clinical development (2018) and cyclic peptide therapeutics 
approved between 1962 and 2017.116,118 
Historically, cyclic peptides found application in a wide variety of primary disease areas, with 
the majority of the drugs approved to treat infertility and obstetric/gynecologic disorders, 
cardiovascular and metabolic diseases (CVMD), and endocrinology-related diseases (Figure 
11a).116 This fact has now been challenged by the cyclic peptides currently under clinical 
development, where oncology features as the main player in the therapeutic areas’ field, closely 
followed by respiratory, inflammatory and autoimmune (RIA) diseases (Figure 11).118 
 
Figure 11 - Primary therapeutic areas of approved cyclic peptide drugs (a) and cyclic peptides currently under clinical 
studies (b). OB/GYN = obstetrics and gynaecology; CVMD = cardiovascular and metabolic diseases; RIA = respiratory, 
inflammatory, auto-immune diseases. 
It should be noted that the interest of pharmaceutical companies working on cyclic peptides 
goes beyond oncology and RIA, with discovery pipelines focusing on the development of cyclic 
peptides for complement-mediated diseases (Ra Pharmaceuticals),119 CVMD, haematology, 
ophthalmology, and anti-infectives diseases (Bicycle Therapeutics),120 and antimicrobials 
(Polyphor).121 It is therefore evident that in the next decades, the primary therapeutic area 
landscape is bound to change significantly again. In addition, considering that cyclic peptides are 
receiving the attention of an increasing number of pharmaceutical companies and academic 
groups, further therapeutic areas will most likely engage this new drug modality. 
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Cellular-self destruction or programmed cell death (PCD) is a fundamental process that allows 
the cells to be eliminated should they become defective, old, and potentially harmful to the living 
organism.122 Apoptosis (type I PCD) is the major form of PCD, followed by autophagy (type II) 
and necrosis (type III). Considering that PCD is of crucial importance to homeostasis, the cells 
are equipped with a multitude of finely regulated mechanisms that allow them to escape 
apoptosis under physiological conditions and trigger it when potentially harmful alterations are 
detected.122 These mechanisms consist of complicated cross-signalling between proteins and 
messengers that occur both intracellularly and extracellularly. The pro- and anti-apoptotic 
signalling pathways are extremely complicated and, in some parts, not fully understood. The 
overall cascades can be divided into four major classes: tumour necrosis factor (TNF) pathway, 
survival pathway, DNA damage and stress pathway, and death ligands pathway as exemplified in 
Figure 12.123,124  
 
Figure 12 - Apoptotic and anti-apoptotic pathways divided by class. The figure does not intend to represent the pathways 
in full, and it provides an overview of the complexity of the cascades that regulate cell survival. Proteins and genes which 
play an anti-apoptotic role are shown in red. Activation is depicted as an arrow, inhibition as a dash at the end of the 
line.123,124 
The TNF pathway is considered an anti-apoptotic cascade: the cell signalling protein tumour 
necrosis factor α (TNFα) binds and activates the TNF receptors expressed on the cell membrane. 
The receptor, in turn, activates the complex-1 which triggers the NF-κβ protein complex 
initiating the transcription of anti-apoptotic genes.125 The survival pathway is activated by a 
variety of extracellular ligands including hormones, chemokines, survival factors, collagen and 
laminin. Binding of these ligands to their receptors activates cytosolic kinases which all converge 
on the phosphorylation and activation of the AKT/PKB pathways resulting in the inhibition of 
the pro-apoptotic Bcl-2 proteins (such as Bad).122 When the pro-apoptotic Bcl-2 proteins are 
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inhibited, the anti-apoptotic proteins of the same family are activated and prevent the release of 
the cytochrome C with consequent activation of caspases, resulting in inhibition of apoptosis. 
The action of the survival pathway can be reinforced by the activation of the inhibitor of 
apoptosis proteins (IAPs) which inhibit the caspases, thereby preventing apoptosis from 
happening. Conversely, the phosphatase and tensin homolog protein PTEN can block the 
activation of the AKT/PBK pathways by PI3K kinase, inducing apoptosis.122 On the other hand, 
stress and DNA damage trigger apoptosis by activating the pro-apoptotic Bcl-2 proteins and by 
activating p53, among other effectors, in the nucleus.126 Activation of pro-apoptotic Bcl-2 
proteins (BH3-only proteins) means that mitochondria lose their outer membrane potential, the 
cytochrome C is released, and caspases are activated to exert apoptosis. Finally, apoptosis can be 
triggered by the so-called death ligands, namely FasL and TRAIL. The latter can indirectly 
stimulate the death-inducing signalling complex (DISC) to activate caspase 8 and therefore 
apoptosis.126 Anti-apoptotic proteins such as FAIM3 and FLIP prevent the apoptosis by inhibiting 
components of this cascade. The death ligands pathway is often referred to as extrinsic 
apoptosis to differentiate it from the intrinsic apoptosis, which is mitochondria-associated.123,124 
Dysregulations that break the equilibrium between the activity of pro- and anti-apoptotic 
proteins are linked to the development and progression of pathological conditions, the most 
studied of which is cancer. Alterations that result in the cells becoming able to escape apoptosis 
include: activation or up-regulation of mitogenic signals (i.e. Erk1/2, AKT), inactivation or 
downregulation of pro-apoptotic proteins (i.e. Bax and Bak), and up-regulation of genes 
encoding for anti-apoptotic proteins (i.e. Bcl-2 proteins).122 
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2.1. Inhibition of anti-apoptotic proteins  
Considering the central role of anti-apoptotic proteins in regulating cell lifespan, it is not 
surprising that their dysregulation is implied in a variety of diseases. Restoring the naturally-
occurring apoptotic activity in diseased organisms by acting on anti-apoptotic proteins has been 
reported to be a more successful strategy than targeting pro-apoptotic proteins.122 Anti-
apoptotic proteins play important roles in neurodegenerative conditions including Alzheimer’s 
and Parkinson’s disease, as well as during heart attacks or ischemic strokes.127–130 Under these 
pathological conditions, there is a decreased activity of anti-apoptotic proteins in favour of a 
more pronounced apoptotic activity. On the contrary, in a number of physio-pathological 
conditions cells escape apoptosis to a much larger extent due to increased anti-apoptotic 
activity. Examples of such conditions include auto-immune diseases, inflammation, animal 
hibernation, and cancer.123,124,131,132 
Resistance to PCD is the hallmark of cancer cells, and inhibition of anti-apoptotic proteins is a 
well-exploited strategy in oncology. Such inhibition is achieved by targeting the apoptotic 
cascade at any level: mitochondrial outer membrane proteins (i.e. Bcl-2), proteasomes, 
nonproteolytic death effectors, death receptors, nuclear factors, stress kinases (Figure 12).133 
Depending on the desired target, apoptosis is induced utilising different approaches: for 
instance, anti-apoptotic gene transcription can be switched off; alternatively mRNA degradation 
can be induced using antisense oligonucleotides, then again small molecules, peptides, and 
antibodies can be developed to either inhibit the activity of a specific protein, or to prevent the 
cross-talk between proteins (PPIs).133  
 
The aforementioned pro- and anti-apoptotic pathways are the subject of intense study and 
scrutiny. Many of the proteins involved have been the subject of drug discovery campaigns, or 
probe-designing efforts, but several of their mechanisms still require elucidation. In an effort to 
analyse and comprehend these mechanisms better, two main proteins will be the focus of this 
dissertation: CK2 and Bcl-2. 
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2.1.1. Anti-apoptotic CK2 protein kinase 
CK2 (formerly named protein Casein Kinase 2) is a protein kinase which plays crucial roles in 
multiple intracellular pathways including the regulation of cell proliferation and cell growth; it is 
also believed to be an anti-apoptotic protein in both healthy and cancer cells.134,135 It is, however, 
overexpressed in various cancer cell lines including breast, lung, prostate, colorectal, renal, 
leukaemia and glioblastoma brain tumours.136,137 
CK2 is a heterotetrameric enzyme composed of two catalytic subunits (α and/or α’)f and two 
regulatory subunits (β) (Figure 13).  
 
Figure 13 - Human CK2 holoenzyme (PDB code: 1JWH).138 Catalytic subunits are shown in cyan (α) and green (α’), 
regulatory subunits in yellow and purple (β).  
CK2 is constitutively active and uses ATP or GTP as co-substrate.139 Interestingly, these 
characteristics are not common to other eukaryotic protein kinases (EPKs),139 and the 
mechanisms that control its catalytic activity are unique to CK2.140  
Formation of the holoenzyme occurs via dimerisation of the β subunits followed by 
complexation with the N-terminal domain of CK2α. The surface contact between the α and the β 
domains is relatively small compared to other PPIs (832 Å2). Thereby, the activity of the CK2 
enzyme can be affected either by acting on the α subunits or by preventing the formation of the 
holoenzyme. 
2.1.1.1. CK2α subunit  
CK2α is composed of two domains, the N- and C-terminal domain with the ATP active site 
located between them (Figure 14).140 The N-terminal domain (red-orange) contains five 
stranded β-sheets (β1-β5) and one α-helix (αC) situated next to the inter-domain cleft. The αC-
helix contains basic lysine residues and has, therefore, a preference for acidic substrates.138
 
The 
N- and C- terminal segments are linked via the hinge/αD region, and the αD pocket that will be 
                                                          
f The α subunit presents 20 additional amino acids at the C-terminus that are absent in the α’ subunit.144 
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discussed in this work is located in close proximity to the αD helix. The C-terminal segment 
(green, blue and purple) is formed of α-helices and two double-stranded β-sheets at the inter-
domain cleft and contains the activation loop. The conformation of the activation segment, as 
well as the glycine-rich loop (β1β2-loop), is important for the catalytic activity of the protein.140 
 
Figure 14 - Crystal structure of CK2α subunit (PDB code 3NSZ).141 In orange-yellow the N-terminal domain and in green-
blue the C-terminal domain of the catalytic subunit. The key parts of the protein are labelled in the figure. 
The mechanisms that control the catalytic activity of CK2 are distinct from most other EPKs, 
namely the catalytic activity of CK2 is not controlled by phosphorylation (within the activation 
loop) or by interaction with regulatory proteins.140 Instead, the conformation of the DWG motif 
(Asp175-Trp176-Gly177) in the activation segment and the adopted active conformation of the 
αC-helix make CK2α constitutively active. In this conformation, the activation segment is open 
and allows for substrate binding and phosphor-transfer reactions. Specifically, the N-terminal 
segment establishes extensive contacts with the αC-helix and the activation loop, stabilising 
CK2α in a constitutively active conformation.140,142 The ability of CK2α to maintain the activation 
segment in this active form, unlike most EPKs, has also been attributed to differences in its 
sequence.140
 
Most EPKs contain a DFG motif, whereas CK2α feature a DWG motif. In EPKs, such 
as CK2’s closest analogue CDK2, the central Phe is dynamic and variable between the active and 
inactive states (green in Figure 15). In CK2 (purple in Figure 15) an additional hydrogen bond 
between the indole-nitrogen of the Trp176 and the backbone carbonyl of Leu173 is established, 
thereby maintaining the active state conformation.140 
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Figure 15 - Overlay of the activation segments of CK2α (PDB: 1LP4, purple)
 
and inactive form of CDK2 (PDB: 1HCK, 
orange).
 
The DWG motif in CK2α allows for an additional hydrogen bond to Leu173 as shown by the dashed black line. 
Upon complexation with CK2β, a major conformational change occurs in CK2α: the β4β5-loop of 
CK2α, which is in the open form in X-ray crystal structures of the holoenzyme, switches to the 
closed form in the monomeric form.143
 
2.1.1.2. CK2β 
The CK2β subunit is smaller than the catalytic α domains (~28 kDa and ~48 kDa respectively) 
and, although it is not required to activate CK2α, it regulates the activity of the kinase. In 
particular, CK2β increases the thermostability of CK2 and enhances its catalytic activity. In 
addition, intracellular localisation of CK2 is influenced by the presence of CK2β which is 
required for the protein shuttling between intracellular compartments. Moreover, CK2β acts as a 
docking station for some CK2 substrates (i.e. Nopp140, p53, FAF-1, topoisomerase II, FGF-2, and 
eIF2β)144 by bringing the α subunit into proximity with them. In addition, CK2β is needed to 
dock to and penetrate the nuclear membranes.145 CK2β is present as a homodimer in solution 
and comprises of a body and a tail (Figure 16). The body includes the N-terminus and the 
dimerisation domain, which comprises the zinc binding site. The zinc is anchored by three-
stranded anti-parallel β sheets and four cysteine residues; The tail includes the C-terminus, and 
it is formed by a β-turn and a short α-helix.  
The β-turn includes the hydrophobic hotspot residues which are essential for the docking to the 
CK2α subunit. In particular, the lack of residues Arg186, Tyr188, Phe190, and His193 is 
detrimental to the holoenzyme formation. Unlike for CK2α, no major conformational changes 
occur in CK2β upon holoenzyme assembly, as documented by the X-ray structures of the subunit 
in isolation and complexed with CK2α.138 
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Figure 16 – Structure of CK2β (PDB code: 1JWH).138 a) CK2β homodimer: the two CK2β subunits are shown as blue and 
green ribbons, the zinc ions as orange spheres. b) Details of the CK2β domain: N-terminal domain is shown as yellow-
orange-green and contains the dimerisation domain; the C-terminal domain (purple) contains the portion of CK2β that 
binds to CK2α. 
2.1.1.3. Signalling pathways involving CK2 
CK2 is involved in a multitude of subcellular pathways at different levels and has a substantial 
impact on cell growth, proliferation, and apoptosis.146 The importance of CK2 in cell proliferation 
and growth is evident considering the increase in its expression level in healthy cells during cell 
proliferation. Moreover, CK2α-CK2β knockout mice models led to mice death, emphasising the 
essential role of this protein in cell survival.134 The mechanisms through which CK2 acts as an 
apoptosis-suppressor involve several signalling pathways, including the secreted cysteine-rich 
glycoproteins (Wnts), IAPs, reactive oxygen species (ROS), caspases, TNF pathway, and 
PI3K/AKT thereby acting on multiple pathways of the apoptotic cascades (Figure 17).146 For 
example, CK2 promotes degradation of the NF-κB-inhibitory-protein Iκβ and consequent 
activation of the transcription factor NF-κB.147 In addition, CK2 activates different components of 
the Wnt pathway, such as the dishevelled protein (Dvl) via phosphorylation: it phosphorylates, 
stabilises, increases the transcriptional activity of β-catenin and recruits other Wnt regulators. 
When activated, Wnt signalling inhibits the so-called disruption-complex, preventing 
apoptosis.148 As reported by Piazza et al., PIP3 (phosphatidylinositol 3,4,5-triphosphate) is 
generated by the kinase PI3K and causes the activation of several downstream protein kinases of 
the survival pathway (vide supra), including AKT/PKB, which critically regulates cell survival, 
proliferation, and oncogenesis. Moreover, PTEN is a lipid and protein phosphatase able to 
dephosphorylate PIP3, and it is an essential tumour suppressor. CK2 phosphorylates PTEN in 
the C-terminal region, stabilising the protein against ubiquitin-mediated proteasomal 
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degradation, and enhancing PTEN activity. In addition to its direct regulation of PTEN, CK2 is 
able to activate AKT through direct phosphorylation and prevent dephosphorylation of its active 
form via an indirect mechanism.148 
 
Figure 17 - Overview of the central role of CK2 in the apoptotic pathways. Anti-apoptotic proteins are shown in red. 
Activation is depitched as an arrow, inhibition as a dash at the end on the line. 
The link between CK2 and ROS has been investigated by Ahmad et al. using various prostate 
cancer models.149 The research group discovered that when CK2 is inhibited, the intracellular 
levels of H2O2 increased leading to the release of pro-apoptotic signals such as cytochrome c, 
activation of caspase 3, downregulation of Iκβ, translocation of NF-κB, and DNA fragmentations. 
Moreover, expression levels of the anti-apoptotic IAPs are diminished when CK2 is inhibited.149 
2.1.1.4. Approaches towards the inhibition of CK2 in oncology  
Among other features, cancer cells present dysregulated proliferation and deregulated apoptotic 
activity, leading to uncontrolled cell growth.150 The well-established overexpression of CK2 in 
cancer cells has been attributed to a new basal level of CK2 protein expression taking place 
when healthy cells morph into cancer cells. The new and dysregulated basal level disrupts the 
cell homeostasis and makes the cells more sensitive to CK2 inhibition.150 In healthy cells, 
however, the level of CK2 expression increases only during controlled proliferation.146 The 
ability of CK2 to affect cell proliferation and apoptosis in both normal and cancer cells has been 
validated using several in vivo and in vitro experimental models.134,135 Therefore, as reported by 
Trembley et al.,146 the importance of targeting CK2 for anti-cancer purposes can be understood 
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considering: 
-CK2 appears to be largely affected by mitogenic signals; 
-Downregulation of CK2 expression has a strong influence on inflammation, 
angiogenesis, and drug efflux pathways to the benefit of cancer cell elimination; 
-Dysregulated expression of CK2 in cancer cells is an index of the pathological status of 
the tumour; 
-CK2 downregulation results in inhibition of cell growth, proliferation, and an increased 
apoptotic activity;
 
-CK2 is crucial for cell survival, and there appear to be no redundant pathways to 
compensate for its downregulation.  
All this evidence together makes CK2 inhibition an attractive target for cancer therapy.146 
A wide variety of approaches have been used to inhibit CK2, and both RNA knockdown and small 
molecules strategies have been embraced. The first antisense oligonucleotide was developed by 
Faust et al.151 Although the oligodeoxynucleotide was able to cause an antisense-mediated 
disruption of CK2 leading to apoptosis, it proved less efficacious in reducing the expression level 
of the protein.152 Therefore, small molecules were preferred to induce CK2 inhibition as they 
have the potential to be more selective, with different strategies being applied and reported 
herein (Table 3). 
The most common one is the inhibition of CK2 with small molecules that bind at the ATP-binding 
site; however, despite their efficiency in providing low nM-range inhibitors, they suffer the 
drawback of having off-target activity towards other kinases with a similar ATP-binding 
sites.135,152 Several ATP-competitive inhibitors showing a range of potency and selectivity have 
been developed either in industry or in academia – e.g. tetrabromobenzimidazole derivatives 
(TBB, TBI, DMAT),153 condensed polyphenolic derivatives,154 indoloquinazoline-based 
compounds155 and pyrazolo[1,5-a]pyrimidine derivatives.156 Among these, the ATP-competitive 
CK2 inhibitor CX4945, Silmitasertib, developed by Cyclene Pharmaceutical, represents the first 
orally bioavailable inhibitor of CK2 currently undergoing clinical trials.139 CX4945 inhibits CK2 
with an IC50 of 1 nM, and its selectivity was screened against a panel of 238 kinases; 7 of these 
were inhibited at more than 90% showing that CX4945 is able to engage kinases other than CK2. 
139 
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Table 3 - An overview of some inhibitors of CK2 grouped by type of inhibition. 
Inhibition type Inhibitor 
ATP competitive 
inhibitors 
 
 
 
 
Displacer of 
CK2α substrates 
C W TGLM S P R H C Y
 
Inhibitors of the 
PPI between 
CK2β and its 
substrates 
G K ALPM N G V L W P LYLS R L
 
Allosteric 
inhibitors with 
unknown 
binding mode 
D C KIMR G L I V L H
 
Inhibitors of the 
α/β PPI  
 
Due to potential selectivity issues linked to targeting the highly conserved ATP-binding site, an 
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increasing interest has arisen in the development of non-ATP-competitive and allosteric 
inhibitorsg.157 CK2 inhibition exploiting binding sites outside the catalytic ATP pocket has been 
achieved using a variety of approaches (Table 3).  
An interesting approach towards non-ATP-competitive inhibition is the one used by Perera et al. 
displacing the CK2 substrates. CK2 targets present an acidic phosphoro-acceptor site which 
allows for phosphorylation, and peptide P15 was designed to bind to these appendices to inhibit 
substrate phosphorylation in a non-ATP-competitive fashion.158
 
Other approaches target the CK2β regulatory subunit. For instance, peptide P1 binds to the N-
terminal domain of the β subunit, triggering cell apoptosis by preventing key interactions of the 
α subunit with specific anti-apoptotic protein substrates.159 
 
An additional interesting non-ATP-competitive strategy is the disruption of the α/β subunit 
interaction. Inhibition of the PPI between the α catalytic subunit and the β regulatory subunit 
results in prevention of the holoenzyme assembly, with negative consequences on substrate 
recognition, protein shuttling between different intracellular compartments, and the stability of 
the catalytic subunit, thereby impacting the cell cycle and cell progression. The inhibition of the 
holoenzyme assembly by targeting the interface has been reported to be a more selective and 
elegant way of affecting the activity of CK2, especially in the light of the fact that the catalytic α 
subunit remains active towards some of its substrates and that the protein interface is not 
conserved among other kinases.160  
The interface of the isolated CK2 protein was successfully targeted using small molecules such as 
the podophyllotoxin indole analogue W16160 or using the cyclic disulfide bridged peptide Pc.161 
Interestingly, the small molecule W16 inhibited the catalytic activity of CK2α in an allosteric 
manner whilst Pc resulted in an enhancement of the catalytic activity.160,161 The potency of these 
two compounds in a cellular context is unknown. Similarly, Raaf and et al. showed that the 
known CK2 inhibitor DRB was also able to bind at the interface although, with a low binding 
affinity insufficient to cause a biological response.162 Lately, a 12-mer peptide, named B2 was 
identified using phage-display technology. B2 is able to disrupt both the PPI and the catalytic 
activity with an identical IC50 of 0.8 μM; however, it is not clear how the 12-mer peptide binds to 
CK2α and how it inhibits the catalytic activity of the protein.163 Recently, a cyclic peptide 
analogue of Pc was reported in the literature: the Pc peptide was conjugated with a TAT cell-
penetrating peptide to gain cell-permeability, and the disulfide bond in Pc was replaced with a 
                                                          
g Allosteric inhibition aims to develop a ligand for a site different from the active site, but able to cause a change in the protein 
structure which will impede catalysis.287 
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head-to-tail lactam. Although cell-permeable, there are no reports of the binding mode or target 
engagement of TAT-Pch.164 Data on the stability of the complex under physiological conditions 
are also missing. It is therefore clear that, despite recent advances, selective, stable, and potent 
inhibitors acting at the CK2 PPI are still missing. The discovery of molecular probes able to 
disrupt the PPI of CK2 in cells and, potentially, in vivo would shed light on the regulatory 
mechanisms of the protein and the importance of the holoenzyme to cancer progression.
                                                          
h Cell-penetrating peptide derived from the transactivator of transcription domain (TAT) of human immunodeficiency virus. The 
sequence of TAT peptide is GRKKRRQRRRPQ. 
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2.1.2. Anti-apoptotic Bcl-2 proteins 
Bcl-2 proteins are a family of proteins with well-established roles in apoptosis. The family 
comprises membrane-associated and cytosolic proteins with both pro- and anti-apoptotic 
functions acting on mitochondria outer membrane permeabilization (MOMP), thereby 
representing an essential component of the intrinsic apoptotic cascade.165 The proteins of the 
Bcl-2 family can be divided as follows: pro-apoptotic (Bim, Bad, Bid, Bmf, Noxa, Puma, Hrk, Bik); 
anti-apoptotic (Bcl-xL, Bcl-w, Bcl-2, Mcl-1, and A1); effectors of apoptosis (Bax and Bak).165 They 
share the so-called Bcl-homology (BH) domains that can be grouped as follows: BH1, BH2, BH3, 
and BH4.166 The Bcl-2 family members interact with each other via a series of PPIs made 
possible by the BHs. The BHs, in fact, are necessary for the formation of homo- and hetero-
complexes. The pro-apoptotic proteins are often referred to as BH3-only proteins since they 
conserve the BH3 domain only. The anti-apoptotic proteins, on the other hand, can present all 
four homology domains, with BH1 and BH2 necessary to interact with the effectors of apoptosis 
Bax and Bak.166 The exact mechanisms by which apoptosis is induced by the Bcl-2 family 
members is highly debated and not fully understood. It is widely accepted that the pro-apoptotic 
proteins form a heterodimer with the anti-apoptotic proteins thereby inducing conformational 
changes that displace the effectors of apoptosis from their complex with the anti-apoptotic 
proteins (Figure 18a). Once freed, Bax and Bak become able to trigger apoptosis by affecting the 
MOMP. Alternatively, the BH3-only proteins bind and activate Bax and Bak directly: proteins 
that can interact with the effectors of apoptosis directly are called activators (Bid, Bim, Puma), 
whereas proteins that bind to the anti-apoptotic proteins are called sensitisers (Bad, Bmf, Bik, 
Noxa, Hrk) (Figure 18a).  
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Figure 18 - Exemplified overview of the Bcl-2 pathways inducing apoptosis. a) Activation mechanisms within the Bcl-2 
family: the pro-apoptotic proteins directly activate the effectors of apoptosis (blue) or can bind to the anti-apoptotic 
proteins (pink) and induce conformational changes that result in the anti-apoptotic protein releasing the effectors of 
apoptosis. Once Bax and Bak become active, they exert their apoptotic activity. b) PPIs between members of the Bcl-2 
family.  
It should be noted that the activators can also act as sensitisers, but sensitisers do not act as 
activators. When active, Bax and Bak oligomerise on the mitochondria membranes by means of 
the BH3-domain, resulting in the formation of pores, and hence triggering apoptosis.165–168 It 
should be noted that members of the Bcl-2 family may also interact with proteins outside of 
their group. In addition, the PPI between pro- and anti-apoptotic Bcl-2 proteins occur in a very 
selective manner, with BH3-only proteins interacting with specific Bcl-2 anti-apoptotic proteins 
only as exemplified in Figure 18b.  
2.1.2.1. The function of Bcl-2 proteins in the survival of nucleated cells  
As for all the anti-apoptotic proteins, the Bcl-2 family members act as guardians of cell death and 
survival; therefore, alteration in gene expression or activity of Bcl-2 proteins leads to 
pathological conditions. For example, the expression levels of Bcl-2 anti-apoptotic proteins have 
been found to be particularly elevated in a number of cancers.169 Cancerous cells over-
expressing anti-apoptotic Bcl-2 proteins can easily escape apoptosis and therefore are not 
eliminated by the organism. Elevated expression levels of Bcl-2 anti-apoptotic proteins can be 
attributed to the loss of endogenous mRNAs that represses Bcl-2 gene expression under 
physiological conditions, to changes to the gene structures, the number of copies, and gene 
hypomethylation.169 It is not surprising that inhibition of anti-apoptotic proteins of the Bcl-2 
family is an attractive, well-exploited strategy used in oncology to restore the physiological level 
of apoptosis, and hence allowing the organism to eliminate defected, cancerous cells via the PCD.  
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2.1.2.2. Approaches towards the inhibition of anti-apoptotic Bcl-2 proteins 
The role of the anti-apoptotic Bcl-2 proteins (Bcl-2, Bcl-xL, Bcl-w, Mcl-1, A1) is to sequester the 
effectors of apoptosis Bax and Bak, therefore, preventing their pro-apoptotic activity. Any 
molecules that can antagonise the action of the anti-apoptotic proteins by displacing or 
liberating the effectors of apoptosis are known as Bcl-2 inhibitor. Since the BH3 only proteins act 
as inhibitors of the anti-apoptotic Bcl-2 proteins, the majority, if not all of the Bcl-2 inhibitors 
known to date are BH3 mimetics: they bind to the hydrophobic groove of the anti-apoptotic 
proteins in the same way that BH3-only proteins do with their α-helical BH3 domain (Figure 
19).170  
 
Figure 19 - Typical binding mode of BH3-only proteins to Bcl-2 anti-apoptotic proteins. The interaction between Bim and 
Bcl-2 is shown here (PDB: 1PQ1).171 a) View from the top of the BH3 domain of the Bim protein (green) complexing with 
Bcl-xL. b) Side-view of the complex showing the binding of the helical Bim protein into the hydrophobic groove of Bcl-xL. 
Protein surface is coloured according to the electrostatic potential: grey (hydrophobic), blue (negatively charged) and 
red (positively charged). 
All the BH3 mimetics developed to date can be divided into two categories: true BH3 mimetics – 
characterised by high affinity for the target and no off-target effects – and putative BH3 mimetics 
– showing low affinity for the anti-apoptotic targeted protein and several off-target effects.170 
Although non-selective, putative BH3 mimetics are often used to investigate resistance 
mechanisms in cancer cells.170 BH3 mimetic therapeutics comprise both small molecules and 
peptides, and they all find application as anti-cancer drugs. Table 4 lists some notable 
compounds inhibitors of the anti-apoptotic Bcl-2 proteins that were promoted to the late stages 
of the drug discovery process. 
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Table 4 - Non-comprehensive list of notable Bcl-2 inhibitors in advanced phases of drug discovery. 
Drugs Structure Target Stage 
ABT-73721 
 
Bcl-2, Bcl-
xL, Bcl-w 
Stopped after 
pre-clinical 
studies 
Navitoclax 
(ABT-263)172 
 
Bcl-2, Bcl-
xL, Bcl-w 
Stopped after 
phase II 
studies 
Venetoclax 
(ABT-199)173 
 
Bcl-2 Approved 
Gossypol174  
 
Bcl-2, Bcl-
xL, Bcl-w 
Phase I/II 
Obatoclax175 
 
Bcl-2, Bcl-
xL, Bcl-w, 
A1, Mcl-1 
Stopped after 
phase II  
SHABa Bad176 
 
Bcl-2, Bcl-
xL, Bcl-w 
Preclinical 
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SHABa Bid176 
 
Bcl-2, Bcl-
xL, Bcl-w, 
A1, Mcl-1 
SHABa Bim177 
 
 
ABT-199 (Venetoclax) is the first marketed Bcl-2 inhibitor. ABT-737 and ABT-263 (Navitoclax) 
are analogues of Venetoclax whose clinical trials were stopped due to a dose-limiting 
thrombocytopenia. Venetoclax was developed to overcome this limitation by interacting with 
the anti-apoptotic Bcl-2 protein selectively. The thrombocytopenia caused by ABT-737 and 
Navitoclax inspired scientists to investigate the role of the Bcl-2 proteins in platelets. 
2.1.2.3. The function of Bcl-2 proteins in platelets apoptosis and activation 
Platelets are short-lived (8-10 days in humans), anucleated cells produced from megakaryocytes 
in the bone marrow, spleen, and foetal liver, and they constitute a key component of the blood.178 
Even though platelets do not have a nucleus, they contain the endoplasmic reticulum (ER), Golgi 
apparatus, mitochondria, and some mRNAs.179 Platelets play essential roles in 
pathophysiological conditions including haemostasis, cardiovascular thrombotic events, cancer 
metastasis, inflammation and autoimmune diseases.180–182 In particular, platelets maintain 
fluidity of the circulating blood and become active to trigger clot formation in the event of 
wounds, thereby preventing the organism from bleeding to death. During cardiovascular 
thrombotic events, the number of platelets in circulation increases and, in addition, platelets are 
considered responsible for the formation of atherosclerotic plaques, inflammatory processes, 
immune responses, and play a role in neurodegenerative conditions.180–182 Similarly, platelets 
are important in cancer metastasis, where they help to tether circulating cancer cells, therefore 
increasing their invasiveness.183  
Platelet activation and lifespan are regulated by complex PPIs, the understanding of which has 
received increasing attention in recent years due to the relevance of this type of cell to many 
pathological conditions.184,185  
The proteins of the Bcl-2 family have a key role in regulating intrinsic apoptosis and the lifetime 
of platelets.167,178,186,187 The role of Bcl-2 proteins in platelet survival has been investigated using 
transgenic animal models, and more recently, BH3-only small molecule mimetics ABT-737, 
Navitoclax and ABT-199, that find application in oncology. Interested in the dose-limiting 
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thrombocytopenic side-effect of ABT-737 and its orally available analogue Navitoclax, Debrincat 
et al. investigated the effect of these Bad-like BH3 mimetics on platelet apoptosis.178 They found 
that the anti-apoptotic protein Bcl-xL is indispensable to platelet survival and its inhibition 
causes platelet death. On the contrary, ABT-199, a selective Bcl-2 inhibitor, does not cause 
platelet apoptosis. Similarly, concomitant depletion in mice of Bcl-2 and Mcl-1 was found not to 
be detrimental to platelet survival.178  
It is interesting to note that activated platelets go through apoptotic-like changes, and the 
apoptotic and activation pathways converge on the loss of mitochondrial membrane polarisation 
(MMP) and the occurrence of phosphatidylserine (PS) exposure (Figure 20). It is the essential 
roles of Bcl-2 proteins in regulating MMP that suggested they might have a central role in both 
platelet apoptosis and activation. However, the mechanistic differences between the apoptotic 
and activation signalling are poorly understood.179,188,189 The main divergences between the two 
pathways are described by Vogler et al.188 as follows, and these conclusions derived from the use 
of ABT-737 in platelets: 
- Bcl-2-mediated apoptosis is slower than Bcl-2-mediated platelet activation; 
- Activation of caspases is essential for apoptosis but not for activation, at least in the first 
stages of platelet activation to a pro-coagulant phenotype; 
- Platelet activation is a calcium-dependent mechanism, whilst apoptosis is not. 
 
Figure 20 - Exemplified differences between apoptosis and activation in platelets. Apoptosis (pink) is induced by ageing, 
stress, hypoxia etc. and activates the intracellular intrinsic pathway that culminates with loss of MMP, the release of 
cytochrome c from the mitochondria, activation of caspases, PS exposure. Activation (yellow) in response to agonist or 
collagen overlaps to some degree with the apoptotic pathway. Once active, the platelets change shape, release granules 
and expose glycoprotein receptors to facilitate aggregation at a later stage. The factors released by pro-coagulant 
platelet trigger the coagulation phase (green) that culminates with the clot formation enabled by fibrin. 
CHAPTER 2: Anti-apoptotic proteins – Bcl-2 
 
 
41 
 
In addition, Vogler et al. have shown that inhibition of the anti-apoptotic proteins Bcl-2 and Bcl-
xL by the Bad mimetic ABT-737 inhibits platelet activation whilst resulting in platelet apoptosis, 
supporting the hypothesis of distinct roles for the Bcl-2 proteins in platelet activation and 
apoptosis.188,190  
Once platelets are activated by agonists or adhesion to the collagen exposed on the blood vessel 
following an injury, they secrete granules (i.e. α- and dense granules) necessary to trigger the 
coagulation cascade, change shape, and expose glycoproteins (i.e. GPIIβ/IIIα). All these events are 
necessary for the fibrinogen binding and clot formation (Figure 20). 
Whilst the role of some Bcl-2 proteins in platelet survival and activation has been elucidated 
(Bad, Bcl-2), a deep understanding of the involvement of all the members of the Bcl-2 family in 
platelet apoptosis and activation is still missing. 
The lack of a nucleus in platelets makes the use of conventional recombinant techniques 
ineffective and hampers the study of PPIs, and hence the elucidation of intracellular pathways. 
As for nucleated cells, the use of small molecules to study PPIs can lead to selectivity problems 
due to the lack of specificity among related proteins.25 In addition, as highlighted earlier, the 
design and development of small molecules targeting a shallow protein-protein interface can be 
challenging.191 On the other hand, an alternative way to study PPIs in platelets is provided by the 
use of transgenic animal models. Nevertheless, the generation of such models is time-consuming, 
expensive, may be prone to side-effects during the development of the embryo, and may not be 
representative of the human situation.192  
The understanding of PPIs in human platelets could aid the discovery of selective and specific 
anti-platelet therapeutics which could find use in the treatment of cardiovascular diseases, 
inflammation and cancer therapy. Therefore, there is an unmet need for new, complementary 
and efficient approaches to study medicinally-relevant PPIs that can be used in human platelets 
directly overcoming the above-mentioned limitations. Macrocyclic peptides may be a suitable 
solution; however, there are no reports of their use in platelets.193 
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2.1.3. Brief considerations on selectivity 
The main problem associated with targeting anti-apoptotic proteins is selectivity. Whilst 
overexpressed in diseased cells, anti-apoptotic proteins are also present in healthy cells, and 
therefore, side-effects may be an issue. Off-target effects and unspecific cytotoxicity can be 
minimised by exploiting any small structural differences between the targeted protein in the 
diseased and healthy cells or by taking advantage of specific receptors on the surface of the 
targeted cell-type that may facilitate the entrance of the therapeutic agent. Biologics are often 
used to this end due to their high specificity, however, they suffer from poor PK properties, have 
high development costs, and can lead to immunogenicity;194,195 small molecules, on the other 
hand, can be more easily tuned to optimise their PK properties, but they often lack the high 
specificity of more complex macromolecules.24 This can lead to off-target effects. Such off-target 
effects can be minimised by taking advantage of allosteric sites that are not well conserved in a 
family of proteins.157 Short peptides sit in between these two categories of drugs, sharing the 
high specificity of biologics, and, if properly modified, the PK properties of small molecules. They 
can act at the interface of protein signalling, disrupting PPIs, thus targeting shallow and 
relatively large surfaces (800-2000 Å2), instead of deep binding pockets.3,25,40 
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3.1. Summary 
CK2 (formerly Casein Kinase II) protein kinase plays crucial roles in cell growth, cell 
proliferation, and apoptosis. It is overexpressed in a wide range of cancer cells, and due to the 
lack of compensatory mechanisms, CK2 inhibition is an attractive strategy used in oncology: the 
small molecule CX4945 is currently under phase II clinical studies.139,146 
This chapter describes the discovery of novel CK2 inhibitors targeting poorly-conserved binding 
sites within the α catalytic subunit to overcome the limitations of existing inhibitors namely, lack 
of specificity for CK2 and poor drug-like properties.  
Using a fragment-based drug-discovery (FBDD) approach, 3l and 3g were developed. 3l is the 
first selective CK2α inhibitor, with drug-like properties, that engages the cryptic αD pocket of 
CK2α and does not interact with the highly-conserved ATP-binding site (Figure 21). 3g is the 
first fragment-sized molecule that binds at the interdomain surface of CK2 and that could act as 
a starting point for the development of novel inhibitors of the holoenzyme assembly (Figure 21). 
 
Figure 21 - Previous and current approaches to develop CK2 inhibitors. Structures of compounds 3g and 3l are shown at 
the bottom of the figure.  
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3.2. Project background 
The Spring group and collaborators at the University of Cambridge became interested in 
developing novel CK2 inhibitors acting outside the ATP-binding site to engage this exciting 
target. Prior to the work described in this thesis, pioneering studies on CK2 inhibition using a 
FBDD approach were conducted by Dr Chris Stubbs in the Abell Group (Department of 
Chemistry, University of Cambridge)196 and Dr Paul Brear in the Hyvönen Group (Department of 
Biochemistry, University of Cambridge). An initial FBDD approach was adopted, and X-ray 
crystallography used to screen 400 fragments from the ‘NMRi fragment library’ developed in the 
Abell Group. The screening provided promising preliminary results, yielding several hits that 
showed promiscuity for several binding sites within the α catalytic subunit; interestingly, some 
fragments were found to bind at the α/β interface of the protein, whereas others revealed a new 
pocket in proximity to the αD helix, referred to as the αD pocket.197,198 It was therefore decided 
to optimise the fragments for the two above-mentioned binding sites in an independent manner 
in order to improve the binding affinity of the initial hits and, ultimately, avoid undesired 
promiscuity. Optimisation of the fragments binding at the protein interface was predominantly 
carried out by Dr Kathy Hadje Georgiou during her PhD in the Spring Group197 whereas, 
optimisation of fragments binding in the hidden αD pocket was performed by Dr Claudia De 
Fusco and Dr Laura Carro, Postdoctoral fellows in the Spring Group.  
3.2.1. Preliminary work on fragments binding in the αD pocket 
Although the αD pocket was mentioned in work by Kinoshita and co-workers,199 the full size of 
this pocket was only revealed upon binding of the fragments synthesised in the Spring Group 
(Figure 22). Considering the αD helix of CK2α is less conserved than the ATP site amongst 
related protein kinases of the CMGCj family,4 it was thought that this pocket could be exploited 
further to develop selective CK2α inhibitors. 
 
                                                          
i Library assembled for NMR screening of other targets. In this project, the library was screened by X-ray crystallography. 
j Family of kinases including CDK, CDKL, CK2, CLK, DYRK, GSK, MAPK. 
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Figure 22- X-ray crystallographic structures of fragments NMR154L and F5 in complex with CK2α. a) The opening of the 
αD pocket in the apo-structure (black dashed line), in the presence of glycerol (red dashed line) and NMR154L (grey 
surface). b) F5 binding in the pocket. c) Met163 is not able to displace the ATP when F5 binds. Figures adapted from 
Brear et al. ChemSci, 2016.198 
Following initial screening, the fragments that bound at the αD pocket, as confirmed by electron 
density seen in X-ray co-crystallography, were elaborated using iterative cycles of design, 
synthesis, and biological testing. The structure and binding affinity (Kd values obtained by ITC) 
of some of the fragments are shown in Figure 23. 
 
Figure 23 - Structure and binding affinity of some of the fragments synthesised prior to this work. The original hit 
fragment NMR154L is shown in pink, the highest affinity fragments obtained during the first round of elaboration are 
shown in green and the ones from the second round of optimisation are presented in yellow.  
In summary, using a FBDD approach the initial hit NMR154L was successfully elaborated into 
F6 with a Kd of 41 μM and a ligand efficiency (LE) of 0.38 Kcal mol-1 heavy atom-1.  
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Although the optimisation of the fragments improved the affinity due to their ability to expand 
the αD pocket, inhibition of CK2 activity was not observed. X-ray crystal structures of the 
molecules bound to CK2α showed that the residue Met163 did not flip to the ‘out’ conformation 
and did not displace the ATP from its binding site hence resulting in no inhibition of 
phosphorylation (Figure 22).198,200 Such a residue-flip is thought to be essential for the inhibition 
of the catalytic activity of CK2α. It was envisioned that growing the fragments towards the ATP-
binding site would allow for ATP displacement by triggering the Met163 flip while keeping the 
selectivity over other kinases by the interacting with the poorly-conserved αD pocket.198 To this 
end, a series of compounds bearing aliphatic, aromatic and heteroaromatic moieties were 
synthesised and testedk.200 The most promising compound, CAM4066 inhibited phosphorylation 
of CK2 substrates by successfully linking fragment F5 to a weakly binding ATP fragment via a 
flexible linker (Figure 24).198,200 
 
Figure 24 – Structure of CAM4066: the first CK2 inhibitor targeting the αD pocket and its biological evaluation. Initial 
fragments (F5 in blue and an ATP fragment in red), their biological data and X-ray structures are also shown. The linker 
used to link the two fragments together is shown in dark green in CAM4066. 
The ability of CAM4066 to arrest cell proliferation in cancer cells was comparable to that of the 
clinical candidate CX4945 (GI50 8.8 μM vs 4.8 μM respectively).139,198 However, CAM4066 proved 
to be more selective than the ATP-competitive inhibitors reported in literature: unlike CX4945, 
none of the closely related kinases of the CMGC family were inhibited by CAM4066.198  
Although CAM4066 was the first CK2 inhibitor to bind to the cryptic αD pocket, the compound 
presented several limitations. In particular, the molecule featured a high number of amide 
bonds, rotatable bonds, hydrogen-bond donors (HBDs) and acceptors (HBAs), and a drop-off of 
activity in cells which required the formulation as a methyl ester pro-drug (pro-CAM4066) to 
                                                          
k Synthesis performed by Dr Claudia De Fusco, Dr Kathy Hadje Georgiou, Dr Laura Carro; biological evaluation performed by Dr Paul 
Brear. 
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gain cell entry due the presence of the carboxylic acid. In addition, the compound still included a 
weakly-binding portion interacting with the highly-conserved residues of the ATP binding site.  
3.2.2. Preliminary work on fragments binding at the α/β interface 
It emerged from a literature search at the time that only three classes of molecules are reported 
to bind at the α/β CK2 interfacel:  
-DRB, a small molecule binding at the interface and at the ATP binding site;162  
-W16 and azonaphthalene derivatives for which no x-ray structural information is 
available;160,201  
-Pc peptide and its analogues, cyclic peptides with poor drug-like properties that can 
disrupt the interaction between the α and β subunits.161,164  
The limitations of these molecules regarding activity and drug-likeliness led the Spring group to 
further elaborate on NMR154L. Such a fragment was identified as hit from the initial X-ray 
screening and it was found to bind at the protein interface as well as in the αD pocket. The 
ultimate goal was to deliver drug-like chemical tools to study regulatory mechanisms of CK2 by 
acting at the interface. This fragment elaboration was carried out prior to the work described in 
dissertation, and in parallel to the optimisation of the αD fragments. Seventy fragments were 
synthesisedm elaborating from the initial molecule NMR154L, and some of them are represented 
in Figure 25.202 
                                                          
l For chemical structures vide 2.1.1.4 
m Synthesis carried out by Dr Kathy Hadje Georgiou and part III students Alexandra Lubin and William Green 
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Figure 25 - Some of the elaborated fragments made by previous members of the Spring group to develop CK2 inhibitors 
of the α/β interface. In yellow, substituents on the amine motif of NMR154L, in green substituents of the 4-chlorine atom, 
in pink substituents of the ethylamine group. 
Unfortunately, despite the many fragment elaboration steps carried out in the group, none of the 
molecules showed affinity below the high μM range. 
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3.3. Project aim and overview 
In this dissertation, the FBDD approach towards CK2 project aimed to overcome the limitations 
of CAM4066 to develop selective second-generation CK2 inhibitors targeting the αD pocket. In 
particular, the project aimed to develop drug-like molecules with a reduced number of rotatable 
bonds, HBDs, HBAs, able to inhibit CK2α without interacting with the well-conserved ATP 
binding pocket and that could exert their biological activity without needing to be administered 
as a pro-drug. 
This chapter describes the rational design, synthesis, and biological testing of the elaborated 
fragments binding to the αD pocket of CK2. We envisioned that the need for the interaction with 
the ATP binding site could be avoided and selectivity enhanced by increasing the affinity of the 
αD-binding motif of CAM4066. To this end, various substituents on the lower and upper 
aromatic rings of F5 were explored to interact with vacant parts of the αD pocket. The 
combination of the best substitution patterns and a fragment merging strategy resulted in the 
development of a second-generation CK2 inhibitor (3l) with improved drug-like properties. 
During the initial optimisation of the fragments for the αD pocket, some molecules were found to 
bind predominantly at the α/β interface of the CK2 protein. Their synthesis, biological testing, 
and X-ray crystallographic structures are described in this chapter. 
An overview of the molecules subject of this chapter is provided in Scheme 4.  
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Scheme 4 - Overview of the molecules discussed in this chapter. Compounds shown in black were found to bind in the αD 
site, compounds in grey were found to bind predominantly at the protein interface. The compounds are grouped 
according to the rationale behind their design and synthesis. 
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3.4. Results and discussionn 
All of the compounds were synthesised and co-crystallised with CK2α, and the results are 
reported in this section. The fragments that showed electron density in the αD pocket or at the 
α/β interface were further tested in assays to determine their affinity for the protein as well as a 
phosphorylation assay to assess their ability to inhibit the catalytic activity of the protein. Ligand 
Efficiency (LE) was also calculated in order to assess the relative-quality of the fragments. 
Biological testing and X-ray crystallography were carried out by our collaborator Dr Paul Brear 
in the Hyvӧnen group, Biochemistry Department, University of Cambridge.  
The molecules whose synthesis and biological evaluation are described in the following 
paragraphs were synthesised according to the generic synthetic route adapted from previous 
reports198 and outlined in Scheme 5.  
 
Scheme 5 – Generic synthetic route leading to the molecules synthesised in this project. 
The appropriately substituted aryl derivative 1 underwent a Suzuki cross-coupling reaction with 
the desired aryl boronic acid or ester to afford the biaryl of generic structure 2. Intermediate 2 
was reduced in its nitrile or aldehyde functionality to afford the desired final amine of generic 
structure 3. 
3.4.1. Fragments exploring vacant parts of the αD pocket 
3.4.1.1. 1-Methanamine, 3-chloro biaryl fragments: 3a-3e 
The X-ray structure of F5 and F6 (synthesised by Dr Kathy Hajde Georgiou and Dr Laura Carro 
prior to this work) co-crystallised with CK2α provided the basis for the design of compounds 3a-
3e. In particular, functional groups with different properties were employed with the aim of 
exploring the vacant part of the αD pocket (Figure 26). It was envisioned that the affinity of the 
                                                          
n The work described in this chapter has been published in scientific journals. In particular, the synthesis and biological evaluation of 
compounds 3a-3d and 3i-3l have been reported in Iegre et al., ChemSci, 2018206 and the synthesis and biological evaluation of 
compound 3g has been published in Brear et al., BMC, 2018.202 Part of the text and figures presented in this chapter has been adapted 
from the above-mentioned publications. 
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fragments could be enhanced by engaging additional interactions within the said pocket. The 
availability of the starting materials was also a factor influencing the design. 
 
Figure 26 – Chemical structures (a) and co-crystal structures of F5-F6 in the αD pocket showing the pocket expansion 
going from F5 (b) to F6 (c).  
The first step of the synthetic route leading to the 1-methanamine, 3-chloro biaryl fragments 
was envisioned to be a Sukuki-Miyaura cross-coupling between 2-chloro benzonitrile of generic 
structure 1 and the appropriate boronic acid to afford the biaryl derivative 2. Nitrile reduction of 
2 would yield the desired amine 3 (Scheme 6).198 
 
Scheme 6 – Generic synthesis of 1-methanamine, 3-chloro biaryl fragments of generic structure 3. 
The Suzuki-Miyaura step required optimisation as initial attempts to synthesise the first biaryl 
intermediate 2a following previously reported procedures198 resulted in low yields (Table 5). 
3-chloro-4-bromo-benzonitrile and 2-isopropylphenyl boronic acid were employed as 
substrates in the presence of Pd(PPh3)4, Na2CO3, and DME according to literature precedent.203 
However, the reaction did not proceed to complete conversion, and several unidentified 
impurities were formed, which proved inseparable from the desired product via column 
chromatography. We attempted to reduce the amount of by-products by varying reaction time 
(between 1 and 3 h), catalyst equivalents (0.005 and 0.010) or type of heating (microwave 
irradiation and thermal). Pleasingly, the desired product 2a was obtained in good yield (85%) 
when the reaction was performed using the triflate derivative of 1 (1a hereinafter) and thermal 
heating (entry 6, Table 5). The same reaction performed under MW irradiation gave the desired 
product 2a in poorer yield (entry 4, Table 5).  
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Table 5 - Optimisation of Suzuki coupling conditions to obtain compound 2a. 
 
Entry R 
Catalyst 
equivalents 
Heating Temperature 
Reaction 
time 
Results 
1 -Br 0.01 MW 130 °C 3 h 
Aryl bromide/ 
unidentified impurity 
2 -Br 0.005 MW 130 °C 1 h 
Aryl bromide/ 
unidentified impurity 
3 -Br 0.005 MW 110 °C 2 h Unidentified impurities 
4 -OTf 0.005 MW 130 °C 2 h 20% conversion to 2a 
5 -Br 0.005 Thermal 90 °C 3 h Unidentified impurities 
6 -OTf 0.005 Thermal 90 °C 3 h 85% conversion to 2a 
 
These optimised cross-coupling conditions employing 1a were successfully applied to the 
synthesis of the biaryl fragments shown in Table 6. Compound 1a was obtained in 91% yield by 
treating the commercially available 4-hydroxy-3-chloro-benzonitrile with Tf2O in pyridine 
(Table 6).204 
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Table 6 - Compounds obtained using the same Suzuki-Miyaura reaction conditions shown in entry 6, Table 5. 
 
Entry Compound number Ar, R Yield (%) 
1 2b 
 
61 
2 2c 
 
67 
3 2d 
 
97 
4 2e 
 
90 
 
Nitrile precursor 2c was obtained via Suzuki cross-coupling using the same conditions as 
described above with the exception that the corresponding pinacol boronic ester was used 
instead of the boronic acid for commercial availability reasons. In all Suzuki couplings described 
in Table 6, by-products tentatively assigned to be the result of incorporation of phenyl groups 
from PPh3 in the products were obtained in small amounts, as previously reported.205 Traces of 
the de-boronated derivative of the boronic acid were also found in most cases. 
The nitrile groups of the obtained biaryl fragments (generic structure 2, Scheme 6) were 
reduced to the corresponding primary amines 3 by treatment with LiAlH4 and AlCl3 in Et2O.197 
For compounds stable in acidic conditions, the corresponding amines were converted into 
hydrochloride salts using 4 M HCl in 1,4-dioxane. The salt proved to have greater kinetic 
solubility in the aqueous buffer used in biological testing than the corresponding free amines 
(Table 7).  
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Table 7 - Results of the nitrile reduction steps (entries 3 and 5) and treatment with HCl (entries 1, 2 and 4). 
 
Entry Compound number Ar R Yield (%) 
1 3a 
 
-NH3+Cl- 77a 
2 3b 
 
-NH3+Cl- 43a 
3 3c 
 
-NH2 55b 
4 3d 
 
-NH3+Cl- 32a 
5 3e 
 
-NH3+CF3COO- 54b 
a overall yield of nitrile reduction and salt formation; b yield of the nitrile reduction only 
 
Moderate yields could be attributed to the formation of the de-chlorinated analogues as 
observed by 1H-NMR analysis of the crude reaction mixture, as well as a small amount of 
unreacted starting material and loss of mass during the purification step.o  
Treatment of 3c with HCl led to degradation of the compound, most likely by polymerisation at 
the indole 3-position as shown by the lack of signal of the corresponding proton of the indole 
(NMR analysis of crude mixture). 
                                                          
o The amines synthesised were purified either on silica gel or aluminium oxide gel by flash chromatography. Silica gel was chosen 
over aluminium oxide due to its better separation potential. When this purification method was chosen, silica was deactivated using 
various percentages of 7 M NH3 in MeOH in the eluent. However, due to the nature of silica gel and the polarity of the amine, an 
amount of product was inevitably lost in the purification due to the streaking of the compound through the column. For purifications 
where the difference between Rf of the impurities and the product was greater than 0.05, aluminium oxide was used as stationary 
phase and the streaking of the compounds was minimal. 
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Compound 3e was submitted for crystallisation as a trifluoroacetate salt since its corresponding 
amine was purified via preparative HPLC using acidic conditions (0.05-0.1% TFA). Purification 
of this compound using reversed-phase preparative HPLC was possible due to its increased 
polarity. 
The so-obtained compounds were co-crystallised with CK2α. The electron density for compound 
3a was observed at both the αD pocket and at the α/β interface showing promiscuity and partial 
occupancy of each site (Figure 27a-b). However, its binding mode in the αD pocket suggested the 
possibility of exploiting a space that opened up around the 6’ position of the bottom ring in 
addition to the usual 2’ position (Figure 27a).  
The X-ray structures of 3b and 3d showed the compounds adopting the typical binding modes 
for these fragments in the αD pocket. Unlike the other fragments, the top aromatic ring of 3d 
seems to rotate as shown by the electron density for the chlorine atom observed at both the 3 
and 5 positions (Figure 27c). 
 
Figure 27 - Crystallographic structure of 3a (PDB code: 5OS7),206 3c, 3d (PDB code: 5OS8),206 and 3e binding to CK2α. a) 
3a in the αD pocket; b) 3a at the interface; c) 3d in the αD pocket; d) 3c showing two different binding modes (blue and 
green) in the αD pocket; e) Fragment 3e binding at the interface. The protein surface is represented in grey, secondary 
structure as cyan ribbons and ligand in green or blue. The H-bonds between the ligands and the Val162 are represented 
as white dashed lines. 
The amine remains in the same position as the other fragments creating an H-bond interaction 
with the carbonyl of Val162 indicating that this is a strong interaction and an anchor point for all 
the fragments (Figure 27c). Interestingly, the X-ray structure of 3c showed two different binding 
modes in the αD site (Figure 27d). One of these poses (blue, Figure 27d) sees the indole motif 
closer to the αD helix while the other (green, Figure 27d) resembles the binding mode 
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characteristic of the biphenyl fragments previously synthesised in the Spring group. The 
combination of these two poses suggested that exploring different aromatic substituent patterns 
on the benzylamine core such as 3-indole-phenyl-methanamine derivatives might be beneficial 
(vide infra 3.4.1.3). 
Biaryl fragments bearing H-bond donor/acceptor substituents at the 2’ methyl position such as 
3e appeared to bind weakly at the α/β interface, and no electron density was observed at the αD 
site (Figure 27e). X-ray crystallography for compounds 3a-3d showed electron density in the αD 
pocket, and therefore, their binding affinity was determined via isothermal titration calorimetry 
(ITC). The results are shown in Table 8. 
Table 8 - ITC and LE of the biaryl fragments F5, 3a-3d. 
Entry Compound number Fragment LE Kd (μM) 
1 F5 
 
0.32 267 
2 3a 
 
0.27 300 
3 3b 
 
0.38 17 
4 3c 
 
>0.25 > 500 
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5 3d 
 
0.32 105 
Pleasingly, fragment 3b showed a significant enhancement in binding affinity compared to F5 
with a Kd of 17 μM representing the fragment with the highest binding affinity and LE of the 
whole series. Unfortunately, fragments 3a and 3c did not show improved binding affinity 
compared to F5 whilst 3d provided a slight improvement. However, their binding modes proved 
to be useful for the design of other fragments. The binding affinity of 3e for CK2α was not 
measured due to the weak electron density observed in the X-ray structure.  
3.4.1.2. Biaryl compound bearing a 5-membered heterocyclic substituent: 3f 
X-ray structures of commercially available and previously synthesised fragments – i.e. 3b and F7 
– led to the proposal of a new biphenyl fragment bearing a 2-methyl-5-membered heterocycle 
on the bottom aromatic ring (Figure 28). By merging the two classes of compounds, it was 
envisioned that new interactions with the protein could be engaged. Docking studies were 
performed to establish the likelihood of these compounds to bind in the αD pocket.p The results 
showed that the proposed compound 3f may lead to the heterocyclic ring expanding the αD 
pocket. 
 
Figure 28 – Fragment merging strategy. a) Overlap of compound 3b (blue) and F7 (green) made by Dr C. De Fusco. b) 
Docking pose of 3f (purple) as a result of the merging of the previously mentioned fragments. CK2α is shown as a cross-
section of the αD pocket. Protein surface is shown in grey. 
                                                          
p Structures of the other compounds docked can be found in the appendix A.3. 
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With the docking study in hand, synthesis of 3f was commenced. In the first synthetic route 
attempted (Scheme 7) the synthesis of 3f started from a cross-coupling reaction between the 
commercially available 2-N-Boc-methanaminebenzeneboronic acid and compound 1a to afford 
biaryl nitrile intermediate 2f.  
 
Scheme 7 - Synthetic route attempted to the synthesise the heterocycle derivative 3f. 
Compound 2f was then treated with HCl to remove the Boc group, and the reaction mixture was 
basified to obtain compound 2f ’ as the free amine. The biphenyl compound was subjected to 
Clauson-Kaas reaction207 in the presence of 2,5-dimethoxytetrahydrofuran and glacial acetic acid 
to afford the corresponding pyrrole derivative 2f ’’ in a 15% yield. Unfortunately, this proved to 
be unstable in the presence of AlCl3, which was used as a Lewis acid catalyst in the subsequent 
attempted nitrile reduction. Reduction in the absence of the Lewis acid also failed to yield the 
desired product 3f and only starting material was returned. An alternative nitrile reduction was 
carried out using H2 in the presence of Raney Nickel to afford trace amounts of impure 3f.  
Considering the elevated cost of the boronic acid required and the low yield of the final two 
steps of the synthetic route, an alternative pathway was used to introduce a 5-membered 
heterocycle into the 2’ position of biphenyl fragments (Scheme 8). The new synthetic pathway 
commenced with a Suzuki coupling between 1a and (2-(hydroxymethyl)phenyl)boronic acid to 
afford biaryl compound 2e, which was subjected to nucleophilic substitution in the presence of 
N-bromosuccinimide.208 The corresponding bromide derivative 2f ’’’ was synthesised in large 
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amounts to allow for potential subsequent diversification. Compound 3f was obtained from 2f ’’ 
upon reaction of 2f    ’’’ with pyrrole in the nucleophilic substitution, followed by nitrile reduction 
using Raney Nickel.209 Due to the potential instability of pyrrole product 3f under acidic 
conditions, the compound was submitted for testing as the free amine. 
 
Scheme 8 - Synthetic route to compound 3f. 
Unexpectedly, X-ray crystallography of compound 3f revealed that only weak electron density 
was observed at the interface and no binding was detected in the αD pocket. Considering these 
results, the biological evaluation of compound 3f was not pursued, and the synthesis of 
analogues not attempted. 
3.4.1.3.  3-Indole-phenyl-methanamine derivatives: 3g and 3h 
The two poses found in the X-ray structure of 3c (Figure 27d) suggested investigating a new 
design set. Docking studies were performed to explore different aromatic substituent patterns 
on the benzylamine core and their ability to push the αD helix outwards.q This strategy was 
regarded as promising since the flexibility of the α-helix is unique to CK2,198 and therefore this 
may help improve the selectivity of the compounds. For compound 3g docking gave promising 
                                                          
q Structures of the other compounds docked can be found in the Appendix A.3. 
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results, the docked compound overlapped with the X-ray structure of compound 3c, and the 
nitrogen of the indole was able to H-bond the carbonyl of the Met255 via a water molecule 
(Figure 29).  
 
Figure 29 - Docked 3g (purple) and X-ray structure of 3c (ligand in blue and protein in cyan).  
 
Compound 3g was synthesised in the hope that this could give information on the tolerability of 
the indole in the 5-position of the aryl ring prior to synthesis of more hindered compounds. 
The synthesis of 3g (Scheme 9) commenced with a Suzuki-Miyaura cross-coupling between 
indole-3-boronic acid pinacol ester and 3-chloro-5-bromobenzonitrile to afford 2g in 48% yield. 
A slightly higher yield (55%) was achieved when the corresponding boronic acid was used in the 
presence of Pd2(dba)3, PCy3 and K3PO4. The choice of reaction conditions was determined on the 
basis of substrate similarity with literature procedures.210 The nitrile group in 2g was then 
reduced with LiAlH4 and AlCl3 to yield the desired product 3g in 79% yield. 
 
Scheme 9 - Synthesis of compound 3g commencing from the commercially available starting material. 
Attempted purification using silica gel on flash chromatography or preparative HPLC of the final 
compound led to degradation of the molecule. It was hypothesised that the degradation was due 
to the acidic nature of the silica gel and mobile phases of the HPLC respectively. Therefore, 
purification was successfully performed via flash chromatography on aluminium oxide under 
basic conditions. The methylamine 3g was submitted for testing as the free-base because, as 
seen for 3c, treatment with acidic solution led to polymerisation at the 3-position of the indole 
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as shown by lack of signal of the proton at the 3-position of the indole (NMR analysis of the 
crude mixture). 
Unexpectedly, co-crystallisation of compound 3g with CK2α showed electron density at the 
interface, with the chlorine atom buried in the lipophilic Phe pocket, much deeper than the 
fragments binding at the interface studied thus far (Figure 30). Weak electron density only was 
observed in the αD pocket.  
 
Figure 30 -Overlay of the X-ray structures of 3g (green, PDB code: 6GIH)202 and 3a (blue, PDB code: 5OS7)206 showing 
how 3g binds deeper into the Phe pocket. 
The fact that the chlorine atom of 3g bound deeply in the Phe pocket resulted in a considerable 
boost in potency. In addition, the compound was able to displace a CK2β-like probe in a 
Fluorescent Polarisation assay (FP) with an IC50 of 44 μM. Pleasingly, compound 3g represented 
the highest affinity fragment binding at the α/β interface developed during our FBDD research.  
3g appeared to be the first CK2 inhibitor acting at the α/β interface with fragment-like 
properties reported in the literature, and therefore, it could be further developed into a drug-
like molecule with high potency and selectivity against CK2 (Table 9).202 
Table 9 - Fragment-like properties of 3g and other known small molecules acting at the α/β interface of CK2. Adapted 
from Brear et al., BMC, 2018.202 
 Property Ideal Range DRB162 W16160 3g 
 
FW <300 319 611 257 
TPSA ≤ 60  87.7 133 41.8 
HBA ≤3 6 11 2 
HBD ≤3 3 1 3 
NRB ≤3 5 7 3 
ATP No Yes No No 
 FW: formula weight in g/mol, TPSA: polar surface area in Å2, HBA: hydrogen-
bond acceptors, HBD: hydrogen-bond donors, NRB: number of rotatable 
bonds, ATP: does the compound bind in the ATP pocket of CK2. Green is 
within the ideal range; amber is within 15% of ideal range; red is over 15% 
from ideal range. 211 
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Considering the binding mode of 3c showed the potential of 3g pushing the αD helix outwards, it 
was decided to synthesise compound 3h – analogue of compound 3g bearing a trifluoromethyl 
group as replacement of the chlorine. In addition, compound 3g showed weak electron density 
in the αD pocket, and it was envisioned that the chlorine-to-trifluoromethyl in 3h would 
abrogate the binding of the molecule at the interface in favour of an enhanced binding in the αD 
pocket considering previous reports.197  
As reported in Scheme 10, synthesis of 3h followed the same synthetic steps and conditions as 
3g except for the nitrile reduction which was performed using hydrogenation with Raney 
Nickel212 due to –CF3 lability in the presence of LiAlH4 and AlCl3. 
Scheme 10 - Synthesis of compound 3h starting from the commercially available starting material. 
Suzuki cross-coupling between the commercially available 3-bromo-5-
(trifluoromethyl)benzonitrile and indole-3-boronic acid in the presence of Pd2(dba)3 and PCy3 
afforded intermediate 2h in 35% yield; 2h was then reduced to the desired compound 3h using 
H2 and Raney Ni (28% yield).  
The introduced trifluoromethyl group decreased the binding affinity for the α/β interface, as 
shown by the poor electron density observed in the X-ray structure, yet, no electron density for 
the compound was observed in the αD pocket. Other compounds binding in the αD pocket gave 
more promising results than the 3-indole-phenyl-methanamine derivatives, and therefore, it was 
decided not to pursue the synthesis of this series of compounds further.  
3.4.1.4. Dichloro-biaryl derivatives: 3i and 3j 
The crystal structures of fragments F5, F6 and 3d binding to the αD pocket showed two binding 
poses that only differ by the position of the chlorine atom, suggesting that slow rotation of the 
biaryl bond occurs. It was envisioned that 3,5-dichloro-biphenyl fragments might result in a 
reduction of the entropy of binding by preventing free rotation around the biaryl bond and 
therefore a decrease in binding energy. 
The first dichloro derivative synthesised was 3i, an analogue of F5, whose synthesis was 
achieved as shown in Scheme 11. 
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Scheme 11 - Steps leading to the dichloro derivative 3i. 
Compound 1b was obtained from the commercially available phenol derivative using Tf2O and 
pyridine; the same conditions successfully used to synthesise compound 1a.204 However, the 
yield of the phenol triflation (74%) was lower than for 1a (91%) probably due to the steric bulk 
around the hydroxyl group. The cross-coupling of 1b with phenylboronic acid to produce the 
essential precursor 2i proved challenging, and a few Suzuki coupling conditions were screened 
as reported in Table 10.  
Table 10 - Suzuki coupling conditions screened to obtain 2i. 
Entry Starting material Catalyst Base 
Reaction 
time 
Outcome Yield  
1 Boronic acid Pd(PPh3)4 Na2CO3 16 h 
Very little desired 
product, 3 unknown 
impurities 
<5% 
2 
Pinacol boronic 
ester 
Pd(PPh3)4 Na2CO3 30 min 
2 unknown aromatic 
by-products 
0% 
3 Boronic acid PdCl2(dppf) K3PO4 2 h (MW) 
Desired product, 
aromatic impurity 
24% 
The use of PdCl2(dppf)·CH2Cl2 in the presence of K3PO4 in DME, EtOH and H2O (entry 3, Table 10) 
appeared to be the best set of conditions.213 The low yield observed was attributed to the loss of 
the desired product during purification. The Rf of the desired product was very similar to an 
unidentified impurity formed during the reaction. Flash chromatography using different solvent 
systems failed to separate the two molecules, which were partially separated using preparative 
TLC.  
Nitrile reduction of 2i with LiAlH4 and AlCl3, followed by treatment with HCl afforded 3i in 48% 
yield (Scheme 11). 
In parallel, it was decided to synthesise the dichloro analogue of the highest affinity fragment 3b. 
The synthesis of 3j started from the 3,5-dichloro-4-hydroxybenzaldehyde which underwent 
treatment with Tf2O and pyridine in CH2Cl2 to afford 1c in 57% yield. Attempts using the 
corresponding nitrile in the Suzuki coupling failed. Coupling using 1c and 2-ethyl-phenylboronic 
acid afforded the intermediate 2j that could not be isolated due to its Rf similar to that of 
unidentified impurities formed. The so-obtained crude compound underwent a reductive Boc 
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amination in the presence of tbutylcarbamate and Et3SiH in TFA to afford 3j in 37% overall yield 
(Scheme 12). 
Scheme 12 - Synthetic steps leading to the dichloro derivative 3j. 
Pleasingly, in crystallisation studies compounds 3i and 3j were the first fragments able to open 
the αD pocket of the more rigid construct of the protein.r In the X-ray structures (Figure 31), the 
bottom ring is twisted 90° relative to the upper aromatic ring. As expected, only one binding 
mode was detected for these compounds suggesting that the two chlorine atoms help to lock the 
molecule in a twisted conformation reducing the rotational freedom of the aromatic rings. 
 
Figure 31 – a) X-ray structures of compound 3i (blue, PDB code: 5OTR)206 and 3j (green, PDB code: 5OTZ)206 co-
crystallised with CK2α. b) Zoomed-in section showing the fragments are not able to flip the Met163 and displace the ATP 
(blue) from its binding site. Protein is shown as cyan ribbon and grey surface. 
Pleasingly, the biological evaluation of compounds 3i and 3j showed a remarkable boost in 
binding affinity compared to the fragments tested thus far (Table 11). Moreover, the LE was also 
improved. 
 
 
                                                          
r For more details about the different constructs used vide 8.1.1. CK2α_KA presents a more flexible β4-β5 motif and αD helix whereas 
CK2α_FP is more rigid.  
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Table 11 - LE and Kd of dichloro derivatives 3i and 3j. 
Compound Structure LE Kd (μM) 
3i 
 
0.42 12 
3j 
 
0.39 6.5 
 
3.4.2. Fragments growing towards the ATP binding site: second-generation CK2 
inhibitors 
Compounds 3i and 3j showed the highest binding affinity and the best LE for the αD pocket over 
the fragments synthesised in the Spring group during the fragment elaboration phase. These 
molecules were not able to inhibit the catalytic activity of CK2 as they did not flip the Met163 
and hence displace the ATP; therefore, they were used as the bottom part of the second-
generation inhibitors. The αD fragments were merged with a benzimidazole fragment that binds 
at the ATP mouth without interacting with conserved residues within the ATP binding site to 
achieve inhibition.206 Optimisation of the benzimidazole fragment was carried out by Dr Claudia 
De Fusco in the Spring group. Unlike CAM4066, it was envisioned that CK2 inhibition could be 
achieved without the need of a fragment binding at the ATP pocket considering the affinity of the 
αD fragment was significantly improved respect to fragment used in CAM4066 (F5 Kd = 267 μM 
vs Kd = 6.5 and 12 μM for 3j and 3i respectively).198 It was decided to merge compounds 3i and 
3j with the benzimidazole motif as an attempt to achieve CK2 inhibition.  
Synthesis of 3k followed the synthetic route reported in Scheme 13. We were gratified to find 
that when 1c was reacted with phenylboronic acid under thermal heating using PdCl2(dppf) 
CH2Cl2, K3PO4, DME, EtOH, and H2O compound 2k was obtained in a superior yield of 54% 
compared to the 24% obtained when the corresponding nitrile (1b) was used (Scheme 11).  
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Scheme 13 – Synthetic route to compound 3k. 
Intermediate 2k underwent a reductive amination in the presence of commercially-available 2-
benzimidazolyl-ethylamine and NaBH(OAc)3, followed by acidification, to afford compound 
3k.214 
Compound 3l was synthesised in a similar way to compound 3k with the exception that isolation 
of the biaryl aldehyde intermediate 2j was not possible, as observed in the synthesis of 3j. The 
crude was therefore carried onto the reductive amination step, and the resulting amine purified 
via preparative HPLC to afford 3l as TFA salt with 13% overall yield (Scheme 14). 
 
Scheme 14 - Synthesis of Second-generation inhibitor 3l. 
The crystallographic structure of 3k and 3l confirmed the expected binding mode with Met163, 
whose position is thought to be essential for the inhibition, flipped into the ‘out’ conformation to 
displace the ATP. As hoped, the benzimidazole motif binds at the mouth of the ATP binding site 
without interacting with residues in the ATP binding site (Figure 32). 
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Figure 32 - Binding mode of 3l as detected in the X-ray crystal structure (PDB code: 5OTZ).206 The molecule occupies the 
αD pocket and the channel connecting it to the ATP binding site. A zoomed-in section of the Met163 in the flipped-out 
position is shown on the right. 
Compound 3k proved to be insoluble under ITC assays condition and in the cell growth media, 
and therefore its biological evaluation was not possible. 
Compound 3l showed improved solubility compared to 3k, but it was still not soluble enough to 
perform ITC direct binding experiments which require a high concentration of the compound. 
Therefore, ITC competition studies were performed (by Dr Paul Brear) to confirm the binding 
mode and to estimate the affinity of 3l for the αD site. Probe molecules that have well 
characterised binding modes and affinities were titrated into CK2α in the presence of 3l. In 
particular, the following experiments were performed, and the following observations were 
made: 
-20 µM 3l inhibited the binding of CAM4066 (first-generation inhibitor) to CK2α. 
-Compound 3j was titrated into CK2α in the presence of 20 µM 3l. This showed that 3l 
inhibited the binding of 3j to CK2α confirming that the binding site of 3l is the αD pocket.  
-2-hydroxyl-5-methyl benzoic acid is a fragment that binds to the conserved Lys68 in the 
ATP site and occupies the right-hand side of the pocket. The binding of this compound 
was not inhibited by 3l confirming that the benzimidazole ring does not interact with the 
right-hand side of the ATP pocket and validates the binding mode derived from the 
crystal structure.  
-CX4945, which from the analyses of crystal structures would clash with 3l in the hinge 
region, was titrated into CK2α in the presence of 3l. 3l was able to inhibit the binding of 
CX4945 to CK2α. This confirmed that the benzimidazole ring flips the Met163 channel 
and blocks access to the ATP site inhibiting the binding of CX4945. 
These competition experiments suggested that the Kd of 3l towards CK2α is approximately 4 µM 
and confirmed that the binding mode of 3l in the αD pocket and mouth of the ATP site 
corresponds to that seen in the crystal structure.206  
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Compound 3l was able to inhibit the CK2 catalytic activity with an IC50 of 7 μM (in vitro 
phosphorylation assay) and a GI50 of 10.0 ± 3.6 μM (cellular assay using HCT116 cells). 
Pleasingly, 3l was able to inhibit the phosphorylation of specific CK2 substrates in a cellular 
context as shown in Figure 33. 
 
Figure 33 – Bioactivity of 3l in cancer cells. a) Dose-response curve for the inhibition of growth of HCT116 cells by 3l, 
pro-CAM4066 and CX4945. Compound concentrations on the x-axis are shown as natural logarithm. All graphs show the 
mean ± SEM of not less than three independent experiments with each in triplicate. b) Western blot analysis showing the 
specific CK2 phosphorylation targets: AKT1 Ser129 and G6DPH. HCT116 cells were treated with 2 × GI50 of CX4945 (20 
μM), 3l (20 μM) or pro-CAM4066 (20 μM) for 72 hours. Adapted from Iegre et al., ChemSci, 2018.206 
3l was subjected to a kinase selectivity panel (Dundee Kinase panel) at 30 μM concentration (4 x 
IC50) to prove that CK2 inhibition from the αD pocket can lead to a more selective inhibitor than 
ATP-competitive compounds. Pleasingly, despite the relatively high concentration used, 3l 
showed good selectivity against 20 closely related kinases (CMGC family, Figure 34a). Even 
though for 4 kinases – CAMK1, SmMLCK, EF2K, SGK1 – out of 140 3l causes more than 50% 
inhibition, the compound showed a more selective profile compared to known CK2 ATP-
competitive inhibitors (Figure 34b). 
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Figure 34- Kinase selectivity panel for 3l. a) Selectivity profile of 3l at 30 µM concentration against closely related CMGC 
family members; b) Selectivity profile of 3l at 30 µM against a panel of 140 kinases. Kinases inhibited by 3l by more than 
50% are highlighted in red. Kinases inhibited by more than 70% by previously reported CK2 kinase inhibitors (namely 
CX4945, D11, TF, CX5279, 7h) are shown as coloured dots. Adapted from Iegre et al., ChemSci, 2018.206 
The ultimate goal of this project was to develop second-generation CK2 inhibitor with improved 
properties in respect to CAM4066. Compound 3l was successful in that as it overcame the 
limitation of the first-generation inhibitor as shown in Table 12. 
Table 12 - Properties and structural features of compound 3l compared to CAM4066.  
Taken from Iegre et al., ChemSci 2018.206 
 
Property Ideal range CAM4066 3l 
FW <500 494 453 
TPSA <140  101 41 
NRB <10 12 8 
HBA <10 4 2 
HBD <5 3 2 
Conserved interaction No Yes No 
Need of a pro-drug No Yes No 
Amide bonds No Yes No 
Drop in potency* No ~10 fold No 
 FW = formula weight in g/mol; TPSA = topological polar surface area in Å2 NRB 
= number of rotatable bonds; HBA = number of hydrogen bond acceptors; HBD 
= number of hydrogen bond donors.211 * Drop in potency between enzymatic 
and cellular assays. 
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3.5. Conclusions and future work 
The work described in this chapter led to the development of 3l: the first CK2 inhibitor that 
targets the allosteric αD pocket and that does not interact with highly conserved residues 
located in the ATP site hence providing selectivity.  
3l was developed using a FBDD approach starting from F5, a fragment with 267 μM affinity for 
the αD pocket. Through iterative cycles of design, synthesis, X-ray crystallography and 
biophysical evaluation the initial fragment was first elaborated into 3j (Kd 6.5 μM) and 
subsequently linked to a benzimidazole-like motif to reach the mouth of the ATP binding site 
and flip the Met163 - a residue seen as important for the catalytic activity. The merging strategy 
adopted in this work led to 3l which was able to bind to CK2α with a Kd of 4 μM, inhibit CK2 in 
vitro (IC50 7 μM), inhibit growth of colorectal cancer cells (GI50 10 μM) and showed promising 
selectivity for CK2 versus 140 other kinases.  
This work showcases the successful application of FBDD to overcome the limitation of the first-
generation inhibitor CAM4066. Compared to CAM4066, 3l presents a reduced number of 
rotatable bonds, HBDs, HBAs, does not contain amide bonds, and it maintains its activity in cells 
without the need of being formulated as a pro-drug.  
In conclusion, 3l present itself as an ideal chemical tool that can be further elaborated into a 
drug molecule. Pleasingly, APOLLO therapeutics became interested in the project and are now 
running a drug-discovery programme to pursue this project further. 
In addition, during the fragment optimisation carried out in this study, a few fragments were 
found to bind at the protein interface predominantly. One of them, 3g was found to bind deep in 
the Phe pocket – the only pocket present at the shallow interface – and it proved to be able to 
displace the CK2β-like probe with an IC50 of 44 μM. 3g is, therefore, the most promising 
fragment binding at the interface with structural information available reported in the literature. 
Due to its fragment-like properties, 3g is an ideal starting point to develop small molecule 
modulators of the CK2 interface. Considering the high number of attempts in the Spring group 
prior to this work to develop high-affinity fragments binding at the interface, it was decided not 
to optimise 3g further.  
Instead, as a continuation of this project, Chapter 4 describes the development of 
conformationally-constrained peptides binding at the α/β interface.  
Furthermore, additional fragment screenings of Diversity-Oriented-Synthesis (DOS) libraries are 
underway in the Spring group to identify novel sp3 reach molecules to disrupt the CK2 PPI.
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4.1. Summary 
The development of molecules able to disrupt the protein-protein interaction (PPI) between the 
α and the β subunits of the protein kinase CK2 has received increasing interest in the last few 
decades.160-164 However, the discovery of a selective, tissue permeable, and stable chemical tool 
that could act at the protein interface and that could be used in vivo is still missing.  
This chapter describes the approach used to efficiently develop peptides acting at the CK2α/β 
interface that are highly functionalised, cell-permeable, stable in serum, and with structural 
information available (Figure 35). The lead probe developed in this work, P7-F1C5, should be of 
great help in understanding the regulatory mechanisms behind CK2 and their implication in 
oncogenesis. 
 
Figure 35 – Functionalised stapled peptide P7-F1C5 described in this chapter. 
Whilst the approach described herein is specific to CK2, a similar strategy could be applied to 
any target needing the fast development of highly functionalised peptide modulators of PPIs. 
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4.2. Project background 
A limited number of small molecules have been developed before this work - namely DRB, W16, 
and azonaphthalene derivatives (structures shown below)160, 162, 201 - with the aim of inhibiting 
CK2 by acting at the protein interface.  
 
However, due to the nature of these small molecules and the characteristics of the interface, 
none of the compounds developed to date is selective for the interface. In some cases, structural 
evidence of the binding at the protein interface is also missing. 
In the Spring group efforts have focused on the development of inhibitors of the CK2 α/β 
interface using a Fragment-Based Drug Discovery approach (FBDD) approach. However, the best 
fragment 3g, whose development is described in Chapter 3, needs to be elaborated further in 
order to identify a higher affinity molecule to act as a useful chemical tool. 
On the other hand, Cochet et al. have used the sequence of the tail of the regulatory CK2β domain 
to design a cyclic peptide that could displace the native CK2β subunit and prevent the assembly 
of the holoenzyme.161 The disulfide-bridged peptide, hereafter known as Pc, showed a sub-
micromolar affinity for CK2α and displaced CK2β in vitro. However, due to the inherent low 
stability of disulfide bonds under reducing conditions, its cellular activity could not be 
investigated.161 Fast forward ten years and the same research group developed a lactam head-to-
tail cyclised variant of Pc that was conjugated to a TAT peptide to gain cell-entry (IC50 = 5 μM).164 
Although cell permeable, no structural information on the new macrocyclic peptide or data on 
the stability of the latter molecule in physiological fluids were reported, and therefore, such 
molecule could not serve as a chemical probe without further validation. 
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4.3. Project aim and overview 
The aim of this project was to develop conformationally-constrained peptide CK2 inhibitors 
targeting the protein interface and that have the potential to act as valuable chemical probes in 
vivo.  
Initially, molecular modelling was carried out using the structural information available on Pc215 
and on the portion of CK2β interacting with the catalytic domain to identify a suitable position to 
place the covalent constraint. It was envisioned that a constraint was necessary to improve the 
peptide affinity for the target by locking it into the binding conformation and simultaneously 
enhance the stability to proteases. Consequently, a series of constrained peptides were 
synthesised and tested in vitro to assess their ability to engage CK2α. The most promising 
peptide was then modified to incorporate fragment-like amino acids to boost the potency. 
Successively, X-ray crystallography revealed insights into the peptide binding mode and guided 
the design further. Lastly, the higher affinity peptide, P7-C5 was efficiently functionalised 
employing a novel multi-functional constraint.  
In total, twenty-two macrocyclic peptides were synthesised; the most promising one, P7-F1C5 
engaged CK2α with sub-micromolar affinity, it is stable in serum, cell-permeable, and active in 
cancer cells. An overview of the workflow is shown in Figure 36. 
 
Figure 36 - Workflow of the project described in Chapter 4. 
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4.4. Results and discussions 
Unless otherwise stated, the peptides described in this chapter were synthesised using standard 
procedures for solid-phase peptide synthesis (SPPS) and peptide macrocyclisation was achieved 
by following standard procedures for two-component copper-catalysed azido-alkyne 
cycloaddition peptide stapling (2C CuAAC PS).38  
Biophysics experiments such as fluorescent polarisation (FP), isothermal titration calorimetry 
(ITC), kinase assays, and X-ray crystallography were performed under the supervision of Dr Paul 
Brear (Hyvönen group, Biochemistry, University of Cambridge). Cellular experiments such as 
cell culture, confocal microscopy, anti-proliferation assay, and cell-viability assay were 
performed under the supervision of Dr David J. Baker (Discovery Sciences, AstraZeneca, 
Cambridge). Molecular dynamics simulations were conducted by our collaborator Dr Yaw Sing 
Tan (A*STAR, Singapore). 
4.4.1. Design of CK2β-like peptides  
Analysis of the portion of CK2β interacting with CK2α has suggested that only a cluster of 8 
amino acid (186-193) contribute to the binding significantly: RLYGFKIH. All of the amino acids 
mentioned above are included in the sequence of the disulfide-bridged Pc peptide developed by 
Cochet et al.161 Therefore, the X-ray crystallographic structure of Pc bound to CK2α (PDB code: 
4I5B)215 was used to understand which of those residues could be replaced by amino acids 
amenable to side-chain cross-linking to form stable cyclic peptides. Computational alanine 
scanning (CAS) and energetic decomposition suggested that any of the terminal residues 
introduced in Pc – namely G1, C2, G11, C12, G13 – could be replaced to introduce the constraint 
as they did not contribute to the binding (Figure 37).  
 
Figure 37 – Molecular modelling done on Pc peptide. a) CAS (top) and energetic decomposition (bottom) of the amino 
acids of Pc. Residues whose mutation to Ala negatively affected the binding significantly are shown in red, residues non-
                                                          
s The work described in chapter has been published in Iegre et al. ChemSci, 2019.288 Part of the text and figures have been adapted 
from this publication. 
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contributing to the binding are shown in green; b) Structure of Pc peptide (from PDB: 4I5B).215 Residues coloured in 
purple (C2 and G11) are the ones chosen to place the constraint in this study. 
It was decided to employ the 2C CuAAC peptide macrocyclisation chemistry to constrain the 
peptides as this cross-linking technology has been successfully used in the past to constrain 
peptides into their binding conformation, improve PK properties and simultaneously allow for 
functionalisation via the constraint rather than via the linear sequence.79,83,84,86,87,216 
C2 and G11 were positioned at a suitable distance from each other to accommodate a 2C double-
click constraint (Figure 37). Consequently, the 13-mer linear peptide would feature the 
sequence Ac-GXRLYGFKIHXGG-NH2 where X indicates the azido amino acids incorporated for 
constraining. The peptide sequence mentioned above will be referred to as P1 hereinafter. It 
was envisioned that the constraint should be rather rigid to minimise entropic penalties upon 
binding that may occur as the result of excessive flexibility. Therefore, the azido amino acid 
selected for cross-linking was azido-alanine (5) which, once reacted with the appropriate 
dialkyne linkage, would generate a cyclic peptide of a generic structure P1-Cn shown in Scheme 
15. 
 
Scheme 15 - Generic structure of the linear and cyclic peptides that are the subject of this work. 
4.4.1.1.  Synthesis of Fmoc-azido-alanine 5 
The synthesis of Fmoc-azido-alanine 5 was performed following literature precedent (Scheme 
16).217 The synthetic route commenced from the commercially available Fmoc-Asn-OH that 
underwent a Hofmann rearrangement in the presence of [bis(trifluoroacetoxy)iodo]benzene 
(PIFA) to afford Fmoc-Dap-OH (4) in 81% yield. The amino acid was then treated with the azido 
transfer reagent imidazole-1-sulfonyl- azide hydrogen sulfate 6 to obtain 5 in 77% yield. 
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Scheme 16 - Synthesis of Fmoc-azido alanine 5 from commercially available Fmoc-Asn-OH. 
Fmoc = Fluorenylmethyloxycarbonyl 
The azido transfer reagent 6 was synthesised in a one-pot procedure from the cheaply available 
starting materials sulfuryl chloride, imidazole, and NaN3 (Scheme 17).218  
 
Scheme 17 - One-pot synthesis of azido transfer reagent 6. 
The Fmoc protected azido amino acid 5 was used to synthesise the linear peptide P1 by SPPS. 
4.4.2. Screening of constrained peptides 
Once the linear sequence was identified and synthesised, the next step aimed to constrain the 
peptide into a conformation that resembles the portion of CK2β binding to CK2α.  
The ultimate goal of this project was to develop highly functionalised peptides in which the 
functionalisation feature was on the constraint rather than the linear sequence itself. This 
strategy was considered advantageous as it requires the synthesis of one linear bioactive 
peptide only, whereas peptidic functionalities such as CPPs and fluorescent tags are added onto 
the constraint via amide coupling. To this end, a functional handle on the constraint would be 
required. However, it was decided to commence the screening of the constraints from 
commercially available materials or easily synthesised plain dialkynes. The plain cyclised 
peptides would then be tested to investigate their ability to displace a CK2β-like probe in an FP 
assay and the most promising ones re-synthesised using constraints bearing a functional handle. 
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4.4.2.1.  Plain constraints: C1-C4 
Molecular modelling performed on the X-ray structures of Pc215 suggested that four possible 
constraints could be used to constrain the peptide into a CK2β-like conformation (Scheme 18). 
 
Scheme 18 - Proposed constraints for peptide macrocyclisation (top) and their corresponding dialkyne precursors 
(bottom). 
Constraints C1 and C2 were commercially available and were used as such in the CuAAC 2C 
macrocyclisation reaction. Initially, it was decided to use a shorter version of the linear peptide 
P1 by removing the three terminal glycine residues (P0, Ac-XRLYGFKIHX-NH2). Molecular 
dynamic simulations (MDs, performed by Dr Yaw Sing Tan, A*STAR, Singapore) showed that the 
terminal glycine residues did not contribute to the binding significantly (calculated ΔH -50.6 ± 
1.7 and -56.6 ± 1.2 Kcal·mol-1 for Pc and shorter Pc respectively). In addition, by removing the 
terminal residues, three coupling and deprotection steps could be avoided. Whilst constraining 
of P0 with C1 successfully provided P0-C1 (82% conversion)t, cyclisation with C2 was not 
achieved, with only the addition of two equivalents of the linker C2 per equivalent of the linear 
sequence P0, as observed by LCMS of the crude mixture. By changing the linear sequence to P1, 
the desired product P1-C2 was obtained (65% conversion) suggesting that the terminal glycine 
residues may help cyclisation. 
Constraints C3 and C4 were not commercially available, and their synthesis is discussed below. 
It was envisioned that C3 could be obtained by TMS deprotection of the commercially available 
TMS-mono-protected analogue by treatment with TBAF for 14-16 h. However, due to the high 
volatility of the product, its isolation was not achieved. It was decided to perform a first CuAAC 
reaction in the presence of the commercially available trimethyl(penta-1,4-diyn-1-yl)silane and 
P0, followed by addition of CsF to remove the TMS group and a second CuAAC reaction (Scheme 
19). Unfortunately, only the addition of two deprotected constraints was detected in the crude 
                                                          
t LCMS conversions are given for peptide macrocyclisation reactions instead of yield due to loss of material during the purification on 
preparative HPLC.  
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mixture. Pleasingly, the same procedure repeated with P1 afforded the desired product P1-C3 
(62% conversion) as shown in Scheme 19.  
 
Scheme 19 - Attempts of cyclising P0 into P0-C3 and P1 into P1-C3 using CuAAC peptide chemistry. 
Considering that the terminal residues were required to obtain the desired cyclisation products 
with C2 and C3, it was decided to use the sequence of P1 for all the successive reactions 
described hereafter.  
Constraint C4 was obtained from the commercially available 1,2-dibromobenzene. The latter 
molecule underwent a Sonogashira coupling in the presence of trimethylsilylacetylene, 
Pd(PPh3)2Cl2, CuI, PPh3, and DIPEA followed by TMS deprotection in the presence of KOH and 
MeOH to afford C4 as a 42% w/v solution in PE 40-60 (Scheme 20). 
 
Scheme 20 - Synthesis of C4 from commercially available 1,2 dibromo-benzene. 
2C CuAAC peptide macrocyclisation between C4 and P1 afforded P1-C4 in 79% conversion.  
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With the four cyclic peptides in hand, their biological activity was investigated using an FP assay. 
In this study, FP was used to determine the ability of the peptide to displace a commercially 
available fluorescent probe meant to mimic the CK2β subunit.u The assay looked at the 
anisotropy resulting from the interaction of CK2α and the fluorescent probe in the presence of 
15 μM peptide concentration. The results included Pc, its shorter analogue, and the linear Pc 
peptides for comparison (synthesised according to previous reports)161, 215. The results are 
expressed as % inhibition and indicate the inhibition of the assembly of CK2α with the 
fluorescent probe (Table 13). The corresponding calculated binding energies are also shown in 
the table. 
Table 13 - % inhibition of the assembly between CK2α and the FP probe at 15 μM peptide concentration. 
Entry Peptide Structure % inhibition (at 15 μM) Calculated ΔH (Kcal/mol) 
1 Pc GCRLYGFKIHGCG (S-S) 79.0 ± 7.0 -50.6 ± 1.7 
2 Short Pc GCRLYGFKIHGC (S-S) 73.8 ± 2.5 -56.6 ± 1.2 
3 Linear Pc GCRLYGFKIHGCG 13.1 ± 2.3 NA 
4 P0-C1 XC1LYGFKIHXC1 0.6 ± 0.1 -50.3 ± 0.6 
5 P1 GXLYGFKIHXGG 12.6 ± 1.7 NA 
6 P1-C2 GXC2LYGFKIHXC2GG NA -57.1 ± 2.1 
7 P1-C3 GXC3LYGFKIHXC3GG 58.4 ± 4.0 -54.1 ± 2.1 
8 P1-C4 GXC4LYGFKIHXC4GG 21.1 ± 1.9 NA 
All the peptides feature an amide at the C-terminus and an acetyl capping at the N-terminus. X = Fmoc-Aza-OH (5). 
The results confirmed that the terminal Gly residues did not contribute significantly to the 
binding as predicted by the molecular modelling (entries 1 and 2, Table 13). P1-C3 appeared to 
be the most promising of the cyclised peptides synthesised so far, and therefore, it was the one 
brought forward. Unfortunately, P1-C2 proved to be insoluble in the assay conditions and its 
evaluation was not possible at that stage. 
                                                          
u Fluorescent probe of sequence FITC-βGly-RLYGFKIHPMAYQLQ. 
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4.4.2.2.  Constraints with a functional handle: C5 and C6 
Although the ability of P1-C2 to displace the CK2β-like probe from CK2α could not be studied 
due to solubility issues, MDs suggested that the peptides P1-C2 and P1-C3 may have a more 
favourable enthalpy of binding than Pc (-57.1 ± 2.1 Kcal·mol-1 for P1-C2, -54.1 ± 2.1 Kcal·mol-1 
for P1-C3 and -50.6 ± 1.7 Kcal·mol-1 for Pc, Table 13) and hence it was decided to consider them 
both for further evaluation. 
It was envisioned that by introducing a suitable functional group – such as carboxylic acid or 
amine - the solubility of peptide P1-C2 in aqueous buffers could be improved and would 
simultaneously set up for the introduction of peptidic functionalities at a later stage.  
Consequently, C2 was modified into the corresponding carboxylic acid arylalkyne C5. The 
synthesis followed previous reports219,220 and commenced from a Sonogashira reaction between 
the commercially available methyl 3,5-dibromobenzoate and trimethylsilylacetylene in the 
presence of Pd2(dba)3, PPh3, CuI in TEA to afford C5-1 in 68% yield (Scheme 21). The 
intermediate was then subjected to ester hydrolysis and TMS deprotection in the presence of 
MeOH and KOH to afford the constraint C5 in 98% yield. 
 
Scheme 21 - Synthesis of constraint C5 from the commercially available 3,5-dibromobenzoate. 
Functionalisation of constraint C3 presented some difficulties. Initially, it was envisioned that 
the desired one-carbon atom linker could be accessed from the cheap methyl formate (Scheme 
22). It was proposed that the treatment of this ester with TMS-acetylene in the presence of nBuLi 
could afford C6-1. However, the reaction did not proceed as expected, and no desired product 
could be isolated. It was thus decided to perform the same reaction starting from 3-
(trimethylsilyl)propiolaldehyde. Pleasingly, the addition onto the aldehyde afforded C6-1 in 
quantitative yield. It was envisioned that the hydroxyl group in C6-1 could be converted into a 
good leaving group that would then allow for the introduction of a carboxylic acid or an amine. 
However, attempts to convert C6-1 into tosyl (C6-2) or into a phthalimide via aza-Mitsunobu 
reaction (C6-3) failed, probably due to polymerisation as suggested by the formation of black, 
insoluble products (Scheme 22). A final attempt started from 3-(trimethylsilyl)propiolaldehyde 
and p-bromo-aniline followed by addition of TMS-acetylene to obtain C6-4 (Scheme 22). As 
observed for C6-2 and C6-3 only black and insoluble products were obtained. If this reaction 
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had been successful, 4-aminobenzoic acid would have been used instead of p-bromo-aniline. The 
latter was used only to test the outcome of the reaction on a simplified substrate. 
 
Scheme 22 - Attempts to synthesise a one-carbon atom linker bearing a functional handle. 
It was proposed to change strategy, and a double Negishi cross-coupling reaction was attempted 
starting from the commercially available 4-(dibromomethyl)benzoic acid and 
ethynylmagnesium bromide to obtain linker C6-5 (Scheme 23). Unfortunately, only unidentified 
by-products were observed. 
 
Scheme 23 - Double Negishi reaction attempted to synthesise C6-5. 
Finally, it was decided to follow an alternative route using a substrate without a functional group 
that may complicate the synthesis. In particular, it was envisioned to start the synthesis from 
methyl 4-bromobenzoate (Scheme 24). The starting material was reacted with TMS-acetylene in 
the presence of nBuLi to afford C6-6 in 93% yield. The TMS protecting groups on the 
intermediate were then removed in the presence of KOH and MeOH to afford C6-7 in 54% yield. 
An attempt to react methyl 4-bromobenzoate with ethynylmagnesium bromide to obtain C6-7 in 
one step failed. It was proposed that the tertiary alcohol in C6-7 could be removed via a 
deoxygenation reaction. However, only unidentified by-products were detected. This result, in 
combination with the failures encountered in the previous routes, suggested that the 
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intermediates deriving from the modifications of the tertiary alcohol group were extremely 
unstable. 
 
Scheme 24 - Synthetic route to access C6-7. 
To see whether the steric hindrance of constraint C6-7 would be tolerated in the 2C-CuAAC 
reaction, C6-7 was reacted with P1. Pleasingly, P1-C6-7 was obtained with 52% conversion. It 
was decided to repeat the reactions that led to C6-7 with a substrate carrying a carboxylic acid 
that could be used as a functional handle. 
The synthetic route proceeded from the commercially available 4-(methoxycarbonyl)benzoic 
acid that underwent a double TMS-acetylene addition onto the ester to afford C6-9 in 46% yield 
(Scheme 25). The yield for this reaction was considerably lower than the analogue that led to 
C6-6 (93%) potentially due to the different electronics of the aromatic rings. The TMS protecting 
groups of C6-9 was removed in the presence of KOH and MeOH to yield C6 in 62% yield.  
 
 Scheme 25 - Synthetic route leading to C6.  
Constraints C5 and C6 were used in the 2C-CuAAC peptide macrocyclisation in the presence of 
P1 to afford P1-C5 and P1-C6 with 92% and 85% conversion respectively.  
The affinity of the newly synthesised peptides for CK2α was measured using an ITC assay. ITC 
provides a more accurate measurement of the binding affinity than FP as it measures the direct 
binding to the protein of interest. However, ITC is not high-throughput and, consequently, was 
not used for the lower affinity peptides. P1-C5 and P1-C6 were soluble in the assay conditions 
and showed a Kd for CK2α of 460 nM and 58 μM respectively. Whilst P1-C6 showed a decreased 
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affinity for the protein compared to the reference Pc peptide (Kd 1 μM), P1-C5 showed higher 
affinity than Pc (Figure 38). 
 
 
 
 
 
 
 
Figure 38 - ITC binding curves of P1-C5, P1-C6, and Pc binding to CK2α. The peptides shown feature an acetyl capping at 
the N-terminus and an amide at the C-terminus. 
With this promising result in hand, the ability of P1-C5 to disrupt the interaction between the α 
and the β subunits of CK2 was investigated using an ITC competition assay. The affinity of the 
CK2β domain for the α was measured using a direct ITC assay and was found to be 9 nM 
(literature value 4 nM).215 The binding was then investigated in the presence of the peptide at 
100 μM concentration.v Pleasingly, no binding of CK2β to α was detected under these conditions.  
Therefore, constraint C5 proved to be the most effective at constraining the peptide in its 
binding conformation, and the resulting cyclic peptide P1-C5 was able to disrupt the PPI of CK2. 
4.4.3. Attempts to develop Conformationally-Constrained Hybrid Peptides 
(CCHPs) 
Chapter 3 described the FBDD approach used in the Spring group to develop CK2 inhibitors 
binding in the cryptic αD pocket and at α/β interface. Fragment optimisation of the molecules 
binding at the interface did not result in significant improvement of the binding affinity 
                                                          
v Concentration in the ITC titrant and ITC syringe. 
P1-C5 
Kd 460 nM 
Pc 
Kd 1 μM 
 
P1-C6  
Kd 58 μM 
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compared to the initial hit fragment NMR154L, except for 3g. Considering that the initial hit 
fragment overlaps with the Phe7 hotspot residue of the CK2α (Figure 39a), it was decided to 
merge fragment NMR154L with peptide P1-C5 (CCHPs) with the aim of increasing the binding 
affinity of the overall peptides and impart selectivity to the fragments. Fragments of bigger size, 
such as the more active 3g, were not considered at this stage as their introduction could lead to 
clashes with other residues within the peptide.  
4.4.3.1.  Chloro-phenylalanine containing peptides: P2’-C5, P2’’-C5, 
P3-C5 
Molecular modelling to design the CCHPs was performed using the X-ray structure of Pc (PDB: 
4IB5)215 and NMR154L (PDB: 5CLP)198 due to the absence of X-ray crystal structures for the 
newly developed P1-C5 peptide (Figure 39). Chlorobenzene probes in ligand-mapping 
simulations indicated that a chlorine atom in the 3 position of Phe7 residue (peptide P2-C5) 
could be introduced without compromising the binding affinity of the peptide (ΔH -58.07 ± 2.92 
Kcal·mol-1 for P2-C5 vs -57.1 ± 2.4 Kcal·mol-1 for P1-C5). The introduction of a chlorine atom in 
the 4 position of Phe7 was also proposed (P3-C5) as the newly inserted atom should not affect 
the binding affinity significantly (ΔH -55.6 ± 2.2 Kcal·mol-1). 
 
Figure 39 – Structure-based design of CCHPs. a) Overlay of the X-ray structures of NMR154L (purple, PDB code: 5CLP)198 
and Pc peptide (green, PDB: 4IB5)215 binding at the CK2 interface. b) Chlorobenzene probe used in MD shows the chlorine 
occupying a region (green mesh) corresponding to the 3-position of the Phe7 of Pc (orange). 
The Fmoc-3-chloro-Phe-OH amino acid (7) required for the synthesis of P2-C5 was synthesised 
from the racemic, unprotected amino acid 3-chloro phenylalanine for availability reasons. The 
free amine was protected using N-(9-fluorenylmethoxycarbonyloxy)succinimide and NaHCO3 
(Scheme 26).  
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Scheme 26 - Synthesis of the amino acid 7. 
As expected, incorporation of 7 in the peptide afforded two diastereomers P2’ and P2’’ which 
were separated by preparative HPLC and cyclised with C5 to afford P2’-C5 and P2’’-C5 
respectively. It was envisioned that X-ray crystallography of the peptides in complex with the 
protein would elucidate the stereochemistry. 
The synthesis of P3 required the amino acid L-Fmoc-4-chloro-Phe-OH that was commercially 
available. Cyclisation of linear peptide P3 with C5 afforded P3-C5 in 53% conversion (Scheme 
27). 
 
Scheme 27 – CuAAC PS of P3 with C5 to afford P3-C5. 
ITC was performed to measure the binding affinities of P2’-C5, P2’’-C5 and P3-C5 for CK2α. 
Unfortunately, none of the CCHPs showed improved binding affinity compared to P1-C5 (Kd of 
460 nM): peptide P2’-C5 was found to have a Kd of 2 μM, P2’’-C5 did not show binding to the 
protein at a concentration below 125 μM whilst P3-C5 was found to have a Kd of 56 μM.  
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4.4.3.2.  Chloro-phenylglycine containing peptides: P4-C5, P5’-C5, 
P5’’-C5 
Considering the lack of structural information available for the first set of CCHPs, it was 
hypothesised that the chloro-Phe residues in the peptides might bind deeper than expected 
making the interactions of the peptide with CK2α less optimal. Consequently, it was decided to 
shorten the Phe side chain of the amino acid residue by one carbon atom, introducing chloro-
phenylglycine derivatives as the Phe7 replacements. 
As for P2-C5, the synthesis of the peptides containing 3-chloro-phenylglycine (contained in 
peptide P4) and 4-chloro-phenylglycine (included in peptide P5) required the protection of the 
commercially available corresponding amines to Fmoc-protected amino acids 8 and 9 
respectively. The 3-chloro-phenylglycine was provided enantiopure whereas the 4-chloro 
analogue was available as a racemic mixture. For both amino acids, Fmoc protection was 
performed using N-(9-fluorenylmethoxycarbonyloxy)succinimide and NaHCO3 (Scheme 28). 
Fmoc protection of 3-chloro-phenylglycine afforded 8 in 86% yield, and 9 was obtained from 4-
chloro-phenylglycine quantitatively.  
 
Scheme 28 - Fmoc protection of 3- and 4- chloro-phenylglycine amino acids 8 and 9. 
The linear peptides P4, P5’ and P5’’ were clicked with C5 to obtain the corresponding cyclic 
peptides P4-C5 (60% conversion), P5’-C5 (53% conversion) and P5’’-C5 (47% conversion). 
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Unfortunately, all the chloro-phenylglycine containing peptides showed no detectable binding to 
CK2α on ITC. The lack of structural information at that stage made it impossible to build any 
SAR. If X-ray structures of the hybrid peptides bound to CK2α can be obtained, the design of 
further CCHPs could be adjusted. 
4.4.4. X-ray crystal structures of the constrained peptides 
Due to the crucial importance of structural information to guide the design further, priority was 
given to X-ray crystallography.  
After several attempts of soaking and co-crystallisation with different commercially available 
and custom-made screens, as well as different constructs of the protein, we were pleased to find 
conditions that yielded crystals of P1-C5 bound to CK2α.w The X-ray structure showed P1-C5 
binding in a conformation that resembles the portions of CK2β and Pc binding to CK2α with the 
hotspot residues occupying their respective pockets (Figure 40a-b). The backbone residues of 
P1-C5 are all slightly shifted compared to Pc especially closer to the constraint. This difference 
can be explained considering that C5 is larger and more rigid than the disulfide bridge in Pc and 
therefore, it holds the two ends of the peptide further apart (12.6 Å vs 9.8 Å, Figure 40c-d). 
 
Figure 40 - X-ray crystal structure of P1-C5 (PDB: 6Q38). a) Overlay of P1-C5 (green) and CK2β (yellow). b) Overlay of 
P1-C5 (green) and Pc (PDB: 4IB5,215 cyan). c) Comparison of binding modes of P1-C5 (green) and Pc (cyan). d) 
Differences between the triazole constraint and the disulfide bridge. 
                                                          
w Details of the crystallisation attempts can be found in the Appendix A.5. 
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Using similar conditions as for P1-C5 and matrix seeding from the co-crystals grown of the 
peptide, P2’-C5 was crystallised with CK2α. The X-ray structure showed that P2’-C5 contained 
the L-enantiomer of the 3-chloro-phenylalanine residue 7 (Figure 41a) and that the modified 
Phe7 did not overlay with the fragments that the modifications and MDs were based upon. 
Indeed, the binding mode of P2’-C5 forces the 3-Cl Phe to sit deeper in the pocket than the 
fragment which potentially leads to a clash with Tyr5 and accounts for the reduction in affinity. 
The structure shows that whilst chlorine in the 3-position could partially be accommodated in 
the Phe pocket (P2’-C5 Kd 2 μM), a chloro atom in the 4-position would disrupt the binding of 
the peptide as confirmed by the ITC experiments (P3-C5 Kd 56 μM). Even though the CCHP 
strategy did not result in an improvement in binding affinity of the peptides, the X-ray crystal 
structure of P2’-C5 with CK2α revealed the protein in complex with a peptide substrate (Figure 
41b).x  
 
Figure 41 - X-ray crystal structure of P2'-C5. a) Overlay of NMR154L (purple) and P2'-C5 (green) showing how the 3-
chlorophenylalanine residue in P2’-C5 binds deeper than NMR154L resulting in no space to accommodate a chlorine in 
the 4-position. b) CK2 substrate (purple) occupying the substrate channel (highlighted by black dashed lines). 
This unprecedented result is of crucial importance to the CK2 kinase community as the 
structural information obtained opens opportunities to develop a novel class of substrate-
competitive CK2 inhibitors and will help to elucidate the phosphorylation mechanism of the 
protein. 
                                                          
x Peptide substrate mimicked by the N-terminal extension of CK2α (GSMDIEFDDDADDDGSGSGSGSGS) in the protein construct used 
CK2α_FP10. 
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4.4.5. Further sequence modification: P6-C5, P7-C5, and P8-C5 
Molecular modelling and rational design based on the available crystal structures of P1-C5 and 
P2’-C5, suggested that further modification of the sequence may result in enhancement of the 
binding affinity of the peptides. 
The first variation of interest involves the substitution of Tyr5 residue (Table 14). This residue is 
located on the portion of the peptide that forms the β-turn in Pc, and it makes hydrophobic 
interactions with the so-called Tyr pocket. Therefore, it was decided to vary the Tyr5 to Pro, a 
residue known to help β-turn formation221 that could make the overall peptide more rigid, 
reducing the entropic penalty upon binding. With this in mind, peptide P6 was synthesised and 
constrained into the cyclic peptide P6-C5 with 88% conversion. 
Table 14 – Sequences modification of peptides P6-, P7-, P8-C5 respect to P1-C5. 
 
Peptide Sequence modification 
P1-C5 Z =Y; X =F; J =I 
P6-C5 Z =P; X =F; J =I 
P7-C5 Z =Y; X =F; J =W 
P8-C5 Z =Y; X =W; J =I 
The second sequence modification concerned the Ile9 residue (Table 14). The X-ray crystal 
structure of P1-C5 (Figure 42a) shows that the Ile9 could be replaced by an amino acid capable 
of π-π stacking with the aromatic ring of C5. Likewise, chlorobenzene probes in ligand-mapping 
simulations indicated an unfilled hydrophobic region around Ile9 (Figure 42b) suggesting that a 
larger, nonpolar side chain could be introduced (ΔH -59.7 ± 1.2 Kcal·mol-1 for P7-C5 compared 
to -57.0 ± 2.1 Kcal·mol-1 for P1-C5, as calculated from MD simulations).  
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Figure 42 – Peptide design guided by the X-ray structure of P1-C5 bound to CK2α. a) X-ray structure of P1-C5 showing 
Ile9 oriented in the right direction to stack with the constraint C5. b) Chlorobenzene mapping on Pc showing a high 
occupancy region by the aromatic carbon atoms of the probe around Ile9. Areas shown as black mash represent regions 
around the CK2α protein (blue) occupied by the hydrophobic chlorobenzene probe during the MD simulation. Peptide P1-
C5 is shown in yellow to show which residues of the peptide correspond to the regions occupied by the probe during the 
MD. Ile9 of P1-C5, which is mutated to Trp in P7-C5, is shown in orange. 
The sequence of P1 was modified to P7 to accommodate the largest aromatic residue Trp. 
Automated MW-assisted SPPS of P7 using standard Fmoc protected amino acids led to on-resin 
aggregation after the attachment of the first five amino acids as suggested by poor Fmoc 
deprotection of the amino acids.y On-resin aggregation was successfully prevented by replacing 
standard Fmoc-Gly-OH with backbone protected Fmoc-(Dmb)Gly-OH residues at the 2- and 8- 
position of the peptide.222 The resulting peptide P7 was macrocyclised with C5 as the linker to 
afford P7-C5 (83% conversion).  
Finally, the last modification was performed to generate a peptide that could be used as negative 
control in the functional and cellular assays. Such peptide (P8) featured a Trp residue as 
replacement of the Phe7 (Table 14). The Trp was chosen as it is the biggest natural amino acid 
and therefore should not be able to fit in the Phe pocket. 
Disappointedly, peptide P6-C5 (Y5P) showed no binding to CK2α as measured by ITC. On the 
other hand, P7-C5 (I9W) appeared to be the highest affinity peptide developed thus far with a Kd 
of 150 nM. In favour of the hypothesis that a suitable constraint may enhance the binding of the 
peptide significantly, the constrained peptide showed a 300-fold improvement compared to the 
linear variant (Kd 44 μM, Figure 43). As for P1-C5, the ability of the peptide to prevent CK2β 
binding to CK2α was investigated using an ITC competition assay. No binding of the regulatory β 
subunit to the catalytic subunit was observed in the presence of 100 μM of the peptide.z  
                                                          
y Fmoc deprotection in automated MW-assisted SPPS is monitored by UV absorbance of the dibenzofulvene (DBF) intermediate 
formed during DIPEA-mediated Fmoc removal.289 
z Peptide concentration in the ITC titrant and syringe. 
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Figure 43 - ITC binding curves of P7-C5 and P7 binding to CK2α. 
X-ray crystal structure of P7-C5 allowed rationalisation of the improved binding affinity of the 
peptide compared to P1-C5. The structure shows the introduced Trp residue π-π stacking with 
the benzene ring of the constraint. No other additional interactions with CK2α were observed. 
Therefore, the increased binding affinity of P7-C5 for CK2 may be rationalised with a reduced 
entropic penalty upon binding due to the rigidifying interaction occurring between the 
constraint and the Trp residue (Figure 44). 
 
Figure 44 – Comparison of P1-C5 and P7-C5 bound to CK2α. a) X-ray crystal structure of P7-C5 bound to CK2α (PDB: 
6Q4Q). b) A comparison of the stacking with C5 in P1-C5 (green) and P7-C5 (green). 
As expected, no binding of the negative peptide P8-C5 was detected in the ITC direct binding 
assay. 
The effect of PPI inhibition on substrate phosphorylation was also studied using CK2β 
dependent and independent substrates. It was shown that P7-C5 was able to inhibit the 
P7-C5 
Kd = 150 nM 
 
P7 
Kd = 44 μM 
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phosphorylation of a β-dependent substrateaa with an IC50 of 206 ± 29 nM. Pleasingly, the 
negative peptide P8-C5 did not cause inhibition of the phosphorylation of the β-dependent 
substrate (Figure 45). The peptide did not affect the phosphorylation of a β-independent 
substrate peptide (RRRADDSDDDD) suggesting that the binding of the peptide at the interface 
site does not displace the ATP. 
 
Figure 45 - Inhibition of phosphorylation of a β-dependent substrate (a) and a β-independent substrate (b). CX4945 was 
used as positive control for its documented ability to inhibit the catalytic activity of CK2α. 
4.4.6. Multi-functionalisation of the constraint C5 
Preliminary confocal microscopy experiments carried out with FITC-labelled peptide P1-C5 
(FITC-P1-C5)bb showed that the peptide was not able to permeate the membrane of human 
colorectal cancer cells (HCT116). Z-stacks of fixed cells showed no green emission 
(corresponding to the FITC signal) whilst only the blue signal corresponding to the nuclei stain 
was observed (Figure 46).  
  
Figure 46 - Cellular uptake of the cell impermeable FITC-P1-C5 using HCT116 cells. Composite of z-stacks obtained on 
confocal microscopy using a 20X objective showed that no FITC-labelled peptide is internalised by the cells. Nuclei are 
stained in blue. 
                                                          
aa β-dependent substrates rely on the CK2β subunit to be bound to CK2α to be phosphorylated. Whilst CK2β does not phosphorylate 
the substrate itself, it acts as a docking station, and it is therefore crucial for substrate recognition. The CK2β-dependent substrate 
used in this work is the transcription factor eIF2β. 
bb Sequence FITC-Ahx-P1 cyclised with C5 to obtain FITC-Ahx-P1-C5 in 56% conversion. 
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Therefore, since both cell-penetrating motifs and fluorescent tags were necessary for the cellular 
assays, it was decided to develop a novel multi-functional constraint that would simultaneously 
constrain the peptide in its binding conformation, enhance stability to proteases, provide cell-
permeability to the CK2 peptide and act as a fluorophore (Figure 47).  
 
Figure 47 - Structures of multi-functional constraints developed in this work. Different functionalities are color-coded as 
shown in the figure legend. P1: Z = F, J = I; P7: Z = F, J = W; P8: Z = W, J = I. 
In addition, it was proposed that the functionalised constraints could be entirely synthesised in 
an automated manner using SPPS and independently from the CK2 peptide. The benzoic acid 
derivative linker was attached on-resin to a cell-penetrating peptide (CPP) via two molecules of 
aminohexanoic acid to avoid steric clashes with the CK2 peptide and the CK2α domain. Several 
reports make use of a poly-arginine tripeptide as a useful CPP to carry peptide cargos into 
cells.81,193. The previously used L-arginine was replaced with the D-arginine isomer to confer 
cell-permeability to the CK2 peptide and provide a proteolysis resistant alternative (F1C5, 
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Figure 47). The CPP was in turn attached to the fluorescent tag FITC via an orthogonally-
protected Lys – namely Lys(ddve)- to monitor peptide uptake into the cells (F2C5). FITC was 
also directly attached to the spacer via the Lys to provide a cell-impermeable fluorescent tag 
(F3C5) to use as a negative control. The functionalised linkers were then reacted with the linear 
peptides to obtain highly functionalised peptides and study their biological activity in cells was 
subsequently studied.  
The ability of the functionalised constraint to improve the overall stability of the peptide to 
proteases was investigated using human serum. Importantly, the cell-permeable lead peptide 
(P7-F1C5) displayed significant stability in human serum (47% intact peptide after 24-hour 
incubation, Figure 48) whilst the linear analogue P7 was degraded entirely after 8-hour 
incubation. 
 
Figure 48 - Serum stability test of P7 (black line) and P7-F1C5 (dashed-black line) in the presence of 20% serum. The 
results shown are the average of two-independent repeats. 
4.4.7. Cellular work on P7-C5 derivatives 
The ultimate goal of this project was to investigate the activity of the peptide in cancer cells. 
Therefore, further cellular experiments were carried out using two cell-lines: HCT116 and U2OS. 
The HCT116 cell line was chosen to study the activity of the peptides in cells due to its 
documented high expression levels of CK2.139 U2OS, on the other hand, was chosen to perform 
intracellular localisation experiments due to its great cytosol/nucleus ratio. 
4.4.7.1.  Intracellular localisation experiments 
The ability of the functionalised constraint F2C5 to impart cell-permeability to the peptide was 
initially investigated using the FITC-labelled peptide P1-C5 which was previously found to be 
cell-impermeable in preliminary experiments (Figure 46). To this end, P1 was constrained with 
the FITC-labelled penetrating constraint F2C5 and with the FITC-labelled impermeable 
constraint F3C5 (Figure 49). 
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Figure 49 - Cellular uptake of P1-F3C5 and P1-F2C3 using osteosarcoma cancer cells (U2OS). Fixed cells were imaged 
using a 40 X objective. Peptides are shown in green, nuclei in blue. 
The results showed that F2C5 was effective at transporting peptide P1 into cells whilst F3C5 
was not. Consequently, F2C5 was used to constrain the lead peptide P7 and investigate its 
intracellular localisation. Confocal microscopy of U2OS osteosarcoma cancer cells treated with 
P7-F2C5 showed the peptide localising to the cell nucleus and also accumulating in proximity to 
the nuclear membrane at different time points (5 minutes to 6 hours) as shown in Figure 50. 
Thus, further studies were undertaken to elucidate the exact intracellular localisation of the 
peptide.  
 
Figure 50 - Uptake of P7-F2C5 by U2OS cells. Cells were incubated with 1.25 μMcc of the peptide at 37 °C for the 
designated time point and then fixed using 4% PFA. Images were recorded on a confocal microscope using 40 X 
magnification. 
There are several reports of positively charged peptides being unable to escape the endosomes 
and ending up in the lysosomes,223 and therefore, imaging experiments were carried out to look 
at co-localisation with endosomal and lysosomal markers. Surprisingly, no co-localisation with 
endosomal markers was detected at any time-point (first and second row, Figure 51). On the 
other hand, partial co-localisation was detected with the lysosome stain (third row, Figure 51). 
                                                          
cc 1.25 μM concentration was chosen for its optimal signal/background ratio compared to the other concentrations screened 
(between 20 μM and 0.2 μM).  
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Figure 51 - Co-localisation experiments of P7-F2C5 with trafficking antibodies: EEA1 marker for early endosomes, Rab7 
marker for late endosomes, LAMP1 marker for lysosomes. Nuclei are stained in blue, antibodies in red and peptide in 
green. 
Despite partial co-localisation of the peptide with the lysosome stain, there was still a significant 
portion of the FITC signal that did not co-localise with any of the markers used thus far. It was 
decided to look at the co-localisation with Trans and Cis Golgi stains and markers for the 
endoplasmic reticulum (ER). These organelles are in proximity to the nuclear membranes and 
are involved with the trafficking of vesicles going in and out the lysosomes. It was envisioned 
that the peptide might co-localise with some of these organelles. Whilst minimal co-localisation 
was observed with the trans-Golgi (TNG46) at the early time-points, the peptide was found to 
co-localise with Cis-Golgi (ZFLP1) and ER markers (Calnexin) as shown in Figure 52. 
 
Figure 52 - Co-localisation experiment of P7-F2C5 with Golgi and ER antibodies: TGN46 marker for trans Golgi, ZFLP1 
marker for Cis Golgi, Calnexin marker for ER. Nuclei are stained in blue, antibodies in red and peptide in green. 
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This is an unexpected and unprecedented result that would need further investigation to 
understand ways of preventing the peptide from becoming trapped in the Golgi and ER. Despite 
this event, the peptide was detected in the nuclei at all time points. CK2 is a protein that shuttles 
between the cytosol and the nucleus; therefore, we proposed that the peptide present in the 
nucleus would be able to interact with CK2 and exert its bioactivity. 
4.4.7.2.  Anti-proliferative activity on colorectal cancer cells treated 
with P7-F1C5 
Disruption of the PPI of CK2 has been reported to arrest cell cycle progression, induce apoptosis 
and slow cell proliferation in a variety of cell lines including human colorectal cancer cells 
(HCT116).144 To this end, the bioactivity of P7-F1C5 in HCT116 was investigated.  
The effect of the peptide on cell proliferation was studied in two ways: (1) monitoring the rate of 
growth of the cells in the presence of increasing concentration of the peptide over 4 days; (2) 
using a Sytox Green™ assay to quantify the cells after 4-day incubation with the peptides. In the 
first case, the cells were treated with the peptide, and their rate of growth monitored at 37 °C. 
Scans of the cell confluency were recorded every 2 hours to give a percentage of the cell 
confluency at each scan (Figure 53). 
The scans showed that P7-F1C5 slows down the proliferation of the cells at a concentration of 
32 μM with 80% inhibition at 100 μM. For this experiment, two types of controls were used: 
CX4945 (positive control), P7-C5 (cell impermeable constrained peptide) and the functionalised 
cell-penetrating constraint F1C5 (cell-penetrating constraint without the peptide). CX4945 is a 
clinical candidate CK2α inhibitor inhibiting CK2 in an ATP-competitive manner.139 It is known to 
inhibit proliferation in HCT116 cells, and it was therefore used as positive control. Due to the 
mechanistic differences between CX4945 and P7-F1C5 a difference in the outcome of the assay 
was expected; whilst inhibition of the CK2α catalytic subunit is known to cause drastic effects in 
cells, inhibition of the holoenzyme assembly has been reported to have less severe consequences 
due to the fact that the activity of the catalytic α subunit is not affected.164 In addition, CX4945 is 
known to inhibit other kinases, and therefore, its more pronounced cytotoxic activity could be 
attributed to off-target effects.198 The constraint F1C5 was used as negative control to ensure 
that the positive charges on it would not cause any unspecific cytotoxicity while P7-C5 was used 
as negative control considering its limited cell-permeability.  
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Figure 53 - Rate of cell growth over 70 hours. HCT116 were treated with increasing concentration of compounds and 
incubated at 37 °C for 70 hours. Results are shown as the average of 4 independent repeats. 
Once it was verified that P7-F1C5 slowed down the proliferation of HCT116 cells, it was decided 
to determine its GI50 using the Sytox Green™ assay. Sytox Green™ is a reagent that would 
generally stain nucleic acids of dead cells. If the detergent Saponin is added to the assay, cellular 
membranes become permeable, and the stain permeates both viable and dead cells and 
therefore gives an indication of the total number of cells. Consequently, the reagents were added 
straight after the peptide addition and after 4-day incubation to provide the number of cells in 
P7-F1C5 
P7-F1C5 
CHAPTER 4: Conformationally-constrained peptides targeting the protein-protein 
interaction of the anti-apoptotic proteins CK2 
 
103 
 
the plate. In this assay, CX4945 was used as a positive control whereas F1C5, the cell 
impermeable P7-C5 and the cell-permeable negative peptide P8-F1C5 were used as negative 
controls. The results are shown in Figure 54. 
 
Figure 54 – Percentage of the proliferation of HCT116 cells after 70-hour incubation with the compounds. a) GI50 curves 
for and CX4945. b) Percentage proliferation of HC116 cells treated with P7-F1C5 and negative peptides at the top 
concentrations (100, 75, 50, 32 μM). 
P7-F1C5 was able to inhibit cell proliferation with a GI50 of 76 ± 4.1 μM whilst the negative 
peptides did not show inhibition. However, the activity drop-off in the cellular assay was 
significant with respect to the enzymatic assays (Kd 170 nM, IC50 370 nM). This result could be 
speculatively rationalised with the fact that the organelle trapping causes a drop-off in the 
concentration of peptide able to interact with CK2 intracellularly. It is also possible that the 
effect of the inhibition of the phosphorylation of CK2β-dependent substrates in outbalanced by 
the phosphorylation of CK2β-independent substrates.  
4.4.7.3.  Cell viability of colorectal cancer cells treated with P7-F1C5 
We went on to investigate the ability of P7-F1C5 to induce apoptosis in cancer cells using the 
CytoTox-Glo™ Cytotoxicity Assay (Promega). As for the proliferation assays, several peptides 
were used as negative controls. Unlike the proliferation assay, the outcome of the cell viability 
assay was determined after 5-hour incubation with the peptides. The results are shown in 
Figure 55. 
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Figure 55 - HCT116 cell viability in the presence of a high concentration of compounds. 
Once again, the EC50 (87.5 ± 6.8 μM) of P7-F1C5 was considerably higher than expected. 
Pleasingly, no cytotoxic effect was detected for P7-C5 and F1C5 whilst 60% viability was 
observed when the top concentration of the negative peptide P8-F1C5 was used. It should be 
noted that no inhibition of the proliferation was observed when the same concentration was 
used in the anti-proliferation assay. Whilst the outcome of the viability assay is determined after 
5-hour incubation, the anti-proliferative effect is measured after 70-hour incubation. Therefore, 
the initial unspecific cytotoxic effect of P8-F1C5 is somehow overcome by the viable cells whose 
long-term proliferation is not affected. 
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4.5. Conclusions and future work 
In this work, conformationally-constrained peptides that act as CK2 α/β PPI inhibitors were 
developed. The lead peptide, P7-C5, presents an enhanced binding affinity for CK2α with respect 
to the previously developed Pc (Kd 150 vs 1000 nM) and it is stable under conditions mimicking 
physiological fluids. Due to the lack of intrinsic cell-permeability of the peptides, an easily-
synthesised multi-functional constraint was developed giving P7-F1C5 which allowed the 
investigation of the intracellular activity. P7-F1C5 was found to arrest cancer cell proliferation 
and induce apoptosis in a dose-dependent manner. Importantly, the multi-functional constraint 
developed herein could be used to lock other peptides into their binding conformation and 
simultaneously functionalise them. 
P7-F1C5 is the first inhibitory peptide of the CK2α/β PPI that is stable in serum, cell-permeable, 
active in cells, able to engage the target and with structural information available. Such a peptide 
could act as a chemical probe allowing study of the CK2 PPI using endogenous levels of proteins 
and could, therefore, be a powerful tool for validating and dissecting biological processes 
associated with CK2.  
The downside of P7-F1C5 is its accumulation in some cytosolic organelles – namely lysosomes, 
Golgi and ER. Future work will focus on understanding the causes of this effect by introducing 
mutations in the peptide sequence or by changing the cell-penetrating tag. In addition, further 
attempts to investigate the ability of P7-F1C5 to engage CK2 intracellularly will be carried out. 
Shorter peptides with improved ligand efficiency will be developed using the X-ray structures 
obtained in this work as a starting point. The ultimate goal is to develop peptides that are cell-
permeable without the introduction of cell-penetrating motifs. Considering that the peptide 
hotspots are known, the shorter peptides will have a sequence based around them (RLYGFK), 
and new constraints will be screened to lock the shorter peptides in their binding conformation. 
At a later stage, the peptides could be merged with fragments found to bind in the Tyr pocket in 
FBDD screening campaigns carried out by collaborators in the Hyvönen group (Biochemistry, 
University of Cambridge). Whilst the CCHP strategy around the Phe7 residue failed in this study, 
shorter peptides should allow more flexibility around the Tyr pocket, and therefore, it is 
envisioned that the CCHP strategy would work with the shorter peptides. 
CK2 is overexpressed in cancer cells but it is also present in healthy cells. Selective cancer-cell 
targeting would improve the therapeutic window of CK2 inhibitors therefore reducing side 
effects. Selective cancer-cell targeting may be achieved with the use of homing peptides – short 
amino acid sequences that recognise the receptor exposed on the membrane of cancer cells. 
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iRGD, for instance, is a homing peptide that targets colorectal cancer cells, and it could be 
attached to the CK2 peptides for CK2 targeting in selected cells. Stapling of the homing peptide 
will be considered to avoid its degradation in the bloodstream.  
Finally, in this work P2’-C5 provided the first X-ray structure of the CK2 substrate binding in the 
substrate channel. Such information will be used to develop high-affinity peptides that could 
displace the native CK2α substrates, and therefore the structural information obtained in this 
work opens up the possibility to develop a novel class of CK2 inhibitors and to fully understand 
the phosphorylation mechanisms of CK2.  
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5.1. Summary 
Platelets are blood cells with numerous crucial pathophysiological roles in haemostasis, 
inflammation, cardiovascular thrombotic events, and cancer metastasis.180-182 Platelet activation 
and survival require the engagement of intracellular signalling pathways that involve protein-
protein interactions (PPIs), and a better understanding of these pathways is crucial for the 
development of selective antiplatelet drugs. Conventional platelet research methods present 
several limitations. For example, small molecule inhibitors can lack selectivity and are often 
challenging to design and synthesise; the development of transgenic animal models is costly and 
time-consuming; and conventional recombinant techniques are ineffective due to the lack of a 
nucleus in platelets.193  
In order to overcome the limitations of conventional research methods, this chapter describes 
the first application of stapled peptides in human platelets to study PPIs of the Bcl-2 protein 
family (Figure 56).  
 
Figure 56 - First application of stapled peptides in platelets to study PPIs. 
This work shows that stapled peptides have the potential to unlock the number of PPIs that can 
be studied in human platelets, and they could help in the development of safer platelet-targeting 
drugs for treatment of a variety of diseases. 
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5.2. Project background 
Of interest is the investigation of the Bcl-2 proteins, in particular, the BH3-only proteins which 
play a crucial role in regulating intrinsic apoptosis and the lifetime of platelets.167,178,186,187 Whilst 
all-hydrocarbon stapled peptides corresponding to the BH3 domains of the BH3-only protein 
family members have previously been used in haematological cancer cells, the efficacy of these 
molecules for use in platelets has yet to be examined. On the other hand, the small molecule Bad-
BH3 mimetic ABT-73721 has been employed in platelets where it was found to cause platelet 
apoptosis but no platelet activation.188,224 The pathways that lead to intrinsic apoptosis in 
platelets overlap to some degree with those leading to platelet activation and clot formation as 
described previously (Figure 20), and it is believed that the different BH3-only proteins may 
trigger activation or apoptosis selectively (Figure 57). The elucidation of these pathways could 
have a remarkable impact on the development of selective platelet-targeting therapy. 
 
Figure 57 – Schematic representation of the Bcl-2 family members and their relationship with each other. Pro-apoptotic 
BH3-only proteins are shown in green (light green for sensitisers and dark green for activators), anti-apoptotic proteins 
in pink and effectors of apoptosis in blue. BH3-only proteins can inhibit one class or both classes of anti-apoptotic 
proteins, and the effect of inhibiting one class or another on platelet activation and apoptosis is not known. 
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5.3. Project aim and overview 
This project aimed to develop stapled peptides able to mimic the BH3-only proteins of the Bcl-2 
family and utilise these to dissect their role in platelet apoptosis and activation.  
Initially, uptake experiments were carried out using model peptides with different tags on the 
staple. This showed how the nature of the tags impacted on the ability of the stapled peptides to 
permeate the membrane of the platelets. The model peptides were based on the p53 sequence 
and did not affect platelet activation or apoptosis: platelets are anucleated cells, and p53 is a 
nuclear protein. Successively, the tags that allowed the p53-based model peptides to enter the 
cytosol of platelets were used to staple Bim-BH3-based peptides at an i,i+4 position, and their 
effect on platelet activation and apoptosis studied. At a later stage, the ability of the peptides to 
engage with their target was investigated in vitro. Mechanistic differences between the Bim-BH3 
peptide and the small molecule Bad-BH3 mimetic ABT-73721 utilised as positive control inspired 
us to investigate the effects of all the other BH3-only proteins on platelet activation and 
apoptosis. Initially, we intended to employ an i,i+11 stapling strategy to constrain the BH3 
peptides; however, due to problematic functionalisation of the linker, an i,i+7 stapling chemistry 
was applied instead. The workflow described in this chapter is summarised in Figure 58. 
 
Figure 58 - Overview of the work described in this chapter. 
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5.4. Results and discussiondd 
Unless otherwise stated, the peptides described in this chapter were synthesised using standard 
procedures for solid phase peptide synthesis (SPPS) and peptide macrocyclisation was achieved 
by following previously reported procedures for two-component copper-catalysed azido-alkyne 
cycloaddition peptide stapling (2C CuAAC PS).38 
The cellular experiments reported in this chapter were performed at Anglia Ruskin University, 
Cambridge, under the supervision of Dr Nicholas Pugh. The Surface Plasmon Resonance (SPR) 
assay was performed at AstraZeneca, Cambridge, under the supervision of Dr Kara Herilhy. 
5.4.1. Uptake and bioactivity of model stapled peptides in human 
platelets 
Since no reports existed in the literature on using stapled peptides in platelets, we started 
investigating cell permeability. To this end, a panel of sixteen model stapled peptides 
(synthesised by Dr Yuteng Wu) was used.225 The model peptides were TAMRA labelled to allow 
for fluorescent visualisation on flow cytometry, and their sequence was based on the p53 
protein (a nuclear effector) and should have no effect on anucleated platelets. In addition, the 
model peptides were stapled with functionalised peptidic and non-peptidic groups providing 
enough variety to understand which groups are more effective at carrying the cargo peptides 
into platelets (Figure 59). Functionalised groups included: polycationic peptidic chains,81 the 
nuclear localisation sequences PKKKRKV (NLS) and a polyguanidine small molecule carrier 
(SMoC)226–230. Moreover, a panel of anionic and polar peptidic chains was also screened. 
 
Figure 59 - TAMRA-labelled functionalised stapled peptides synthesised by Dr Yuteng Wu used to analyse platelet uptake 
of peptides. Schematics of the different peptidic (blue), non-peptidic functionalised staples (green) and a SMoC staple 
(yellow). * indicates unlabelled peptides (N-terminus capped as acetyl). Adapted from Iegre et al., ChemSci, 2018.193 
                                                          
dd The work described in paragraphs 5.4.1 and 5.4.2 have been published in a scientific journal prior to publication of this PhD thesis 
and some text and figures reported herein have been adapted from the publication Iegre et al., ChemSci, 2018.193 
CHAPTER 5: Targeting of anti-apoptotic Bcl-2 proteins in platelets using stapled peptide 
 
 
112 
Flow cytometry was employed to assess the uptake of the peptides into platelets at different 
time points: internalisation of the TAMRA labelled peptides resulted in fluorescent platelets with 
emission at 550 nm (Figure 60a).ee Treatment with M13-M15 (carrying NLS) or M16 (bearing 
the SMoC motif) showed the highest platelet fluorescence after a 3-hour incubation (96.1 ± 
0.8%, 98.1 ± 1.1%, 97.5 ± 1.4% and 96.1 ± 2.2% respectively) indicating a substantial association 
of the platelets with the stapled peptide. Similarly, M2 (ethyl ester) and the poly-arginine 
stapled peptides M4 and M5 showed significant uptake (88.8 ± 5.6%, 73.0 ± 13.3 % and 87.0 ± 
7.3% respectively) whereas only 34.9 ± 7.8% of platelets were fluorescent following treatment 
with M8 (poly-lysine). No changes in fluorescence were observed with the other peptides, 
indicating that the other tags were ineffective as cell-penetrating peptides (CPPs).  
 
Figure 60 – Uptake experiments using model peptides M1-M16. a) Platelets fluorescence after 1 h (white), 2 h (grey) and 
3 h incubation (black). b) Peptide uptake of model peptides monitored during the first 60 minutes of treatment. : 
vehicle (DMSO), : M16, : M15,▲: M14, : M13, : M8, : M5, : M2. c) Five-minute real-time measurement of 
peptide uptake. Unlabelled platelets were recorded for 30 sec prior to addition of the given peptide. d) Confocal 
microscopy images of live platelets incubated with the TAMRA-model peptides. Adapted from Iegre et al., ChemSci 
2018.193 
For the peptides that showed maximum fluorescence after 3-hour incubation, the uptake was 
monitored after 15, 30, 45, and 60 minutes (Figure 60b). More than 50% of platelets became 
fluorescent during the first 15 minutes of incubation with M13-M16 with a further increase 
after the first 45 minutes. Some 40-50% of platelets were fluorescent after 15 minutes following 
treatment with M2, M5 or M8, and no further increase was detected thereafter. Continuous 
                                                          
ee In all the flow cytometry experiments described in this chapter, the fluorescence associated with untreated platelets (no 
compounds, no fluorescently-labelled markers) was recorded and used to normalise the results. In particular, the peak 
corresponding to the untreated platelet signal read on the laser of interest was considered as zero. Shift of such peak towards the 
right was considered as positive platelet and quantify accordingly (vide 9.2.2, Figure 72 for more details). 
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assessment of platelet fluorescence in the first 5 minutes of treatment demonstrated that 
peptides M5 and M16 were instantly internalised by a fraction of the cells (Figure 60c).  
Peptide uptake experiments of the most permeable model peptides M5, M13-M16 were 
repeated in the presence of platelet-rich plasma (PRP) to ensure realistic conditions. The results 
showed only a small reduction in peptide uptake between 10 and 20% compared to buffer, 
indicating that the uptake is not prevented by the interaction of the peptides with the other 
components of the plasma.  
Whilst flow cytometry quantifies the fluorescence of the platelet population, is not indicative of 
whether the fluorescence is a result of peptide internalisation or association with the 
membranes. Consequently, confocal microscopy of live platelets was carried out to elucidate the 
peptide localisation. It should be noted that platelets are small-sized (∅ ~ 2 μm); therefore, 
confocal microscopy cannot assign pixel localisation unequivocally but can, nonetheless, indicate 
whether the fluorescence comes from the platelet membrane or cytosol. Live platelets were 
imaged after 1-hour incubation with the TAMRA-labelled model peptides, and the results 
suggested that peptides M5 and M13 permeated into the platelet cytosol. On the contrary, M2, 
M8, and M16 localised predominantly on the platelet membrane (Figure 60d).  
Conventional platelet apoptosis and activation responses were assessed to investigate potential 
off-target effects following treatment with the platelet-permeable model peptides. As a response 
to external stimuli, platelets expose phosphatidylserine (PS) on the plasma-oriented surface of 
their membrane. It is widely recognised that plasma-exposed PS plays a regulatory part in blood 
coagulation acting as a secondary messenger and is an index of apoptosis (in both platelets and 
nucleated cells).231 When exposed on the platelet surface, PS binds the marker Annexin V in the 
presence of Ca+2 ions. If the marker is fluorescently labelled (i.e. with a FITC groupff), its signal 
can be used in flow cytometry to detected PS exposure (Figure 61). Similarly, other platelet 
activation markers (dense and α granules release, integrin αIIbβ3) can be detected using flow 
cytometry when specific fluorescently-labelled antibodies are used. For instance, exposure of 
integrin αIIbβ3 on the platelet surface can be detected by the antibody PAC-1 (Figure 61). When 
platelets become activated, they expose integrin αIIbβ3 to bind substrates that once complexed, 
promote platelet aggregation and clot formation. 
                                                          
ff Different excitation/emission wavelengths for TAMRA (Ex-max 546 nm/Em-max 579 nm) and FITC (Ex-max 494 nm/520 nm Em-
max) allowed selective detection of a fluorescent signal over the other. 
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Figure 61 - Schematic of the detection of PS exposure and platelet activation using fluorescently labelled antibodies. PS is 
represented in black, dense granules in red, α granules in aubergine, integrin GPαIIbβ3 in blue. 
Since the model peptides used were based on the sequence of the nuclear effector p53, and 
platelets have no nucleus, no biological effect was expected after treatment with the peptides. As 
expected, only low activation changes were observed following treatment with NLS-bearing 
peptides M13-M15 and SMoC peptide M16 (Figure 62a and b). No change in platelet activation 
markers was found for the other peptides, indicating that the treatment of platelets with the 
model peptides did not cause unspecific responses. Undesired platelet aggregation - as noted by 
analysis on the aggregometer - was detected in response to treatment with peptide M16, but not 
for the other peptides (Figure 62c). Thus, peptide M16 was excluded from further studies. 
 
Figure 62 – a) Annexin V binding for model platelet-permeable peptides; b) PAC-1 binding:  : Thrombin 1U/mL,  : 
vehicle (DMSO), : M16, : M15, ▲: M14, : M13, : M8, : M5, : M2. c) Platelet aggregatory responses to 
treatment with model peptides. Vehicle control (DMSO) and thrombin were used as negative and positive control 
respectively. 
This data set provides evidence that functionalisation of stapled peptides is required for the 
uptake of peptides into platelets, with the NLS sequence (M13-M15) and poly-arginine staple 
(M5) being the most effective. In addition, these preliminary experiments showed that the 
staples themselves do not exert any unspecific activity in platelets. 
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5.4.2. Investigation of the Bim/Bcl-xL PPI in platelets using i,i+4 stapled 
peptides 
Once it was confirmed that platelets were able to uptake stapled peptides, further experiments 
were performed to investigate whether peptides based on biologically relevant sequences could 
elicit a relevant intracellular response in platelets.  
The role of BH3-only proteins in the development of a pro-coagulant platelet phenotype has 
been investigated using the Bad-BH3 mimetic small molecule ABT-737.21 This induces 
mitochondrial membrane depolarisation, activation of caspases -9, -8 and -3, PS exposure, and 
causes inhibition of the platelet activation process by interacting with the pro-survival Bcl-2 
proteins.188,189,224,232 However, the role of the other BH3-only proteins (Bid, Bim, Bmf, Noxa, 
Puma) in platelet activation and apoptosis is not fully understood. Previous work has 
demonstrated that an all-hydrocarbon (AH) Bim sequence-based peptide (denoted Bim SAHBa, 
Table 15) induces Bax mediated apoptotic responses in nucleated cancerous cells.177,233,234 To the 
best of our knowledge, the implication of the interaction of Bim-BH3 mimetics with the anti-
apoptotic Bcl-2 proteins in platelets is unknown. Hence, CuAAC 2C stapled peptides based on the 
Bim-BH3 sequence were synthesised and utilised to investigate their effects on platelet 
processes. The CuAAC 2C peptide stapling methodology was chosen as it allows to access 
multiple stapled peptides from one linear sequence in a combinatorial manner. This results in a 
more efficient access to libraries of functionalised peptides. 
5.4.2.1.  Design and synthesis of i,i+4 Bim-BH3 stapled peptides 
Inspired by the work of Walensky et al.,177 we decided to synthesise i,i+4 stapled peptides based 
on the SAHBa sequence. Molecular dynamic simulations (MDs) were performed by Dr Yaw Sing 
Tan on the complex form by the Bcl-xL proteingg and the peptide mimicking the BH3-only domain 
of the protein Bim to suggest amino acid and staple combination to use to retain the binding 
affinity of the native Bim peptide. MDs simulations suggested employing the azido ornithine 
amino acid (12) as the unnatural amino acid to perform the 2C CuAAC stapling. This would 
facilitate the synthesis of different stapled peptides from one linear precursor (P9, Figure 63a). 
3,5 dialkyne benzoic acid (C5) was used as the linker for stapling. MDs simulations of the 
peptide complexed with Bcl-xL suggested that the stapled peptide P9-C5 (Figure 63b) would 
retain an α-helical conformation upon binding and that its binding affinity would be comparable 
to that of the unstapled wild-type (WT) peptide (P10) (ΔH -107.6 ± 4.9 Kcal·mol-1 vs -108.3 ± 1.5 
Kcal·mol-1, Figure 63). 
                                                          
gg An anti-apoptotic Bcl-2 protein which is known to be expressed in platelets.178 
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C-terminus
N-terminus
Bcl-XL
 
Figure 63 – a) Structures of P9, P10 and P9-C5. b) Snapshot taken from the end of the MD simulation of P9-C5 in 
complex with Bcl-XL. The surface of Bcl-XL protein is shown in grey, peptide secondary structure in green and peptide 
residues in orange. 
Synthesis of peptide P9 required Fmoc-azido ornithine amino acid 12 which was synthesised 
according to literature precedent.235 The synthesis commenced from the commercially available 
Fmoc-Ornithine(Boc)-OH that underwent Boc deprotection in the presence of 4 M HCl in 1,4-
dioxane to afford Fmoc-Ornithine-OH 11. The crude product was then subjected to treatment 
with azido-transfer reagent imidazole-1-sulfonyl azide hydrogen sulfate (6) in the presence of 
CuSO4 · 5H2O to yield the desired product 12 in 78% yield (Scheme 29).  
 
Scheme 29 - Synthesis of azido amino acid 12 starting from commercially available Fmoc-Ornithine(N-Boc)-OH. 
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Synthesis of the azido-transfer reagent 6 and constraint C5 are described in Chapter 4. 
Synthesis of staples F4C5 and F5C5 was achieved using the standard procedure for SPPS (Figure 
64). The N-terminus of the peptides were capped with C5 before peptide cleavage from the 
resin, trituration with Et2O and purification. 
 
Figure 64 - Structures of constraints C5, F4C5 and F5C5. 
Based on the platelet permeability results of the model peptides, P9 was then stapled with C7 
(non-functionalised staple to be used as negative control), F4C5 (poly-arginine staple) and F5C5 
(NLS staple) where F4C5 and F5C5 are the same functionalised staples as the model peptides 
with the highest cytosolic platelet uptake M5 and M14. A list of all the peptides used in this 
study and conversions of the CuAAC 2C-PS reactions can be found in Table 15. 
Additionally, a negative cell-permeable peptide was synthesised and used as a negative control. 
The negative peptide (P11-F4C5) presented an R153D mutation in its sequence which was 
found not to exert the Bim-BH3 biological effect in nucleated cells.177 FITC-labelled analogues of 
all the stapled peptides were also synthesised to monitor their uptake into platelets. In this 
study, FITC was attached to the N-terminus of the peptides by treating the on-resin Fmoc-
deprotected peptide with FITC and DIPEA in the dark for 14-16 hours. An aminohexanoic acid 
spacer (Ahx) was placed between the N-terminal peptide residue and the FITC group to avoid 
steric clashes. The SAHBa peptide, which inspired this work, and its FITC-labelled analogue, 
were also synthesised for comparison.  
Table 15 - Names and structures of the peptides used in this study, conversions of the 2C-PS stapling and schematic 
representation of the 2C CuAAC reaction. 
 
Peptide Sequence Staple Conversions 
P9 Ac-IWIAQELRXIGDXFNAYYARR NA - 
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P9-F4C5 Ac-IWIAQELRXF4C5IGDX F4C5FNAYYARR 
 
59 
FITC-Ahx-
P9-F4C5 
FITC-Ahx-IWIAQELRXF4C5IGDX F4C5FNAYYARR 74 
P9-F5C5 Ac-IWIAQELRXF5C5IGDXF5C5FNAYYARR 
 
87 
FITC-Ahx-
P9-F5C5 
FITC-Ahx-IWIAQELRXF5C5IGDXF5C5FNAYYARR 90 
P9-C7 Ac-IWIAQELRXC7IGDXC7FNAYYARR  
 
 
81 
FITC-Ahx-
P9-C7 
FITC-Ahx-IWIAQELRXC7IGDXC7FNAYYARR NA 
P10 Ac-IWIAQELRRIGDEFNAYYARR 
NA 
- 
FITC-Ahx-
P10 
FITC-Ahx-IWIAQELRRIGDEFNAYYARR - 
P11-F4C5 Ac-IWIAQELDXF4C5IGDX F4C5FNAYYARR 
 
NA 
FITC-Ahx-
P11-F4C5 
FITC-Ahx-IWIAQELDXF4C5IGDX F4C5FNAYYARR 79 
SAHBa Ac-IWIAQELRZIGDZFNAYYARR 
 
- 
FITC-Ahx-
SAHBa 
FITC-Ahx-IWIAQELRZIGDZFNAYYARR - 
All the peptides have an amide at the C-terminus. X = azido ornithine; The schematic structure showed above the table does not 
represent one of the SAHBa peptides which were cyclised using a RCM reaction. Z = (S)-2-(pent-4-enyl) alanine and the AH staple 
is shown in the column “Staple”. a Conversion of stapling reactions as determined by LCMS of the crude reaction mixture. NA = not 
available due to complicated LCMS chromatogram. 
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Synthesis of peptide P9 proved challenging. Standard microwave-assisted SPPS procedure using 
MBHA Rink Amide (0.35 meq/g resin loading) resulted in some impurities with a similar 
retention time to the desired product hence preventing its purification. The use of lower loading 
resin (0.19 meq/g) did not resolve the issue, and neither did room temperature peptide 
synthesis. Pleasingly, a double coupling for each of the amino acids afforded the desired product 
P9. The latter crude peptide presented solubility issues in the solvents used for HPLC 
purification (MeCN, H2O, TFA) and in DMSO. High dilution of the crude material followed by 
several filtrations using 0.45 µm PTFE syringe filters resulted in a clear solution that underwent 
purification successfully. Similarly, synthesis of P10 was achieved on a microwave-assisted 
peptide synthesiser using double coupling for all the amino acid. Unlike P9, P10 did not present 
solubility issues 
5.4.2.2. The uptake of Bim peptides into platelets 
As with the model peptides, flow cytometry was used to detect fluorescent platelets in the 
presence of the FITC-labelled Bim-BH3 peptides. The PRP was incubated with the FITC-labelled 
peptides, and the uptake monitored after 15, 30 and 60-minute incubation (Figure 65a).  
   
Figure 65 - Uptake experiments in the presence of FITC-labelled Bim-BH3 peptides. a) Uptake of Bim-BH3 peptides and 
SAHBa in PRP after 15 minutes (black), 30 (grey), 1 h (white). The results shown are the average of two independent 
repeats and error shown as SEM. b) Images of live platelets incubated with Bim-BH3 FITC-labelled peptides. For each 
peptide, the green channel is shown on the left and the grey on the right. 
The uptake experiment showed that all the peptides tested associated rapidly with platelets 
except for the WT peptide FITC-Ahx-P10. 
Successively, confocal microscopy was used to understand whether the fluorescence observed 
by flow cytometry was cytosolic or associated with the platelet membranes (Figure 65b). 
Consistently with the behaviour of the non-functionalised model peptide M1, the images showed 
poor membrane permeability of peptide FITC-Ahx-P10. Even though flow cytometry of FITC-
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Ahx-P9-C7 suggested high platelet fluorescence in plasma, confocal imaging showed the peptide 
forming aggregates outside the platelet cytosol and hence being unable to reach the target 
protein. Peptide FITC-Ahx-P9-F4C5 was the most effective at localising into the platelet cytosol: 
FITC-Ahx-P9-F5C5, in fact, aggregates partially with the platelet membrane. Both the positive 
and negative control peptides (SAHBa and FITC-Ahx-P11-F4C5 respectively) were successfully 
internalised in the platelet cytosol.  
5.4.2.3. Phosphatidylserine exposure induced by Bim-BH3 peptides: 
a sign of apoptosis or platelet activation  
Once it was confirmed that Bim-BH3 peptide uptake is dependent on a functionalised staple, the 
influence of these peptides on activating processes in washed platelet suspensions was studied. 
The activity of the peptides was compared with ABT-737, the previously reported Bad-BH3 
small molecule mimetic.21,188 Initially, the ability of the peptides to cause PS exposure was 
investigated on flow cytometry using FITC-labelled Annexin V. 
Treatment of platelets with P9-F4C5 or P9-F5C5 resulted in PS exposure (with 78 ± 1.3% and 
42.9 ± 6.0% Annexin V binding after 3-hour incubation), consistent with the generation of a pro-
coagulant phenotype. Of note, P9-F4C5 showed a similar profile to ABT-737 and appeared to be 
more potent than the AH stapled Bim peptide SAHBa (Figure 66). No Annexin-V binding was 
observed following treatment with the WT peptide P10 nor with the non-functionalised stapled 
peptide P9-C7, consistent with their cell-impermeable nature. Pleasingly, the negative peptide 
P11-F4C5 did not result in PS exposure in platelets despite being platelet-permeable, suggesting 
that the effects of the BH3 stapled peptide are specific to biologically relevant processes.  
 
Figure 66 - Functionalised, stapled Bim-BH3 peptides induce PS exposure in platelets. Platelets were treated with 10 μM 
compounds, and changes in Annexin-V binding were quantified using flow cytometry at different time points. : P9-
F4C5,  : P9-F5C5, ▲: P9-C7, : P10, : ABT-737, ◆: vehicle (DMSO), : P11-F4C5, θ: SAHBa. 
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5.4.2.4. Activation marker binding induced by Bim-BH3 peptides: a 
sign of platelet activation  
We then assessed the effect of permeable stapled peptides P9-F4C5 and P9-F5C5 on platelet 
activation markers since previous work has indicated that the small molecule Bad-mimetic ABT-
737 induces apoptosis without causing platelet activation.236–238 As in the previous experiments, 
P11-F4C5 peptide was employed as the negative control. 
In addition to the previously described PAC-1 (vide supra 5.4.1), two other platelet activation 
markers were used in this experiment: CD62P and CD63. CD62P indicates secretion of α 
granules while CD63 is an index of secretion of dense granules.236,238 α granules are secreted by 
activated platelets into the plasma and contain several growth factors - such as IGF-1, PDGFs, 
TGFβ, CXCL4 - and clotting proteins - including thrombospondin, fibronectin, factor V, and the 
VWF – which trigger clot formation. On the other hand, dense granules contain ADP, ATP, 
calcium ions and serotonin; all cofactors required to prompt the coagulation cascade. α and 
dense granules express the adhesion molecules CD62P and CD63 respectively and, when 
exposed on the platelet surface, can be recognised by the corresponding fluorescently labelled-
antibodies.  
Initially, it was decided to use the three antibodies (anti-PAC1, anti-CD63 and anti-CD62P) 
simultaneously as the markers carried different fluorophores that could be detected at three 
different wavelengths by the flow cytometer.hh However, assessment of the three activation 
markers together was not possible as the readings generated inconclusive results with the 
DMSO control giving high response for all the markers. Therefore, the activation markers were 
assessed separately.  
As shown in Figure 67, after 1-hour incubation both Bim-BH3 peptides induced integrin αIIbβ3 
activation (as measured by PAC-1 binding), whilst ABT-737 was ineffective. In particular, 
treatment with P9-F4C5 or P9-F5C5 resulted in 24.1 ± 2.4% and 50.8 ± 0.3% PAC1-positive 
platelets, respectively.ii Treatment with both peptides resulted in similar levels of CD62P 
expression (53.7 ± 2.5% and 62.1 ± 7.8%, respectively), indicating peptide-induced α granule 
secretion. Additionally, both peptides increased CD63 expression (correlated with dense granule 
release), with peptide P9-F4C5 being more effective than P9-F5C5 (72.9 ± 5.3% vs 34.4 ± 6.7% 
respectively). Pleasingly, unspecific activation was not observed when the mutant P11-F4C5 
was used.  
                                                          
hh FITC-labelled PAC-1 (Ex-max 482 nm/Em-max 520 nm); PE-labelled CD62P (Ex-max 496 nm/Em-max 478 nm); APC-labelled 
CD63 (Ex-max 650 nm/Em-max 660). 
ii Positive platelets are ones that showed greater fluorescence than any platelets in the untreated control sample. Vide Figure 72, 
section 9.2.2 for more details. 
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Figure 67 – Induction of activation markers by Bim-BH3 peptides and ABT-737. Platelet activation markers (% positive 
platelets) were investigated following 1 h of peptide treatment.  PAC-1,  CD62P and  CD63 binding. Statistic 
significance compared to P9-F5C5: **** = P <0.0001, *** = P between 0.0001 and 0.0005, ns = non-significant. 
In conclusion, despite having similar effects on PS exposure with respect to the clinical candidate 
ABT-737, our Bim BH3 peptides showed a pronounced increase in activation markers. These 
results highlight that Bim and Bad have different effects on platelet activation, thus pointing to a 
difference in the roles and mechanisms of these two proteins. Further investigation dissecting 
the roles of each BH3-only protein in platelets would help to understand these mechanistic 
differences. 
5.4.2.5. In vitro target engagement using an SPR assay  
Surface Plasmon Resonance (SPR) assay was used to understand whether the peptides were 
able to bind to the anti-apoptotic proteins of the Bcl-2 family (Bcl-xL, Mcl-1, A1, Bcl-2, Bcl-w). In 
particular, the ability of P10, P9-F4C5, P11-F4C5 and SAHBa to bind to Bcl-xL was investigated. 
Bcl-xL was chosen among the other members of the anti-apoptotic family for its well-
documented presence in platelets.178 
In the SPR assay performed in this study, the Bcl-xL protein was immobilised on a flexible 
dextran matrix, and the peptides were allowed to flow across that surface. The SPR assay was 
configured to examine the direct binding of peptides to Bcl-xL derivatised sensor surfaces and 
generate apparent affinity values (Kdapp) to provide ranking data for the series of peptides under 
examination.  
The results confirm that the WT peptide P10 and platelet-permeable stapled peptide P9-F4C5 
were able to engage with Bcl-xL protein (Kdapp 7.3 ± 0.2 and 26 ± 0.3 nM respectively) supporting 
the hypothesis that P10 does not exert a biological response in platelet due to the lack of cell-
permeability. Interestingly, the AH stapled Bim-BH3 peptide SAHBa showed a reduced binding 
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affinity compared to the WT and peptide P9-F4C5 (Kdapp > 33 nM).jj No binding was observed for 
the negative peptide P11-F4C5.  
5.4.2.6. Effect of stapling on the peptide secondary structure and 
stability to serum proteases  
Circular dichroism (CD)kk was used to elucidate the effect of the i,i+4 stapling on the secondary 
structure of the Bim peptides. To this end, the functionalities that P9-F4C5 and P9-F5C5 carry 
on the staples were removed to avoid interference, and P9 was stapled with C5 (3,5-dialkyne 
benzoic acid, 58% conversion). The secondary structure of P9-C5 was measured in a 50:50 
mixture of MeCN and H2O at a concentration of 50 μM. For comparison, the structure of the WT 
Bim-BH3 peptide P10 in solution was determined using the same conditions (Figure 68). 
 
Figure 68 - Mean Residue Ellipticity of the Bim-BH3 peptides P9-C5 (green) and P10 (red). 
The spectra showed that P9-C5 was able to maintain a helical structure although its % helicity 
(at 222 nm) was reduced compared to the WT peptide P10 (10% vs 20%, respectively). 
In order to understand whether stapling via 2C CuAAC enhanced the proteolytic stability of the 
peptides to proteases, serum stability tests were undertaken for the stapled peptide P9-C5 and 
the WT linear peptide P10. 
                                                          
jj Exact quantification of the Kdapp for SAHBa was not possible due to solubility issues encountered when concentrations higher than 
33 nM were used. 
kk Circular dichroism (CD) is a technique used to investigate the peptide secondary structure in solution. For α-helical peptides, a 
typical CD spectrum shows a characteristic double minimum at 208 and 222 nm. CD provides a simple method for estimating α-
helical content of peptides and proteins but should not be considered definitive.  
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Figure 69 - Stability of Bim-BH3 peptides P10 (blue) and P9-C5 (red) in human serum. The results are the average of 
three independent repeats, and the error is shown as SEM. 
The staple was effective at improving the stability of the peptide to the serum proteases: the WT 
peptide P10 was fully degraded after 4 hours while 20% of the stapled peptide was still detected 
after 26-hour incubation. 
5.4.2.7. Considerations on the use of i,i+4 Bim-BH3 peptide in 
platelets 
The results obtained thus far showed that platelets are amenable to treatment with stapled 
peptides. In particular, a functionalised staple was required to translocate p53 and Bim-based 
2C CuAAC stapled peptides into the platelet cytosol. The i,i+4 stapled peptides developed in this 
work proved to be more stable than the WT peptide to serum proteases. Besides, the peptides 
engaged the Bcl-xL target with nM affinity and were able to cause platelet activation.  
5.4.3. Dissecting the role of Bim, Bad, and Bid protein in platelets using 
stapled peptides 
Intrigued by the results obtained when comparing Bim to Bad mimetics, we decided to 
investigate the effect of mimics of each member of the pro-apoptotic proteins of the Bcl-2 family 
on platelet activation and apoptosis. In nucleated cells, Noxa-BH3 antagonises exclusively the 
anti-apoptotic proteins Mcl-1 and A1. Bim, Puma, and Bid inhibit all of the anti-apoptotic 
proteins whereas Bad, and Bmf engage Bcl-2, Bcl-xL, and Bcl-w (Figure 57).168 To this aim, Bim, 
Bad and Bid-BH3 mimetics were synthesised, and their characterisation is described in this 
work; Noxa, Puma, and Bmf-BH3 peptides were synthesised by Josephine Gaynord, PhD student 
in the Spring group. 
5.4.3.1. Looking at i,i+11 stapling 
The i,i+4 stapling of the Bim-BH3 peptides synthesised in the first part of this study did not 
enhance the helicity of the WT peptide (Figure 68). It is highly debatable whether the 
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enhancement of helicity results in an improved binding affinity for the BH3 peptides; however, 
the majority of reports indicate that greater helicity results in greater binding.176,186,239  
Consequently, alternative stapling positions to the i,i+4 were considered to impart greater 
helicity on the peptides. The use of i,i+11 stapling in 2C CuAAC is highly underexplored with only 
one study done on one model peptide sequence: a 3,6-diethynyl-9H-carbazole used in 
combination with azido-ornithine amino acids was the most effective, among other stapling 
combinations explored, at inducing α-helical structures.240 In addition, the proteolytic stability 
as a result of constraining 11 residues instead of 4 may be improved further. Encouraged by this 
evidence, we decided to synthesise i,i+11 Bim, Bad, and Bid BH3 peptides using a carbazole 
linker as the staple. 
5.4.3.1.1. Design and synthesis of i,i+11 stapled peptides 
The i,i+11 stapled peptides were designed from the X-ray structures available. The staple was 
placed on those residues that did not contribute to the binding and that are solvent exposed to 
avoid clashes with other residues on the peptide or the target proteins. A summary of the i,i+11 
stapled peptides proposed, their corresponding WT peptides, a schematic representation of the 
stapling reaction, and the reference PDB codes can be found in Table 16. 
Table 16 – WT and i,i+11 Bim, Bad, Bid stapled peptides subject of this work. 
 
Protein PDB WT peptide Azido-linear peptide Stapled peptide Conversionsa  
Bim 2YQ7241 
IAQELRRIGDEFNAYYARR 
(P10) 
IAXELRRIGDEFNXYYA 
(P14) 
P14-C8 NA 
Bad 1G5J242 
RYGRELRRMSDEFVDSF 
(P12) 
XYGRELRRMSDXFVDSF 
(P15) 
P15-C8 90% 
Bid 5C3F243 
IIRNIARHLAQVGDSMDRS 
(P13) 
IIRNIAXHLAQVGDSMDXS 
(P16) 
P16-C8 60% 
All the peptides present an amide at the C-terminus and are capped with an acetyl group at the N-terminus. X in the linear peptides 
refers to the azido-ornithine (12). a Conversion of stapling reactions as determined by LCMS of the crude reaction mixture. NA = 
conversions of stapling reaction not available due to complicated LCMS chromatogram  
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Synthesis of the a 3,6-diethynyl-9H-carbazole staple (C8) required for peptide stapling was 
carried out according to literature reports.244 The synthetic route commenced from the 
bromination of the commercially available carbazole in the presence of NBS (Scheme 30). The 
reaction afforded the desired intermediate C8-1 which was then subjected to a Sonogashira 
coupling in the presence of TMS-acetylene, Pd(PPh3)2Cl2, PPh3, and CuI to afford the TMS-
protected analogue of C8. The latter compound underwent basic treatment in the presence of 
K2CO3 and MeOH to afford the desired staple C8 in 81% yield.  
 
Scheme 30 - Synthetic route leading to the carbazole staple C8. 
The synthesis of 12 was described in section 5.4.2.1. 
Peptides were assembled using microwave-assisted SPPS performing double coupling for all 
amino acids with the exception of azido amino acid (12), which was coupled using longer, single 
coupling under MW.  
The crude mixture of Bim-derived peptide P14 presented solubility issues prior to purification 
as observed for its analogue P9. High dilution and multiple filtrations resolved the issue with 
loss of crude material. 
Assessment of the i,i+4 Bim-BH3 stapled peptides in platelets showed that the peptides required 
a functionalised staple (preferably a tri-arginine tag) to gain cytosolic entry. It was decided to 
functionalise the staple C8 using SPPS, so as to make it easily accessible. To achieve that, a 
chemical handle in the form of carboxylic acid was introduced. It was decided to employ 6-
bromo hexanoic acid so that it would act as a functionalisable spacer. Reaction of C8 with KOH 
under ultrasonic waves at 35 °C for 2 hours afforded the title staple C9 bearing a carboxylic acid 
as a functional handle (Scheme 31). 
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Scheme 31 - Synthesis of functionalisable staple C9 starting from C8. 
In a similar method for functionalising the CK2 peptides described in Chapter 4, a tri-D-arginine 
tag was chosen as the tag to attach to C9 to improve cell permeability and stability to proteases 
of the overall construct. However, C9 appeared to be unstable under the acidic conditions used 
to cleave the peptide from the resin. After capping the tri-peptide with C9, the TFA cleavage 
cocktail was added to the resin either at room temperature or 42 °C: the resin instantly turned 
black, and LCMS could detect no desired product once the crude reaction mixture was 
concentrated and triturated with Et2O. To confirm whether the instability could be attributed to 
the staple itself, C9 was subjected to treatment with TFA in solution leading to the same 
problem: formation of a black product that was insoluble in any NMR solvents preventing its 
characterisation. An alternative, milder cleavage cocktail was used to cleave the peptide from 
the resin.245 However, the TFA-free cocktail (containing 0.1 M HCl in hexafluoroisopropanol) led 
to the same issue. Before attempting the time-consuming synthesis of the functionalised staple 
in solution, it was decided to investigate the secondary structure of the i,i+11 stapled peptides 
using CD. 
5.4.3.1.2. Helicity of i,i + 11 stapled peptides 
CD spectra for all the i,i+11 stapled peptides and their corresponding linear WT peptides were 
recorded in a 50:50 mixture of H2O/MeCN at a concentration of 100 μM and the results are 
shown in Figure 70. 
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Figure 70 - Mean Residue Ellipticity (θMRE) of i,i+11 stapled BH3 peptides (blue) and corresponding linear WT peptides 
(red). a) Spectra of Bim-BH3 peptides; b) Spectra of Bid-BH3 peptides; c) Spectra of Bad-BH3 peptides. 
The staple significantly disrupted the helicity of the Bad peptide (7% compared to 54% of the 
WT) whilst it did not affect the helicity of the Bid-BH3 peptide (17% compared to 18% of the 
WT). The i,i+11 stapling negatively affected the structure of the Bim-BH3 peptide even more 
than the previously used i,i+4 stapling (20% helicity for the WT, 10% for the i,i+4 and 7% for the 
i,i+11). 
Considering the difficulties associated with the staple functionalisation and the fact that the 
i,i+11 stapling did not enhance the helicity of the peptides, it was decided not to pursue this 
strategy further.  
5.4.3.2. Looking at i,i+7 stapling 
The use of the i,i+7 stapling is well-established, and the combination of azido-ornithine amino 
acids (12) and 3,5-dialkyne benzene derivatives has been used on several occasions to induce α-
helical structures to peptides with helical propensity.81,86,87 In addition, the 3,5-dialkyne benzoic 
acid staple (C5) has been straightforwardly functionalised on-resin in a variety of different 
ways.81,84,86,87 Taking into account the problems encountered with the i,i+11 stapling, it was 
decided to staple the BH3 peptides using the i,i+7 stapling technique to cross-link the side chains 
of azido-ornithine amino acids with the staple C5. 
5.4.3.2.1. Design and synthesis of i,i+7 BH3 stapled peptides 
In a similar method described for the i,i+11 stapled peptides, the design of the new peptides was 
based on the available X-ray structures of the proteins of interest. The staple was placed in a way 
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to avoid clashes with other residues on the peptide or the target proteins. A list of the i,i+7 
stapled peptides synthesised, their corresponding linear peptides, the reference PDB codes, and 
a schematic representation of the stapling reaction can be found in Table 17.  
The synthesis of the peptides presented in the table was achieved using double coupling for all 
amino acids. Solubility problems were encountered with the crude P17-C5 peptide which, as 
previously, required high dilution and filtrations before purification. Percentage conversion of 
the stapling reactions are reported in Table 17. 
Table 17 – i,i+7 stapled and linear Bim, Bad, Bid peptides subject of this work.  
 
Protein PDB Azido-linear peptide Staple  Conversion 
Bim 2YQ7241 IAQXLRRIGDXFNAYYA (P17) 
R = -OH (P17-C5) 92% 
R = -NH-(Ahx)2-[(D)R]3-NH2  
(P17-F1C5) 
92% 
Bad 1G5J242 YGRXLRRMSDXFVDSF (P18) 
R = -OH (P18-C5) 68% 
R = -NH-(Ahx)2-[(D)R]3-NH2  
(P18-F1C5) 
77% 
Bid 4QVE246 IIRXIARHLAXVGDSMDRS (P19) 
R = -OH (P19-C5) 97% 
R = -NH-(Ahx)2-[(D)R]3-NH2  
(P19-F1C5) 
72% 
All the peptides present an amide at the C-terminus and are capped with an acetyl group at the N-terminus. X in the azido-
linear peptides refers to azido-ornithine as shown in the reaction scheme. R on the 3, 5 dialkyne benzene ring is a 
functional group as specified in the column “Staple”.a Conversion of stapling reactions as determined by LCMS of the crude 
reaction mixture. 
5.4.3.2.2. Helicity of i,i+7 stapled peptides 
As for the other peptides, the secondary structure of the i,i+7 stapled BH3 peptides was 
investigated using CD spectrometry. Only the structure of the peptides without a functional tag 
was analysed as it was envisioned that the tag would interfere with the analysis. The results are 
shown in Figure 71. 
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Figure 71 - CD spectra of i,i+7 stapled BH3 peptides (black) and corresponding linear wild-type peptides (red). a) Spectra 
of Bim-BH3 peptides; b) Spectra of Bad-BH3 peptides; c) Spectra of Bid-BH3 peptides. 
The results showed that the i,i+7 stapling was effective at enhancing the helicity of the Bim-BH3 
peptide (47% helicity for the stapled peptide and 20% for the WT) whilst did not affect the 
structures of the Bad (35% vs 28%) and Bid peptides (22% vs 17%) significantly.  
 
With these peptides in hand, their effect on platelet activation and apoptosis will be investigated 
in a similar manner to that reported for the i,i+4 Bim-BH3 peptides (vide supra, 5.4.2.3, 5.4.2.4). 
 
 
 
 
 
 
 
 
 
 
CHAPTER 5: Targeting of anti-apoptotic Bcl-2 proteins in platelets using stapled peptide 
 
 
131 
5.5. Conclusions and future work 
This work is the first to describe the use of functionalised stapled peptides to perturb and 
investigate signalling pathways in human platelets. Using a panel of model stapled peptides, it 
was found that the nature of the motif incorporated onto the staple impacts the ability of the 
peptides to enter the platelet cytosol and modulate activity. Utilising the functionalised staples 
that allowed the model peptide to permeate the platelet membranes, stapled i,i+4 Bim peptides 
were synthesised to investigate PS exposure in platelets. The most promising peptide, P9-F4C5, 
showed a binding affinity of 26 nM for Bcl-xL, and its bioactivity in platelets was comparable to 
that of the small molecule Bad mimetic ABT-737. Importantly, unlike ABT-737, stapled peptide 
Bim-BH3 mimetics caused platelet activation, demonstrating a differential activation of 
signalling pathways.  
In order to dissect the role of each BH3-only protein in platelet apoptosis and activation, i,i+7 
Bad, Bim and Bad peptides have been synthesised, and their bioactivity in platelets will be 
studied. 
Perturbation of the Bcl-2 pathway demonstrates the considerable potential of functionalised 
stapled peptides to investigate other PPIs in human platelets and for future development of new 
antiplatelet drugs. One of the advantages of this technology over small molecule use is the ease 
of design and synthesis of the peptides, as they are a mimetic of the natural components. 
Moreover, limitations such as the lack of membrane permeability and poor serum stability are 
overcome by the presence of the staple. The double click approach only requires one linear 
peptide to enable the generation of a variety of functionalised stapled peptides, which facilitates 
the exploration of various functionalities on the linker and thus the properties of the overall 
peptide. Most importantly, this methodology allows testing in human platelets directly, avoiding 
the inter-species difference, cost and time limitations of transgenic animal models. 
Further work on the peptides developed in this project would involve co-immunoprecipitation 
assays to elucidate intraplatelet target engagement and rationalise the biological results 
obtained. In addition, Bcl-2 proteins are present in nucleated cells and therefore a way of 
targeting platelets selectively or under specific pathological conditions would be investigated to 
develop novel therapeutics. During this project, it was observed that the peptides require a cell-
penetrating tag to gain platelet entrance. Consequently, a homing-peptide that recognises 
membrane receptors expressed on the membrane of platelets but not on the membrane of 
nucleated cells could be incorporated on the staple to gain selectivity for the desired cell type. 
An alternative approach could see the use of a thrombin-sensitive tag attached to a cell-
impermeable sequence. When the thrombin levels increase, such as during cardiovascular 
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thrombotic event, the thrombin-sensitive tag is recognised by the thrombin protease, which will 
cleave the cell-impermeable tag off. This will reveal the stapled cell-permeable peptide, which 
would be able to exert its bioactivity under pathological conditions only. 
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All experiments were carried out in oven-dried glassware under an atmosphere of N2 using 
distilled solvents unless otherwise stated.  
Reagents: Chemicals were purchased from commercial sources and used without further 
purification.  
Yield: refer to chromatographically and spectroscopically pure compounds unless otherwise 
stated and are reported as follows: mass, moles, percentage. 
Temperature: Reaction temperatures of 0 °C were maintained using an ice-water bath and those 
of -78 °C using dry-ice and acetone; room temperature (rt) refers to 20-25 °C.  
Flash chromatography: Analytical thin layer chromatography was carried out on SiO2 Merck 
Kieselgel 60 F254 plates with visualisation either by ultraviolet light or staining with potassium 
permanganate or ninhydrin dips made using standard procedures. Retention factors (Rf) are 
quoted to 0.01. Flash column chromatography was performed using silica gel 60 (230-400 
mesh), or standardised aluminium oxide 90 (150 mesh), under a positive pressure of N2. Eluent 
systems are expressed in % v/v. NH3 used in flash chromatography is a 7 N solution in MeOH.  
Nuclear Magnetic Resonance (NMR): 1H, 13C and 19F NMR spectra were recorded using an 
internal deuterium lock at ambient probe temperatures on the following instruments: Bruker 
Avance III 400 MHz HD Smart Probe Spectrometer, Bruker Avance III 400 MHz HD 
Spectrometer, Bruker 400 MHz QNP Cryoprobe Spectrometer, Bruker 500 MHz DCH Cryoprobe 
Spectrometer, Bruker Avance III 500 MHz HD Smart Probe Spectrometer. The following 
deuterated solvents were used: chloroform (CDCl3), dimethylsulfoxide (DMSO-d6) and methanol 
(CD3OD). 1H-NMR chemical shifts (δ) are quoted in ppm to the nearest 0.01 ppm, relative to the 
residual non-deuterated solvent peak and coupling constants (J) are quoted to the nearest 0.1 
Hertz (Hz). 13C-NMR chemical shifts are quoted to the nearest 0.1 ppm, relative to the solvent 
peak and coupling constants are quoted to the nearest 0.1 Hz. 19F-NMR chemical shifts are 
quoted to the nearest 0.1 ppm. Spectral data is reported as follows: chemical shift, integration, 
multiplicity (s, singlet; d, doublet; t, triplet; q, quartet; sept, septet; m, multiplet; br, broad; or as 
a combination of these e.g. br s, dd, dt), coupling constant(s) and assignment. The numbering 
system used in the assignments does not necessarily follow the IUPAC convention. Assignment 
of all spectra is supported by DEPT, COSY, HSQC and HMBC or done by analogy to fully assigned 
spectra of closely related compounds. 
Infra-red spectroscopy (IR): Infra-red spectra were recorded neat on a Perkin Elmer Spectrum 
One FT-IR spectrometer fitted with an Attenuated Total Reflectance (ATR) sampling accessory. 
Selected absorption maxima (νmax) are quoted in wavenumbers (cm-1) with the following 
abbreviations: w, weak; m, medium; s, strong; vs, br, broad.  
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Liquid chromatography-mass spectrometry (LCMS): LCMS was carried out using a Waters 
ACQUITY H-Class UPLC with an ESCi Multi-Mode Ionisation Waters SQ Detector 2 spectrometer 
using MassLynx 4.1 software; ESI refers to the electrospray ionisation technique; LC system: 
solvent A: 2 mM NH4OAc in H2O/MeCN (95:5); solvent B: MeCN; solvent C: 2% formic acid; 
column: ACQUITY UPLC® CSH C18 (2.1 mm × 50 mm, 1.7 μm, 130 Å) at 40 °C; gradient: 5 – 95% 
B with constant 5% C over 1 min at flow rate of 0.6 mL/min; Injection volume: 5 μL. 
Chromatographs were monitored by absorbance using diode array detection at a wavelength 
range of 190-600 nm, interval 1.2 nm. 
High resolution mass spectrometry (HRMS): HRMS was carried out using a Waters LCT 
Premier® Time of Flight (ToF) mass spectrometer or the ThermoFinnigan Orbitrap Classic mass 
spectrometer. Reported mass values are within the error limits of ± 5 ppm mass units. ESI refers 
to the electrospray ionisation technique. ASAP refers to the atmospheric solids analysis probe 
ionisation technique. 
Analytical HPLC: Chromatographs were obtained on an Agilent 1260 Infinity® using a reversed-
phase Supelcosil ABZ+PLUS column (150 mm x 4.6 mm, 3 μm) eluting with a linear gradient 
system (solvent A: 0.05% (v/v) TFA in water, solvent B: 0.05% (v/v) TFA in MeCN) over 15 min, 
unless otherwise stated, at a flow rate of 1 mL/min. HPLC was monitored by UV absorbance at 
220 and 254 nm.  
Preparative HPLC: Preparative HPLC was carried out on an Agilent 1260 Infinity® using a 
reversed-phase Supelcosil ABZ+PLUS column (250 mm x 21.2 mm, 5 μm) eluting with a linear 
gradient system (solvent A: 0.1% (v/v) TFA in water, solvent B: 0.05% (v/v) TFA in MeCN) over 
20 min at a flow rate of 20 mL/min. HPLC was monitored by UV absorbance at 220 and 254 nm.  
Automated Solid Phase Peptide Synthesis (SPPS): automated SPPS was carried out on solid-
phase using a Fmoc-protecting group strategy on a CEM Liberty Blue® automated microwave 
peptide synthesiser. 
Microwave irradiation: Microwave irradiation was performed in a Biotage® microwave reactor.  
Melting points: Melting points were measured using a Büchi melting point B545 apparatus and 
are uncorrected.  
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6.1. Experimental synthetic details 
6.1.1. Small molecules 
General method 1: Phenol triflation.204 
To a solution of phenol (1.0 equiv) in anhydrous CH2Cl2 (reaction molarity 3.00 mM) was added 
anhydrous pyridine (1.6 equiv). The solution was cooled to 0 °C and trifluoromethanesulfonic 
anhydride (1.4 equiv) was added dropwise over 30 minutes. The reaction was allowed to warm 
to rt and stirred for 16 hours. CH2Cl2 was removed under reduced pressure, the residue was 
diluted with H2O and extracted with EtOAc. The organic layer was washed successively with 
10% aqueous HCl, 5% aqueous NaHCO3, brine, dried (MgSO4), and concentrated under reduced 
pressure. The crude residue was purified by column chromatography to yield the desired 
product. 
General method 2a: Suzuki-Miyaura coupling.203  
To a solution of aryl triflate (1.6 equiv) and the appropriate boronic acid (1.0 equiv) in 
anhydrous DME (0.16 M) was added 2 M aqueous Na2CO3 solution (1.6 equiv). The reaction 
mixture was degassed by bubbling N2 through the solution for 15 minutes before the addition of 
Pd(PPh3)4 (2.0-2.5 mol%). The solution was refluxed for 3-7 hours.
 
The reaction was allowed to 
cool to room temperature and then diluted with EtOAc and H2O. The aqueous phase was 
extracted with EtOAc (3 ×). The combined organic extracts were washed with brine, dried 
(MgSO4), concentrated under reduced pressure, and purified by column chromatography to 
yield the desired product. 
General method 2b: Suzuki-Miyaura coupling.210  
To a solution of the appropriate boronic acid (1.5 equiv) and the appropriate aryl bromide (1.0 
equiv) in 1,4-dioxane was added 1.75 M aqueous K3PO4 solution (1.7 equiv). The mixture was 
degassed by bubbling N2 for 10 minutes before PCy3 (0.5 mol%) and Pd2(dba)3 (0.25 mol%) 
were added. The mixture was refluxed for 4-8 hours. The crude mixture was diluted with EtOAc 
and filtered through Celite. The organic phase was washed with H2O and dried (MgSO4). The 
solvent was evaporated, and the product purified by column chromatography to yield the 
desired product. 
General method 2c: Suzuki-Miyaura coupling.213  
A mixture of the aryl triflate (1.0 equiv), appropriate boronic acid (1.2 equiv), PdCl2 
(dppf)·CH2Cl2 (1 mol%) and K3PO4 (2.0 equiv) were solvated with DME (0.2 M), EtOH (1.7 M) and 
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H2O (2.5 M). The reaction mixture was degassed by bubbling N2 through the solution for 15 
minutes and then heated in the MW to 110 °C (2-3 hours) or refluxed (1-6 hours). The reaction 
was allowed to cool to room temperature, filtered through Celite™, washed with Et2O and the 
solvent removed under reduced pressure. The residue was dissolved in Et2O and H2O, the phases 
were separated, and the organic layer was extracted with Et2O (3 ×). The combined organic 
extracts were washed with brine, dried (MgSO4), filtered, and concentrated under reduced 
pressure. The crude product was then purified by flash column chromatography or preparative 
TLC to yield the desired product. 
General method 3: Nitrile reduction using LiAlH4.197 
To a suspension of LiAlH4 (2.0 equiv) in Et2O (0.27 M) at 0°C was added AlCl3 (1.0 equiv) and the 
mixture stirred for 10 minutes. The appropriate benzonitrile (1.0 equiv) was added and the 
reaction mixture stirred at rt for 30 minutes and then refluxed for 16 hours. The mixture was 
cooled to 0 °C, diluted with EtOAc and a saturated aqueous solution of potassium sodium 
tartrate tetrahydrate was added. The suspension was stirred for 1 hour and then poured into a 2 
M aqueous solution of Na2CO3. The aqueous phase was extracted with EtOAc (3 ×). The combined 
organic phases were washed with brine and dried (MgSO4). The product was purified by column 
chromatography to yield the desired product. 
General method 4: Nitrile reduction using Raney Nickel and H2.212 
To a solution of the appropriate nitrile in NH3 (8% in MeOH, 0.15 M) was added a spatula of 
Raney Nickel (slurry solution). An atmosphere of H2 was applied and the reaction mixture was 
vigorously stirred at rt for 16 hours. After this time, EtOAc was added and the suspension 
filtered under gravity. The filtrate was concentrated under reduced pressure, and the crude 
material purified by column chromatography to yield the desired product. 
General method 5: Formation of hydrochloric amine salts.247 
The appropriate amine (1.0 equiv) was dissolved in the minimum amount of anhydrous CH2Cl2 
and HCl (2 M in 1,4-dioxane, 10 equiv) was added dropwise. The reaction mixture was stirred at 
rt for 1 hour. The resulting precipitate was filtered and washed with cold Et2O to afford the 
desired salt. 
General method 6: Reductive amination.214 
Anhydrous DCE (0.33 M) was added to a flask charged with the appropriate aldehyde (1.0 
equiv), the amine (1.5 equiv) and molecular sieves (4 Å). The mixture was stirred at rt for 2.5 
hours. After this time NaBH(OAc)3 (1.4 equiv) was added in three portions over 15 minutes and 
the mixture stirred at rt for 16 hours. The reaction was quenched with a NaHCO3 aqueous 
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solution and the product extracted with EtOAc (3 ×). The combined organic phases were dried 
(Mg2SO4), and the solvent evaporated under reduced pressure. The residue was purified by 
column chromatography to afford the free amine. 
General method 7: Fmoc protection of primary amine.248 
Solid NaHCO3 (4.0 equiv) was dissolved in H2O (0.2 M) and the solution was diluted with MeCN 
(0.2 M). To the solution were added the amine (1.0 equiv) and N-(9-
fluorenylmethoxycarbonyloxy)succinimide (1.5 equiv). The mixture was stirred at rt for 24-48 
hours. The organic solvent was removed under reduced pressure, and the aqueous phase was 
washed with CH2Cl2 (3 ×). The aqueous phase was adjusted to pH 2 with concentrated HCl to 
form a white precipitate. The precipitate was filtered, and the aqueous phase extracted with 
EtOAc (3 ×). The organic phases were combined with the precipitate, dried (MgSO4), and the 
solvent evaporated under reduced pressure. The crude material was purified by column 
chromatography to yield the desired product. 
General method 8: TMS deprotection.220 
Aqueous 6 M KOH (10 equiv) was added to a stirred solution of the TMS-protected alkyne (1 
equiv) in MeOH (0.45 M). The mixture was stirred at rt for 18 hours. MeOH was removed under a 
stream of N2 and the aqueous phase was acidified to pH 4 with HCl (6 N) and extracted with 
EtOAc (3 ×). The combined organic phases were dried (MgSO4), and the solvent evaporated 
under reduced pressure to yield the desired compound. 
General method 9: Addition of TMS-alkyne to esters and anhydride.249 
Trimethylsilylacetylene (1.5-3 equiv) in anhydrous THF (1.2 M) was cooled down to -78 °C. 
nBuLi 1.6 M in hexane (3 equiv) was added dropwise and the reaction mixture was stirred at -78 
°C for 1 hour. After this time, the reaction was warmed to 0 °C for 10 minutes and then cooled 
down to -78°C. The appropriate benzoate or aldehyde (1 equiv) in anhydrous THF (1.1 M) was 
added over 10 minutes and the mixture stirred at rt for 2 hours. After this time, the reaction was 
quenched with NH4Cl (saturated aqueous) solution, THF removed under a stream of N2 and the 
product extracted with Et2O (3 ×). The combined organic phases were dried (MgSO4), and the 
residue purified by flash chromatography to give the desired product. 
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6.1.1.1. Fragment-based drug design 
2-Chloro-4-cyanophenyl trifluoromethanesulfonate (1a)  
 
Prepared following general method 1 using 3-chloro-4-hydroxybenzonitrile (2.00 g, 13.0 mmol), 
CH2Cl2 (40.0 mL), pyridine (3.20 mL, 39.6 mmol) and trifluoromethanesulfonic anhydride (2.84 
mL, 16.9 mmol). After work-up, the crude residue was purified by column chromatography on 
silica gel (5% EtOAc/hexane) to yield 1a as a white crystalline solid (3.37 g, 11.8 mmol, 91%).  
Rf = 0.68 (20% EtOAc/hexane); Mp = 61-62 °C;
 
δH (400 MHz, CDCl3): 7.88 (1H, d, J = 2.0 Hz, H5), 
7.70 (1H, dd, J = 8.6, 2.0 Hz, H1), 7.53 (1H, d, J = 8.6 Hz, H2); δC (101 MHz, CDCl3): 148.5 (C3), 
134.9 (C5), 132.2 (C1), 128.9 (C4), 124.2 (C2), 118.5 (q, J = 227.3 Hz, C8), 116.0 (C7), 114.9 (C6); 
δF (376 MHz, CDCl3): -74.1 νmax: 2245 (C≡N, m), 1575 (C=C, w), 1478 (C=C, m); LCMS: Rt = 1.56 
min, [M-H]-
 
284.0. 
Characterisation data in accordance with literature.198  
2,6-Dichloro-4-cyanophenyl trifluoromethanesulfonate (1b)  
 
Prepared following general method 1 using 3,5-dichloro-4-hydroxybenzonitrile (500 mg, 2.66 
mmol), CH2Cl2 (2.40 mL), pyridine (300 μml, 4.26 mmol) and trifluoromethanesulfonic 
anhydride (600 μL, 3.46 mmol). After work-up, the crude residue was purified by column 
chromatography on silica gel (10% EtOAc/hexane) to yield 1b as white solid (630 mg, 1.97 
mmol, 74%).  
Rf = 0.40 (10% EtOAc/hexane); Mp = 93-96 °C; δH (400 MHz, DMSO-d6): 8.50 (2H, s, H1); δC (101 
MHz, DMSO-d6): 144.7 (C4), 134.4 (C1), 129.2 (C3), 117.3 (q, J = 225.3 Hz, C5), 115.6 (C6), 113.9 
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(C2); δF (376 MHz, CDCl3): -71.7; νmax: 2238 (C≡N, m), 1204 (=C-H, s); LCMS Rt = 4.07 min, 
[M+K]+
 
358.21. 
2,6-Dichloro-4-formylphenyl trifluoromethansulfonate (1c) 
 
Prepared following general method 1 using 3,5-dichloro-4-hydroxybenzaldehyde (200 mg, 1.05 
mmol), trifluoromethanesulfonic anhydride (260 μL, 1.52 mmol), pyridine (150 μL, 1.88 mmol) 
and CH2Cl2 (1.50 mL). After work-up, the crude material was purified by column 
chromatography on silica gel (10% EtOAc/hexane) to yield 1c as a colourless oil (191 mg, 600 
μmol, 57%). 
Rf = 0.19 (10% EtOAc/hexane); δH (500 MHz, CDCl3): 9.95 (1H, s, H6), 7.95 (2H, s, H1); δC (126 
MHz, CDCl3): 187.8 (C6), 146.2 (C4), 136.1 (C2), 130.8 (C3), 130.2 (C1), 117.0 (q, J = 320 Hz, C5); 
δF (376 MHz, CDCl3): -71.3; νmax: 1706 (C=O, s), 1429 (H-C=O, s), 1210 (C-F,) 1129 (SO2, s); 
HRMS (ESI+): m/z found [M+H]+
 
322.9153, C8H4O435Cl2F3S
 
required 322.9159 (Δ -1.9 ppm).  
2-Chloro-2’-isopropyl-[1,1’-biphenyl]-4-carbonitrile (2a) 
 
Prepared following general method 2a using (2-isopropylphenyl)-boronic acid (50.0 mg, 230 
μmol), 2 M aqueous Na2CO3 solution (300 μL, 530 μmol), DME (5.00 mL) and Pd(PPh3)4 (10.5 mg, 
10.0 μmol). The reaction was refluxed for 3 hours. After work-up, the crude material was 
purified by column chromatography on silica gel (20% EtOAc/hexane) to yield 2a as a colourless 
oil (40.0 mg, 150 μmol, 85%).  
Rf = 0.25 (20% EtOAc/hexane); δH (400 MHz, CD3OD): 7.94 (1H, dd, J = 1.6, 0.3 Hz, H5), 7.74 (1H, 
dd, J = 7.9, 1.6 Hz, H1), 7.45-7.40 (3H, m, H2, H11, H12), 7.27-7.25 (1H, m, H13), 7.03 (1H, ddd, J 
= 7.2, 1.8, 0.7 Hz, H10), 2.58 (1H, sept, J = 6.7 Hz, H14), 1.20 (3H, d, J = 6.7 Hz, H15), 1.07 (3H, d, J 
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= 6.7 Hz, H15);
 
δC (101 MHz, CD3OD): 147.5 (C3 or C8), 147.3 (C3 or C8), 138.0 (C9), 135.9 (C4), 
133.9 (C5), 133.7 (C2), 131.6 (C1), 130.2 (C11 or 12), 130.0 (C10), 126.8 (C13), 126.6 (C11 or 
12), 118.4 (C7), 113.9 (C6), 31.7 (C14), 24.8 (C15), 23.4 (C15);
 
νmax: 2962 (=C-H, m), 2326 (C≡N, 
m), 1473 (CH3, m), 1383 (CH3, m);
 
HRMS (ESI+): m/z found [M]+
 
256.0893, C16H14N35Cl
 
required 
256.0893 (Δ 0.0 ppm).  
2-Chloro-2'-ethyl-[1,1'-biphenyl]-4-carbonitrile (2b) 
 
Prepared following general method 2a using 3-chloro-4-bromobenzonitrile (300 mg, 1.39 
mmol), 2-ethylphenylboronic acid (208 mg, 1.39 mmol), Pd(PPh3)4 (80 mg, 0.07 mmol), K2CO3 
(383 mg, 2.77 mmol), DME (3.0 mL) and H2O (1.0 mL). The reaction was refluxed for 4 hours. 
After work-up, the crude product was purified by flash column chromatography (10% EtOAc/PE 
40-60) to yield 2b as a clear oil (206 mg, 0.85 mmol, 61%). 
Rf = 0.40 (10% EtOAc/PE 40-60); δH (400 MHz, CDCl3): 7.79 (1H, d, J = 1.5 Hz, H5), 7.62 (1H, dd, J 
= 7.9, 1.5 Hz, H1), 7.45-7.36 (3H, m, H2, H10, H11), 7.30 (1H, app. td, J = 7.5, 1.7 Hz, H12), 7.10 
(1H, dd, J = 7.5, 0.9 Hz, H9), 2.56-2.33 (2H, m, H13), 1.10 (3H, t, J = 7.6 Hz, H14); δC (101 MHz, 
CDCl3): 145.8 (C8), 141.7 (C3), 137.1 (C4), 134.8 (C7), 132.8 (C5), 132.2 (C1), 130.2 (C2), 129.1 
(C9), 129.0 (C10), 128.6 (C11), 125.9 (C12), 117.6 (C15), 112.7 (C6), 26.2 (C13), 15.1 (C14); 
νmax: 2967 (=C-H, m), 2232 (C≡N, m), 1472 (CH3, m), 1445 (CH3, m); HRMS (ESI+): m/z found 
[M+H]+
 
242.0735, C15H13N35Cl
 
required 242.0737 (Δ -0.8 ppm).  
3-Chloro-4-(1H-indole-4-yl)benzonitrile (2c) 
  
Prepared following general method 2a using 4-(1H-indole)-boronic acid pinacol ester (150 mg, 
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620 μmol), 1a (125 mg, 440 μmol), 2 M aqueous Na2CO3 solution (700 μL, 1.32 mmol), DME 
(15.0 mL) and Pd(PPh3)4 (25.4 mg, 20.0 μmol). The mixture was refluxed for 3 hours. After work-
up, the crude material was purified by column chromatography on silica gel (20% 
EtOAc/hexane) to yield 2c as a dark orange oil (104 mg, 410 μmol, 67%).  
Rf = 0.44 (20% EtOAc/hexane); δH (400 MHz, CD3OD): 7.94 (1H, d, J = 1.6 Hz, H13), 7.73 (1H, dd, 
J = 8.0, 1.6 Hz, H11), 7.61 (1H, d, J = 8.0 Hz, H10), 7.46 (1H, dd, J = 7.3, 0.8 Hz, H8), 7.27 (1H, d, J = 
3.2 Hz, H3), 7.20 (1H, t, J = 7.3 Hz, H7), 6.99 (1H, dd, J = 7.3, 0.8 Hz, H6), 6.15 (1H, dd, J = 3.2, 0.8 
Hz, H4);
 
δC (101 MHz, CD3OD): 146.8 (C2), 137.9 (C5), 135.4 (C14),
 
134.3 (C13), 134.0 (C10), 
131.4 (C11), 130.9 (C3), 128.0 (C1), 126.5 (C12), 121.9 (C7),
 
121.0 (C6), 118.8 (C15), 113.4 (C8), 
112.8 (C9), 101.5 (C4);
 
νmax: 3402 (N-H, br), 2231 (C≡N, m);
 
HRMS (ESI+): m/z found [M+H]+
 
253.0545, C15H10N235Cl
 
required 253.0533 (Δ 4.7 ppm).  
2-Chloro-4'-fluoro-2'-methyl-[1,1'-biphenyl]-4-carbonitrile (2d) 
 
Prepared following general method 2a using compound 1a (66.0 mg, 230 μmol), 4-fluoro-2-
methylphenyl boronic acid (50.0 mg, 320 μmol), Pd(PPh3)4 (13.0 mg, 10.0 μmol), 2 M aqueous 
Na2CO3 solution (300 μL) and DME (5.00 mL). The reaction mixture was refluxed for 4 hours. 
After work-up, the crude product was purified by flash column chromatography on silica gel (0 
to 5% EtOAc/hexane) to yield 2d as a colourless oil (55.0 mg, 220 μmol, 97%). 
Rf = 0.37 (20% EtOAc/hexane); δH (500 MHz, CDCl3): 7.80 (1H, d, J = 1.4 Hz, H5), 7.64 (1H, dd, J = 
7.8, 1.4 Hz, H1), 7.36 (1H, d, J = 7.8 Hz, H2), 7.11-6.97 (3H, m, H10, H12, H13), 2.12 (3H, s, H14); 
δC (126 MHz, CDCl3): 163.8 (d, J = 242.5 Hz, C11), 144.9 (C3), 138.4 (d, J = 8.1 Hz, C9), 134.8 (C4), 
133.5 (d, J = 3.3 Hz, C8), 132.9 (C5), 132.1 (C2), 130.5 (d, J = 8.6 Hz, C13), 130.3 (C1), 117.4 (C7), 
116.9 (d, J = 21.3 Hz, C10), 112.9 (C6), 112.8 (d, J = 21.4 Hz, C12), 19.8 (d, J = 1.8 Hz, C14); δF 
(375 MHz, CDCl3); 114.3; νmax: 2233 (C≡N, w), 1383 (CH3, s); HRMS (ESI+): m/z found [M+H]+ 
246.0486, C14H10N35ClF required 246.0493 (Δ 2.8 ppm). 
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2-Chloro-[2'-(hydroxymethyl)- 1,1'-biphenyl]-4-carbonitrile (2e) 
 
Prepared following general method 2a using 2-hydroxymethyl-benzeneboronic acid (432 mg, 
2.84 mmol), compound 1a (600 mg, 2.20 mmol), Pd(PPh3)4 (128 mg, 110 μmol), 2 M aqueous 
Na2CO3 solution (2.80 mL) and DME (73.0 mL). The reaction was refluxed for 7 hours. After 
work-up, the crude material was purified by column chromatography on silica gel (20 to 30% 
EtOAc/hexane) to yield 2e as a colourless oil (490 mg, 1.99 mmol, 90%). 
Rf = 0.25 (20% EtOAc/hexane); δH (400 MHz, CDCl3): 7.78 (1H, d, J = 1.6 Hz, H9), 7.63-7.60 (2H, 
m, H3 or H4, H11), 7.51 (1H, app. td, J = 7.8, 1.6 Hz, H3 or H4), 7.42 (1H, d, J = 7.8 Hz, H12), 7.39 
(1H, app. td, J = 7.8, 1.0 Hz, H2 or H5), 7.14 (1H, dd, J = 7.8, 1.0, H2 or H5), 4.51 (1H, d, J = 12.9 Hz, 
H13), 4.38 (1H, d, J = 12.9 Hz, H13); δC (101 MHz, CDCl3): 144.6 (C7), 138.3 (C1), 136.5 (C8), 
134.5 (C6), 132.8 (C9), 132.1 (C12), 130.2 (C11), 129.3 (C3 or 4), 129.2 (C2 or 5), 128.2 (C3 or 
4), 127.8 (C2 or 5), 117.4 (C14), 113.1 (C10), 62.9 (C13); νmax: 2988 (OH, br), 2226 (C≡N, w); 
HRMS (ESI+): m/z found [M+H]+ 244.0537, C14H11NO35Cl required 244.0529 (Δ -3.3 ppm). 
tert-Butyl ((2’-chloro-4’-cyano-[1,1’-biphenyl]2-yl)methyl)carbamate (2f) 
 
Prepared following general method 2a using 1a (131 mg, 460 μmol), 2-(((tert-
butoxycarbonyl)amino)methyl)phenyl)boronic acid (150 mg, 590 μmol), 2 M aqueous Na2CO3 
solution (700 μL, 1.38 mmol), DME (15.0 mL) and Pd(PPh3)4 (26.5 mg, 20.0 μmol). The reaction 
was refluxed for 3 hours. After work-up, the crude material was purified by column 
chromatography on silica gel (30% Et2O/hexane) to yield 2f as a colourless oil (140 mg, 410 
μmol, 89%). 
Rf = 0.22 (30% Et2O/hexane); δH (400 MHz, CDCl3): 7.77 (1H, d, J = 1.2 Hz, H9), 7.61 (1H, dd, J = 
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7.9, 1.2 Hz, H11), 7.44-7.43 (2H, m, H2, H3), 7.39-7.36 (2H, m, H4, H12), 7.11 (1H, d, J = 7.3 Hz, 
H5), 4.60 (1H, br s, NH), 4.10-4.08 (2H, m, H14), 1.39 (9H, s, H17); δC (101 MHz, CDCl3): 155.6 
(C15), 144.6 (C7), 136.9 (C6 or C8), 136.5 (C6 or C8), 134.5 (C10), 132.9 (C9), 131.9 (C12), 130.3 
(C11), 129.3 (C2), 129.2 (C3), 128.2 (C4), 127.5 (C5), 117.3 (C13), 113.0 (C1), 80.0 (C16), 42.3 
(C14), 28.4 (C17); νmax: 3369 (N-H, br), 2978 (C-H, m), 2233 (C≡N, m), 1696 (C=O, s), 1247 (C-O, 
s); HRMS (ESI+): m/z found [M+H]+ 265.0493, C14H1135ClN2Na
 
required 265.0503 (Δ -3.6 ppm).  
2'-(Aminomethyl)-2-chloro-[1,1'-biphenyl]-4-carbonitrile (2f ’) 
 
Prepared following a literature procedure.250 Compound 2f (60.0 mg, 180 μmol) was dissolved 
in CH2Cl2 (600 μL) and treated with HCl (2 M in Et2O, 1.80 mL, 3.70 mmol). The reaction was 
refluxed for 16 hours. The solvent was removed under reduced pressure, the residue diluted 
with cold Et2O and the white solid collected by filtration. The salt was suspended in EtOAc and 
the free base obtained by addition of 2 M aqueous Na2CO3 solution (2 mL). The solvent was 
evaporated and the residue purified by column chromatography on silica gel (1:9:90 
NH3:MeOH:CH2Cl2) to afford the product as an orange oil (45.0 mg, 170 μmol, 98%). 
Rf = 0.12 (1:9:90 NH3:MeOH:CH2Cl2); δH (400 MHz, CDCl3): 7.80 (1H, d, J = 1.5 Hz, H9), 7.64 (1H, 
dd, J = 7.9, 1.5 Hz, H11), 7.56 (1H, d, J = 7.5 Hz, H5), 7.47 (1H, td, J = 7.5, 1.0 Hz, H4), 7.40 (1H, d, J 
= 7.9 Hz, H12), 7.36 (1H, td, J = 7.5, 1.0 Hz, H3), 7.12 (1H, d, J = 7.5 Hz, H2), 3.69 (1H, d, J = 14.6 
Hz, H14), 3.58 (1H, d, J = 14.6 Hz, H14); δC (101 MHz, CDCl3): 145.1 (C7), 141.2 (C10), 136.5 (C8), 
134.6 (C6), 132.9 (C9), 132.1 (C12), 130.2 (C11), 129.2 (C4), 129.2 (C5), 127.8 (C2), 126.9 (C3), 
117.4 (C13), 112.9 (C1), 43.9 (C14); νmax: 3373 (N-H, w), 2232 (C≡N, m); HRMS (ESI+): m/z 
found [M+Na]+ 265.0493, C14H11N235ClNa required 265.0503 (Δ -3.6 ppm). 
2'-((1H-Pyrrol-1-yl)methyl)-2-chloro-[1,1'-biphenyl]-4-carbonitrile (2f ’’) 
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Prepared following a literature procedure.209 NaOtBu (47.0 mg, 490 μmol) was added slowly to a 
solution of pyrrole (28.0 μL, 410 μmol) in MeCN (5.00 mL). The reaction mixture was stirred for 
5 minutes before compound 2f ’’’ (150 mg, 490 μmol) was added dropwise. The reaction was 
stirred at rt 16 hours. The solvent was then removed under reduced pressure, the reaction 
mixture was diluted with CH2Cl2 and washed with water (2 x 10 mL). The combined organic 
phases were washed with brine and dried (MgSO4). The crude material was purified by column 
chromatography on silica gel (0 to 2% EtOAc/hexane) to yield 2f ’’ as a white film (132 mg, 453 
μmol, 93%). 
Rf = 0.39 (10% EtOAc/hexane); δH (500 MHz, CDCl3): 7.78 (1H, d, J = 1.5 Hz, H1), 7.55 (1H, dd, J = 
7.9, 1.5 Hz, H5), 7.47-7.38 (2H, m, H8, H10), 7.18 (1H, d, J = 7.9 Hz, H4), 7.18-7.12 (2H, m, H9, 
H11), 6.38 (2H, app. t, J = 2.1 Hz, H14), 6.07 (2H, app. t, J = 2.1 Hz, H15), 4.88 (1H, d, J = 15.0 Hz, 
H13), 4.76 (1H, d, J = 15.0 Hz, H13); δC (126 MHz, CDCl3): 144.1 (C7), 136.8 (C12), 135.8 (C3), 
134.3 (C2), 132.7 (C1), 131.9 (C4), 130.4 (C5), 129.4 (C8), 129.3 (C9), 128.4 (C10), 128.0 (C11), 
120.9 (C14), 117.3 (C16), 113.1 (C6), 108.5 (C15), 51.2 (C13); νmax: 2359 (C≡N, w); HRMS 
(ESI+): m/z found [M+H]+
 
293.0835, C18H14N235Cl
 
required 293.0846 (Δ -3.8 ppm). 
2'-(Bromomethyl)-2-chloro-[1,1'-biphenyl]-4-carbonitrile (2f ’’’) 
 
Prepared following a literature procedure.208 A solution of compound 2e (100 mg, 410 μmol) in 
anhydrous THF (2.50 mL) was cooled down to 0 °C. N-bromosuccinimide (153 mg, 860 μmol) 
was added followed by PPh3 (215 mg, 820 μmol). The mixture was allowed to stir at room 
temperature for 5 hours. The reaction was quenched with saturated aqueous NaHCO3 and the 
solvent removed under a stream of N2. The residue was diluted with Et2O and washed with 
water (2 x 10 mL). The combined organic phase was dried (MgSO4), filtered and the solvent 
removed under reduced pressure. The crude material was purified by column chromatography 
on silica gel (20% EtOAc/hexane) to yield 2f ’’’ as a white solid (110 mg, 360 μmol, 88%). 
Rf = 0.30 (20% EtOAc/hexane); Mp = 73-76 °C; δH (400 MHz, CDCl3): 7.80 (1H, d, J = 1.5 Hz, 
H11), 7.66 (1H, dd, J = 7.9, 1.5 Hz, H9), 7.53 (1H, dd, J = 7.6, 1.4 Hz, H1), 7.53 (1H, d, J = 7.9 Hz, 
H8), 7.46 (1H, td, J = 7.5, 1.4 Hz, H3), 7.41 (1H, app. td, J = 7.5, 1.4 Hz, H4), 7.15-7.13 (1H, m, H2), 
4.39 (1H, d, J = 10.4 Hz, H13), 4.13 (1H, d, J = 10.4 Hz, H13); δC (101 MHz, CDCl3): 143.7 (C7), 
137.5 (C5), 135.4 (C12), 134.5 (C6), 132.9 (C11), 132.2 (C9), 130.7 (C3), 130.2 (C8), 129.8 (C1), 
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129.5 (C4), 128.8 (C2), 117.3 (C14), 113.4 (C10), 30.9 (C13); νmax: 2232 (C≡N, m), 1447 (C=C, 
m), 1384 (C-N, m); HRMS (ESI+): m/z found [M+H]+
 
305.9683, C14H10N35Cl79Br
 
required 
305.9685 (Δ -0.7 ppm).  
3-Chloro-5-(1H-indol-4-yl)benzonitrile (2g) 
 
Prepared following general method 2b using 1-H-indole boronic acid (250 mg, 1.55 mmol), 3-
bromo-5-chloro-benzonitrile (167 mg, 1.03 mmol), Pd2(dba)3 (9.50 mg, 10.0 μmol), PCy3 (7.00 
mg, 20.0 μmol), 1.75 M aqueous K3PO4 solution (1.00 mL) and dioxane (3.50 mL). The reaction 
was refluxed for 6 hours. After work-up, the crude material was purified by column 
chromatography on aluminium oxide gel (0 to 20% EtOAc/hexane) to yield 2g as white solid 
(155 mg, 570 μmol, 55%).  
Rf = 0.24 (20% EtOAc/hexane); Mp = 134-137 °C; δH (500 MHz, CDCl3): 8.41 (1H, br s, NH), 7.92 
(1H, t, J = 1.6 Hz, H3), 7.88 (1H, t, J = 1.6 Hz, H5), 7.63 (1H, t, J = 1.6 Hz, H1), 7.48 (1H, d, J = 8.2 Hz, 
H15), 7.33-7.29 (2H, m, H11, H14), 7.15 (1H, d, J = 8.2 Hz, H13), 6.65-6.64 (1H, m, H10); δC (126 
MHz, CDCl3): 144.4 (C2), 136.3 (C12), 135.3 (C4), 133.2 (C3), 130.5 (C9), 130.4 (C5), 129.9 (C1), 
125.7 (C8), 125.5 (C14), 122.4 (C11), 120.0 (C15), 117.8 (C7), 114.0 (C6), 111.9 (C13), 101.2 
(C10); νmax: 3429 (N-H, m), 2236 (C≡N, w), 1566 (C=C, m); HRMS (ESI+): m/z found [M+H]+
 
253.0524, C15H10N235Cl
 
required 253.0527 (Δ -1.0 ppm). 
3-(1H-Indol-4-yl)-5-(trifluoromethyl)benzonitrile (2h) 
 
Prepared following general method 2b using 3-bromo-5-trifluoride benzonitrile (257 mg, 1.03 
mmol), 1H-indole-4-boronic acid (250 mg, 1.55 mmol), Pd2(dba)3 (9.50 mg, 10.0 μmol), PCy3 
(7.00 mg, 20.0 μmol), 1.75 M aqueous K3PO4 solution (1.00 mL) and 1,4-dioxane (3.50 mL). The 
mixture was refluxed for 5 hours. After work-up, the residue was purified by column 
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chromatography on silica gel (0 to 10% EtOAc/hexane) to yield 2h as a sticky, clear oil (110 mg, 
360 μmol, 35%). 
Rf = 0.24 (10% EtOAc/hexane); δH (500 MHz, DMSO-d6): 11.42 (1H, br s, NH), 8.39 (1H, s, H3), 
8.32 (1H, app. s, H5), 8.24 (1H, app. s, H1), 7.53-7.50 (1H, m, H12), 7.50-7.49 (1H, m, H10), 7.24-
7.21 (2H, m, H11, H16), 6.75-6.54 (1H, m, H15); δC (126 MHz, DMSO-d6): 143.8 (C2), 136.9 (C13), 
136.0 (C1), 131.1 (q, J = 32.9 Hz, C4), 129.5 (C14), 129.4 (q, J = 3.6 Hz, C5), 127.9 (q, J = 3.6 Hz, 
C3), 127.4 (C10), 125.7 (C8), 124.0 (q, J = 273.0 Hz, C9), 121.9 (C11), 120.0 (C16), 118.1 (C7), 
113.8 (C6), 113.0 (C12), 99.7 (C15); δF (376 MHz, DMSO-d6): -63.0; νmax: 3378 (N-H, m), 2235 
(C≡N, w), 1105 (C-F, s); HRMS (ESI+): m/z found [M+H]+ 287.0789, C16H10N2F3 required 
287.0796 (Δ -2.4 ppm). 
2,6-Dichloro-[1,1’-biphenyl]-4-carbonitrile (2i)  
 
Prepared following general method 2c using 1b (300 mg, 940 μmol), phenylboronic acid (160 
mg, 1.31 mmol), K3PO4 (239 mg, 1.13 mmol), DME (800 μL), EtOH (600 μL), H2O (150 μL), 
PdCl2(dppf)·CH2Cl2 (48.0 mg, 60.0 μmol). The mixture was heated to 110 °C in the MW for 2 
hours. After work-up, the crude material was purified by flash chromatography on silica gel (0 to 
2% EtOAc/hexane) followed by preparative TLC (100% Hexane) to yield 2i as a white film (55.0 
mg, 220 μmol, 24%). 
Rf = 0.37 (100% hexane); Mp = 100-103 °C; δH (500 MHz, CDCl3): 7.71 (2H, s, H1), 7.52-7.47 (3H, 
m, H6, H8), 7.24-7.22 (2H, m, H7); δC (126 MHz, CDCl3): 144.6 (C3), 136.2 (C4 or C5), 135.3 (C4 
or C5), 131.2 (C1), 128.9 (C7), 128.9 (C6), 128.5 (C8), 116.3 (C9), 113.3 (C2); νmax: 2236 (C≡N, 
m), 1532, 1444 (C=C, m), 1207 (=C-H, m); HRMS (ESI+): m/z found [M+H]+
 
248.0022, 
C13H8N35Cl2
 
required 248.0028 (Δ -2.4 ppm). 
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2,6-Dichloro-1[1,1’-biphenyl]-4-carbaldehyde (2k) 
 
Prepared following general method 2c using compound 1c (162 mg, 50.0 μmol), phenylboronic 
acid (73.3 mg, 600 μmol), and K3PO4 (213 mg, 1.00 mmol), DME (1.00 mL), EtOH (700 μL) and 
H2O (150 μL), PdCl2(dppf)·CH2Cl2 (20.5 mg, 30.0 μmol). The mixture was refluxed for 4 hours. 
After the workup, the crude material was purified by column chromatography on silica gel (0 to 
1% EtOAc/hexane) to yield 2k as a white solid (68.0 mg, 270 μmol, 54%). 
Rf = 0.30 (10% EtOAc/hexane); Mp = 95-97 °C; δH (500 MHz, CDCl3): 9.97 (1H, s, H8), 7.91 (2H, s, 
H1), 7.52-7.44 (3H, m, H10, H5 or H6), 7.28-7.25 (2H, m, H5 or H6); δC (126 MHz, CDCl3): 189.3 
(C8), 145.2 (C3), 136.8 (C7), 136.3 (C2), 136.0 (C4), 129.0 (C1), 128.8 (C5 or C6 or C10), 128.7 
(C5 or C6 or C10), 128.4 (C5 or C6 or C10); νmax: 1707 (C=O, s); HRMS (ESI+): m/z found [M+H]+
 
251.0029, C13H9O35Cl2
 
required 251.0030 (Δ -0.4 ppm). 
(2-Chloro-2’-isopropyl-[1,1’-biphenyl]-4-yl)methanaminium chloride (3a) 
  
Prepared following general method 3 using compound 2a (40.0 mg, 150 μmol), LiAlH4 (11.4 mg, 
300 μmol), AlCl3 (20.0 mg, 150 μmol) and Et2O (3.00 mL). The amine product (35.0 mg, 130 
μmol, 87%) was subjected to general method 5 using 2 M HCl solution in 1,4-dioxane (0.700 mL) 
to yield 3a as a white solid (35.0 mg, 120 μmol, 77%). 
Mp = 218-220°C;
 
δH (500 MHz, CD3OD): 7.68 (1H, d, J = 1.5 Hz, H5), 7.50 (1H, dd, J = 7.8, 1.5 Hz, 
H1), 7.42-7.36 (2H, m, H10, H11), 7.35 (1H, d, J = 7.8 Hz, H2), 7.25 (1H, app. td, J = 6.9, 1.7 Hz, 
H12), 7.03 (1H, dd, J = 6.9, 1.7 Hz, H9), 4.21 (2H, s, H15), 2.65 (1H, sept, J = 7.4 Hz, H13), 1.20 
(3H, d, J = 7.4 Hz, H14), 1.06 (3H, d, J = 7.4 Hz, H14);
 
δC (126 MHz, CD3OD): 146.4 (C6), 141.5 (C3 
or 7), 137.4 (C3 or 7), 134.1 (C4), 132.0 (C8), 131.9 (C2), 129.6 (C9), 129.0 (C5), 128.4 (C10 or 
11), 127.1 (C1), 125.3 (C12), 125.0 (C10 or 11), 42.1 (C15), 30.1 (C13), 23.4 (C14), 22.1 (C14);
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νmax: 2960 (N-H, br), 1478 (CH3, m), 1403 (CH3, m); HRMS (ASAP): m/z found [M]+
 
260.1196, 
C16H19N235Cl
 
required 260.1206 (Δ -3.8 ppm).  
(2-Chloro-2'-ethyl-[1,1'-biphenyl]-4-yl)methanaminium chloride (3b) 
 
 
 
 
Prepared by general method 3 using LiAlH4 (42 mg, 1.1 mmol), Et2O (5.0 mL), AlCl3 (147 mg, 1.10 
mmol) and 2b (132 mg, 0.550 mmol). The crude product was purified by flash column 
chromatography on silica gel (1:5:14 NH3:MeOH:CH2Cl2) to provide the free amine. The free 
amine was then subjected to general method 5 using 2 M HCl solution in 1,4-dioxane (2.75 mL) to 
yield 3b as a white solid (65.0 mg, 0.230 mmol, 43%). 
Rf (amine) = 0.18 (10% MeOH/CH2Cl2); Mp = 181-183 °C; δH (500 MHz, DMSO-d6): 8.63 (3H, s, 
NH), 7.78 (1H, d, J = 1.6 Hz, H5), 7.55 (1H, dd, J = 7.8, 1.6 Hz, H1), 7.39-7.33 (3H, m, H10, H11, 
H12), 7.28-7.24 (1H, m, H2), 7.04 (1H, d, J = 7.3 Hz, H9), 4.09 (2H, s, H15), 2.47-2.24 (2H, m, 
H13), 0.98 (3H, t, J = 7.6 Hz, H14); δc (126 MHz, DMSO-d6): 141.4 (C6), 139.7 (C3), 137.7 (C7), 
135.4 (C4), 132.4 (C8), 131.5 (C2), 129.7 (C9), 129.4 (C5), 128.3 (br s, C10, C11), 127.8 (C1), 
125.7 (C12), 41.3 (C15), 25.7 (C13), 15.1 (C14); νmax: 3300 (N-H, m), 1476 (CH3, m), 1401 (CH3, 
m); HRMS (ESI+): m/z found [M+H]+ 246.1061, C15H17N35Cl required 246.1049 (Δ 4.8 ppm). 
(3-Chloro-4-(1H-indol-4-yl)phenyl)methanamine (3c) 
 
Prepared following general method 3 using compound 2c (95.0 mg, 380 μmol), LiAlH4 (29.0 mg, 
750 μmol), AlCl3 (50.0 mg, 370 μmol) and Et2O (7.00 mL). After work-up, the crude material was 
purified by column chromatography on silica gel (0:2:98 to 1:4:95 NH3:MeOH:CH2Cl2) to yield 3c 
as a white solid (55.0 mg, 210 μmol, 55%). 
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Rf = 0.20 (0.2:1.8:98 NH3:MeOH:CH2Cl2); Mp 150-152 °C; δH (400 MHz, CD3OD): 7.55 (1H, d, J = 
1.5 Hz, H11), 7.43-7.41 (2H, m, H5, H14), 7.34 (1H, dd, J = 7.8, 1.5 Hz, H13), 7.23 (1H, d, J = 3.2 
Hz, H9), 7.17 (1H, t, J = 7.3 Hz, H6), 6.96 (1H, dd, J = 7.3, 0.7 Hz, H7), 6.16 (1H, dd, J = 3.2, 0.7 Hz, 
H8), 3.88 (2H, s, H15); δC (101 MHz, CD3OD): 142.3 (C4), 138.8 (C1), 136.3 (C12), 132.9 (C10), 
131.7 (C14), 131.1 (C2), 128.4 (C11), 127.1 (C3), 125.4 (C13), 124.4 (C9), 120.5 (C6), 119.8 (C7), 
110.4 (C8), 100.5 (C5), 44.4 (C15); νmax: 2983 (N-H, br), 1373 (C-N, s); HRMS (ESI+): m/z found 
[M+H]+ 257.0834, C15H14 N235Cl
 
required 257.0840 (Δ -2.5 ppm).  
(2-Chloro-4’-fluoro-2’methyl-[1,1’-biphenyl]-4-yl)methanaminium chloride (3d) 
 
Prepared following general method 3 using compound 2d (70.0 mg, 280 μmol), LiAlH4 (32.0 mg, 
840 μmol), AlCl3 (56.0 mg, 480 μmol) and Et2O (7.20 mL). After work-up, the crude material was 
purified by column chromatography on silica gel (1:4:95 NH3:MeOH:CH2Cl2) to afford the desired 
amine as a colourless oil (28.0 mg, 110 μmol, 39%). The amine (23.0 mg, 92.0 μmol) was 
converted to its hydrochloride salt via general method 5 with HCl (2 M solution in 1,4-dioxane, 
500 μL) and CH2Cl2 (100 μL) to yield 3d as a white solid (8.00 mg, 30.0 μmol, 32%). 
Rf (amine) = 0.70 (2:8:90 NH3:MeOH:CH2Cl2); Mp = 189-193 C; δH (500 MHz, CD3OD) 7.52 (1H, 
d, J = 1.5 Hz, H5), 7.35 (1H, dd, J = 7.8, 1.5 Hz, H1), 7.19 (1H, d, J = 7.8 Hz, H2), 7.08-7.05 (1H, m, 
H10), 7.03-7.01 (1H, m, H13), 6.96 (1H, app. td, J = 8.5, 2.6 Hz, H12), 3.87 (2H, s, H7), 2.07 (3H, s, 
H14); δC (126 MHz, CD3OD): 163.2 (d, J = 244.5 Hz, C11), 144.1 (C6), 139.9 (d, J = 8.0 Hz, C9), 
136.6 (C3), 134.7 (C4), 132.5 (C8), 132.2 (C5), 132.1 (d, J = 8.4 Hz, C13), 129.6 (C1), 127.3 (C2), 
117.2 (d, J = 21.5 Hz, C10), 113.3 (d, J = 21.5 Hz, C12), 45.6 (C7) 20.0 (d, J = 1.6 Hz, C14); δF (376 
MHz, d6-DMSO): -115.0; νmax: 2981 (N-H, s, br), 1481 (C-F, s); HRMS (ASAP): m/z found [M]+ 
250.079, C14H1435ClFN required 250.0793 (Δ 1.6 ppm). 
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(4'-(Aminomethyl)-2'-chloro-[1,1'-biphenyl]-2-yl)methanol (3e) 
 
Prepared following general method 3 using compound 2e (50.0 mg, 200 μmol), LiAlH4 (15.0 mg, 
400 μmol), AlCl3 (27.0 mg, 200 μmol) and Et2O (3.70 mL). After work-up, the crude material was 
purified by preparative HPLC (5-95% B over 30 mins) to yield 3e as a white solid (27.0 mg, 110 
μmol, 54%).  
Rt (HPLC) = 8.76 mins (5-95% B over 15 mins); Mp = 205-211 C; δH (500 MHz, CD3OD): 7.66 
(1H, dd, J = 7.0, 1.5 Hz, H12), 7.62 (1H, d, J = 1.5 Hz, H9), 7.47 (1H, app. td, J = 7.7, 1.2 Hz, H4), 
7.40-7.38 (2H, m, H3, H11), 7.35 (1H, d, J = 7.7 Hz, H5), 7.12 (1H, dd, J = 7.7, 1.2 Hz, H2), 4.46 (1H, 
d, J = 13.6 Hz, H13), 4.32 (1H, d, J = 13.6 Hz, H13), 4.20 (2H, s, H14); δC (126 MHz, CD3OD): 140.3 
(C10), 139.0 (C1), 137.1 (C7), 134.4 (C8), 133.6 (C6), 131.8 (C12), 129.6 (C9), 129.1 (C5), 128.1 
(C4), 127.1 (C11), 127.0 (C3), 126.8 (C2), 61.3 (C13), 42.1 (C14); δF (376 MHz, CD3OD): -76.9; 
νmax: 3380 (N-H, br), 2977 (O-H, br); HRMS (ESI+): m/z found [M+H]+
 
248.0834, C14H15NO35Cl
 
required 248.0837 (Δ -1.0 ppm).  
(2'-((1H-Pyrrol-1-yl)methyl)-2-chloro-[1,1'-biphenyl]-4-yl)methanamine (3f) 
 
Prepared following general method 4 with compound 2f ’’ (30.0 mg, 100 μmol), Raney Ni and 
NH3 (8% in MeOH, 2.00 mL). After the work-up, the crude product was purified by column 
chromatography on silica gel (0:5:95 to 0.5:4.5:95 NH3:MeOH:CH2Cl2) to yield 3f as a colourless 
viscous oil (8.50 mg, 29.0 μmol, 28%).  
Rf = 0.51 (2:18:80 NH3:MeOH:CH2Cl2); δH (400 MHz, CD3OD): 7.56 (1H, s, H1), 7.35-7.33 (3H, m, 
H5, H9, H10), 7.16 (1H, d, J = 7.5 Hz, H4), 7.14-7.13 (1H, m, H8), 7.03-7.01 (1H, m, H11), 6.48 (2H, 
app. t, J = 2.0 Hz, H14), 6.01 (2H, app. t, J = 2.0 Hz, H15), 4.90 (1H, d, J = 17.0 Hz, H13), 4.80 (1H, d, 
J = 17.0 Hz, H13), 3.86 (2H, s, H16); δC (101 MHz, CD3OD): 142.2 (C6), 138.0 (C12), 138.0 (C3), 
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136.6 (C7), 133.0 (C2), 131.3 (C4), 129.5 (C8), 128.3 (C1), 128.1 (C5), 127.5 (C11), 127.1 (C9), 
126.1 (C10), 120.6 (C14), 107.7 (C15), 50.4 (C13), 44.4 (C16); νmax: 2989 (N-H, br), 1264 (C-N, 
s); HRMS (ESI+): m/z found [M+H]+
 
297.1194, C18H18N235Cl
 
required 297.1153 (Δ -1.2 ppm). 
(3-Chloro-5-(1H-indol-4-yl)phenyl)methanamine (3g) 
 
Prepared following general method 3 using compound 2g (77.5 mg, 280 μmol), LiAlH4 (22.0 mg, 
570 μmol), AlCl3 (38.0 mg, 285 μmol) and Et2O (5.25 mL). After work-up, the crude mixture was 
purified by flash column chromatography on aluminium oxide (2:18:80 NH3:EtOAc:hexane) to 
yield 3g as a white film (57.0 mg, 220 μmol, 79%).  
Rf = 0.40 (0.2:8.2:7 NH3:EtOAc:Hexane); δH (500 MHz, CD3OD): 7.56-7.54 (2H, m, H3, H5), 7.42 
(1H, app. td, J = 8.1, 0.8 Hz, H15), 7.36 (1H, t, J = 1.7 Hz, H1), 7.30 (1H, d, J = 3.2 Hz, H11), 7.21-
7.18 (1H, m, H14), 7.10 (1H, dd, J = 7.4, 0.8 Hz, H13), 6.60 (1H, dd, J = 3.2, 0.8 Hz, H10), 3.85 (2H, 
s, H7); δC (126 MHz, CD3OD): 144.5 (C6), 143.9 (C2), 136.7 (C12), 134.0 (C4), 132.0 (C9), 126.6 
(C3), 123.5 (C5), 125.7 (C1), 125.3 (C14), 125.0 (C11), 121.2 (C15), 118.6 (C13), 110.8 (C8), 99.9 
(C10), 44.8 (C7); νmax: 3437 (N-H, m), 679 (=C-H, s); HRMS (ESI+): m/z found [M+H]+
 
257.0831, 
C15H13N235Cl
 
required 257.0840 (Δ -3.4 ppm). 
(3-(1H-Indol-4-yl)-5-(trifluoromethyl)phenyl)methanamine (3h)  
 
Prepared following general method 4 using 2h (100 mg, 360 μmol), NH3 (8% in MeOH, 2.00 mL) 
and Raney Nickel. The crude material was purified by column chromatography on silica gel 
(1:5:95 NH3:MeOH:CH2Cl2) to yield 3h as a sticky, clear oil (29.0 mg, 100 μmol, 28%). 
Rf = 0.09 (1:5:95 NH3:MeOH:CH2Cl2); δH (400 MHz, CD3OD): 7.92 (1H, s, H2), 7.84 (1H, s, H4), 
7.68 (1H, s, H6), 7.46 (1H, d, J = 8.0 Hz, H8), 7.34 (1H, d, J = 3.2 Hz, H13), 7.23 (1H, t, J = 8.0 Hz, 
H9), 7.15 (1H, dd, J = 8.0, 0.9 Hz, H10), 6.59 (1H, dd, J = 3.2, 0.7 Hz, H14), 3.97 (2H, s, H15); δC 
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(101 MHz, CD3OD): 143.8 (C1), 143.0 (C11), 136.8 (C3), 131.9 (C7), 130.9 (C2), 130.5 (q, J = 32.0 
Hz, C5), 125.9 (C12), 125.1 (C13), 123.2 (q, J = 260.6 Hz, C16), 122.0 (q, J = 3.6 Hz, C4), 121.2 
(C10), 118.7 (C9), 110.9 (C8), 99.7 (C14), 44.9 (C15); δF (376 MHz, CD3OD): -64.8; νmax: 2921 (N-
H, br), 1257 (C-F, m); HRMS (ESI+): m/z found [M+H]+
 
291.1101, C16H14F3N2
 
required 291.1104 
(Δ -0.8 ppm). 
(2,6-Dichloro-[1,1'-biphenyl]-4-yl)methanaminium chloride (3i) 
 
The free amine of compound 3i was prepared following general method 3 using nitrile 2i (22.0 
mg, 90.0 μmol), LiAlH4 (7.00 mg, 180 μmol), AlCl3 (12.0 mg, 90.0 μmol) and Et2O (1.70 mL). After 
work-up, the crude material was purified by flash column chromatography on silica gel (1:9:90 
NH3:MeOH:CH2Cl2) to afford the amine (20.0 mg, 80.0 μmol, 88%). The amine underwent general 
method 5, using HCl (2 M in 1,4-dioxane, 500 μL, 870 μmol) and CH2Cl2 (1.00 mL). Compound 3i 
was obtained as a white solid (12.0 mg, 40.0 μmol, 48%). 
Rf (amine) = 0.44 (1:9:90 NH3:MeOH:CH2Cl2); Mp = 246-250 °C; δH (500 MHz, CD3OD): 7.62 (2H, 
s, H1), 7.50-7.41 (3H, m, H6, H8), 7.22-7.19 (2H, m, H7), 4.17 (2H, s, H9); δC (126 MHz, CD3OD): 
141.7 (C4), 137.7 (C2), 136.6 (C3), 136.4 (C5), 131.7 (C1), 130.7 (C7), 129.8 (C6), 129.5 (C8), 
43.0 (C9); νmax: 3332 (N-H, br), 892, 879 (=C-H, m); HRMS (ASAP): m/z found [M]+
 
252.0337, 
C13H12N35Cl2
 
required 252.0341 (Δ -1.7 ppm). 
(2,6-Dichloro-2'-ethyl-[1,1'-biphenyl]-4-yl)methanamine trifluoroacetic salt (3j) 
 
Prepared following general method 2c using 1c (771 mg, 2.40 mmol), 2-ethyl-phenylboronic acid 
(430 mg, 2.87 mmol), PdCl2(dppf)·CH2Cl2 (98.0 mg, 0.12 mmol), K3PO4 (1.02 g, 4.80 mmol), DME 
(5.60 mL), EtOH (0.35 mL) and H2O (0.06 mL) and refluxed for 3 hours. A solution of crude 2,6-
dichloro-2'-ethyl-[1,1'-biphenyl]-4-carbaldehyde (200 mg), tbutylcarbamate (170 mg, 4.30 
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mmol), Et3SiH (0.66 mL, 4.30 mmol) and TFA (0.21 mL, 2.72 mmol) in MeCN (3.20 mL) was 
stirred at room temperature for 14 h. The mixture was diluted with Et2O and washed with an 
aqueous solution of NaHCO3 and brine. The combined organic layers were dried (MgSO4), 
filtered and concentrated under reduced pressure. TFA (4.5 mL) was added to the N-Boc 
derivative and the mixture stirred at room temperature for 15 minutes. The excess TFA was 
blown off under a stream of nitrogen to give 3j as a white solid (240 mg, 0.900 mmol, 37%). 
Rf (amine) = 0.05 (10% CH2Cl2/MeOH); Mp = 218-222 °C; δH (500 MHz, CD3OD): 7.62 (2H, s, H1), 
7.39-7.35 (2H, m, H5, H6), 7.28-7.24 (1H, m, H7), 6.97 (1H, d, J = 7.4 Hz, H8), 4.17 (2H, s, H12), 
2.33 (2H, q, J = 7.6 Hz, H10), 1.04 (3H, t, J = 7.6 Hz, H11); δC (126 MHz, CD3OD): 141.7 (C13), 
139.9 (C9), 135.6 (C2), 135.2 (C3), 128.9 (C4), 128.7 (C8), 128.4 (C6), 128.2 (C5), 125.7 (C1), 
125.7 (C7), 41.8 (C12), 26.0 (C10), 13.8 (C11); δF (376 MHz, CD3OD): -76.2; νmax: 3373 (N-H, m), 
1674 (N-H, m), 1118 (C-N, m); HRMS (ESI): m/z found [M+H]+ 280.0641, C15H1635Cl2N required 
280.0654 (Δ – 4.6 ppm). 
N-(2-(1H-Benzo[d]imidazol-2-yl)ethyl)-2,6-dichloro-[1,1'-biphenyl]-4-aminium chloride (3k)  
 
Prepared following general method 6 using DCE (1.60 mL), 2k (54.0 mg, 210 μmol), 2-(1H-
benzo[d]imidazol-2-yl)ethan-1-amine (50.8 mg, 320 μmol), 4Å molecular sieves (50 mg), 
NaBH(OAc)3 (62.3 mg, 290 μmol). After work-up, the crude material was purified by column 
chromatography on aluminium oxide gel (5 to 10% MeOH/CH2Cl2) to yield the free amine (32.0 
mg, 90.0 μmol, 42%). The amine underwent general method 5 using HCl (2 M in dioxane, 450 μL) 
to yield 3k as a white solid (14.0 mg, 32.0 μmol, 36%). 
Rf (amine) = 0.48 (10% MeOH/CH2Cl2); δH (500 MHz, DMSO-d6): 7.87 (2H, s, H1), 7.75-7.73 (2H, 
m, H5), 7.52-7.43 (5H, m, H6, H7, H14), 7.24-7.22 (2H, m, H15), 4.32 (2H, s, H9), 3.62-3.59 (4H, 
m, H10, H11); δC (126 MHz, CDCl3): 154.0 (C12), 141.4 (C13), 141.3 (C8), 138.4 (C4), 136.7 (C3), 
135.1 (C2), 129.6 (C6), 128.2 (C5 or C7), 128.1 (C5 or C7), 127.7 (C14 or C15), 122.3 (C14 or 
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C15), 114.9 (C1), 52.8 (C9), 47.0 (C10), 28.9 (C11); νmax: 2720 (N-H, s); HRMS (ESI+): m/z found 
[M+H]+
 
396.1035, C22H20N335Cl2
 
required 396.1029 (Δ 1.6 ppm).  
2-(1H-Benzo[d]imidazol-2-yl)-N-((2,6-dichloro-2'-ethyl-[1,1'-biphenyl]-4-yl)methyl)ethan-1-
amine (3l) 
 
Prepared by general method 2c using 1c (250 mg, 0.770 mmol), 2-ethylphenylboronic acid (139 
mg, 0.930 mmol), PdCl2(dppf)·CH2Cl2 (32.0 mg, 0.390 mmol), K3PO4 (329 mg, 1.55 mmol), DME 
(2.00 mL), EtOH (0.300 mL) and H2O (0.150 mL) and refluxed for 6 hours. The crude material 
(80.0 mg, 0.290 mmol) was then subjected to general method 6 using 2-(1H-benzimidazol-2-
yl)ethylamine (69.0 mg, 0.430 mmol), 4Å molecular sieves (50 mg), DCE (1.00 mL) and sodium 
triacetoxyborohydride (86.0 mg, 0.410 mmol). The crude amine was purified by preparative 
HPLC (5-95% B over 20 mins) to yield 3l as a sticky film (26.0 mg, 0.0400 mmol, 13%). 
Rt (HPLC) = 9.43 mins (5-95% B over 15 mins); δH (500 MHz, CD3OD): 7.76-7.71 (2H, m, H18), 
7.70 (2H, s, H1) 7.53-7.49 (2H, m, H5, H6), 7.40-7.35 (2H, m, H19), 7.29-7.25 (1H, m, H7), 6.97 
(1H, d, J = 7.4 Hz, H8), 3.75-3.63 (4H, m, H13, H14), 3.31-3.29 (2H, m, H15), 2.34 (2H, q, J = 7.6 
Hz, H10), 1.05 (3H, t, J = 7.6 Hz, H11); δC (126 MHz, CD3OD): δ 150.8 (C16), 143.0 (C9), 141.9 
(C17), 137.1 (C12), 136.7 (C2), 134.4 (C3), 134.3 (C4), 130.7 (C8), 130.2 (C7), 130.1 (C6), 129.6 
(C1), 127.1 (C5), 126.7 (C19), 115.2 (C18), 51.2 (C13), 45.6 (C14), 27.2 (C15), 25.1 (C10), 15.1 
(C11); δF (376 MHz, CD3OD): -76.9, -77.1; νmax: 2975 (N-H, s), 1667 (C-Cl, m); HRMS (ESI): m/z 
found [M+H]+, 424.1346, C24H25N335Cl2 required 424.1347 (Δ -0.2 ppm). 
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6.1.1.2. Unnatural amino acids  
Fmoc-Dap-OH (4)  
 
Fmoc-Asn-OH (4.00 g, 11.3 mmol) was added to a solution of [bis(trifluoroacetoxy)iodo]benzene 
(5.40 g, 16.9 mmol) in DMF/H2O (2:1 53.2 mL: 26.4 mL). After 15 minutes, pyridine (2.10 mL) 
was added and the mixture was stirred at rt for 16 hours. The solvent was removed under 
reduced pressure and the oily residue was dissolved in H2O (60.0 mL). Concentrated HCl (2 mL) 
was added and the acidified solution was washed with Et2O (3 x 40 mL). The aqueous phase was 
adjusted to pH 6 with 2 M NaOH solution and the resulting precipitate was filtered, washed with 
H2O, ice-cold EtOH, Et2O and the residual solvent removed under reduced pressure to yield 
Fmoc-Dap-OH as a beige powder (2.99 g, 9.16 mmol, 81%). 
δH (400 MHz, DMSO-d6): 7.89 (2H, d, J = 7.5 Hz, H3), 7.70 (2H, d, J = 6.3 Hz, H4), 7.41 (2H, d, J = 
7.4 Hz, H2), 7.35 (2H, J = 7.3 Hz, H1), 6.77 (1H, d, J = 6.1 Hz, CONH), 4.32-4.24 (3H, m, H5, H6), 
3.69-3.44 (1H, m, H8), 3.00 (1H, dd, J = 10.8, 4.8 Hz, H9), 2.75 (1H, app t, J = 10.8 Hz, H9); δC (101 
MHz, DMSO-d6): 169.1 (C10), 156.3 (C7), 144.4 (C11), 141.2 (C12), 128.1 (C2), 127.8 (C1), 125.8 
(C3), 120.6 (C4), 66.2 (C6), 52.4 (C8), 47.1 (C9), 41.1 (C5); HRMS (ESI+): m/z found [M+H]+
 
327.1343, C18H19O4N2
 
required 327.1339 (Δ 1.2 ppm). 
Characterisation data in accordance with literature.235 
Fmoc-Aza-OH (5) 
 
Compound 4 (4.04 g, 12.4 mmol) was added to a mixture of H2O (60.0 mL), MeOH (180 mL), 
and CH2Cl2 (120 mL). CuSO4·5H2O (20.0 mg, 0.0800 mmol) and 6 (8.08 g, 29.9 mmol) were 
added, the mixture adjusted to pH 9 with saturated K2CO3 and stirred for 18 hours. The 
mixture was then diluted with CH2Cl2 (120 mL), and the aqueous phase isolated. The organic 
phase was extracted with saturated NaHCO3 (2 x 200 mL). The aqueous extract was washed with 
Et2O (2 x 200 mL), acidified to pH 2 with conc. HCl, and extracted with Et2O (3 x 240 mL). The 
organic extracts were dried (MgSO4) and the solvent removed under reduced pressure. The oily 
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residue was re-dissolved in EtOAc and the solvent removed under a stream of N2 to yield 5 as a 
beige, amorphous solid (3.58 g, 9.53 mmol, 77%). 
δH (400 MHz, DMSO-d6): 7.94-7.89 (2H, m, H10), 7.74 (2H, d, J = 7.4 Hz, H7), 7.43 (2H, app t, J = 
7.4 Hz, H9), 7.33 (2H, app t, J = 7.4 Hz, H8), 4.34-4.27 (2H, m, H5), 4.24-4.22 (2H, m, H1, H12), 
3.64-3.62 (2H, m, H3); δC (101 MHz, DMSO-d6): 171.5 (C2), 156.5 (C4), 144.2 (C6), 141.2 (C11), 
128.1 (C9), 127.5 (C8), 125.7 (C7), 120.6 (C10), 66.3 (C5), 54.2 (C1), 51.4 (C3), 47.1 (C12); [α]D25 
-9.9 (c = 1, DMF); HRMS (ESI+): m/z found [M+H]+
 
353.1248, C18H17O4N4
 
required 353.1244 (Δ 
1.0 ppm). 
Characterisation data in accordance with literature.217 
Imidazole-1-sulfonyl azide hydrogen Sulfate (6) 
 
Sulfuryl chloride (16.1 mL, 200 mmol) was added dropwise to an ice-cold suspension of NaN3 
(13.0 g, 200 mmol) in MeCN (200 mL) and the mixture stirred for 16 hours. Imidazole (25.9 g, 
380 mmol) was added and the pink mixture stirred at 0 °C for 5 hours. The mixture was then 
diluted with EtOAc (400 mL) and H2O (400 mL). The organic fraction was isolated and 
washed with H2O (400 mL) and saturated NaHCO3 (2 x 200 mL) and then dried (MgSO4). The 
solvent was reduced to 200 mL under reduced pressure. A solution of conc. H2SO4 (11.0 mL) 
in EtOAc (100 mL) was added to the ice-cold reaction mixture over 30 min. The reaction 
mixture was warmed to room temperature and stirred for 16 hours. The precipitate was filtered, 
washed with EtOAc (3 x 60 mL), and dried under reduced pressure to yield 6 as a white powder 
(34.9 g, 129 mmol, 64%). 
δH  (500 MHz, DMSO-d6): 8.64 (1H, s, H3), 7.97 (1H, app t, J = 1.6 Hz, H1), 7.35 (1H, app q, J = 0.8 
Hz, H2); δC (101 MHz, DMSO-d6): 138.2 (C3), 130.9 (C1), 119.4 (C2); HRMS (ESI+): m/z found 
[M+H]+
 
174.0073, C18H19O4N2
 
required 174.0080 (Δ 4.2 ppm). 
Characterisation data in accordance with literature.218 
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Fmoc-3-Chloro-phenylalanine (7) 
 
Prepared following general method 7 using NaHCO3 (1.59 g, 19.0 mmol), H2O (109 mL), MeCN 
(109 mL), 3-chloro-DL-phenylalanine (1.00 g, 5.00 mmol) and N-(9-
fluorenylmethoxycarbonyloxy)-succinimide (1.86 g, 5.50 mmol). The mixture was stirred at rt 
for 24 hours. After work-up, the crude mixture was purified by flash chromatography on silica 
gel (0 to 20% MeOH in CH2Cl2) to yield 7 as a white solid (650g, 1.96 mmol, 39%).  
Rf = 0.1 (20 % MeOH/ CH2Cl2); Mp = 78.6-87.5°C;
 
δH (400 MHz, DMSO-d6): 7.87 (2H, d, J = 7.5, 
14H), 7.64-7.61 (2H ,m, H17), 7.42-7.19 (8H, m, H5, H7, H8, H9, H15, H16), 4.24-4.10 (4H, m, H1, 
H11, H12), 3.13 (1H, app dd, J = 13.6, 3.9 Hz, H3), 2.91-2.85 (1H, m, H3); δC (101 MHz, DMSO-d6): 
174.1 (C2), 156.1 (C10), 144.4 (C18), 141.7 (C13), 141.3 (C4), 133.2 (C6), 130.4 (C8), 129.6 (C5), 
128.6 (C15), 128.2 (C16), 127.6 (C9), 126.7 (C7), 125.7 (C14), 120.5 (C17), 66.0 (C11), 56.4 (C1), 
47.1 (C12), 36.9 (C3); νmax: 1707 (C=O, s), 757 (C=C, s), 737 (C=C, s); HRMS (ESI+): m/z found 
[M+Na]+
 
444.0964, C24H20O4N35ClNa+
 
required 444.0973 (Δ -1.9 ppm). 
(S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-2-(3-chlorophenyl)acetate (8) 
 
Prepared following general method 7 using NaHCO3 (903 mg, 10.8 mmol), H2O (60 mL), MeCN 
(60 mL), (S)-2-(3-chlorophenyl)glycine (500 mg, 2.69 mmol) and N-(9-
fluorenylmethoxycarbonyloxy)succinimide (998 mg, 2.96 mmol). The mixture was stirred at rt 
for 48 hours. After the work-up, the crude product was purified by flash chromatography on 
silica gel (0 to 15% MeOH in CH2Cl2) to yield 8 as a white solid (940 mg, 2.31 mmol, 86%). 
Rf = 0.54 (10% MeOH/CH2Cl2); Mp = 241.0-242.4 °C; δH (400 MHz, DMSO-d6): 7.89 (2H, d, J = 7.1 
Hz, H16), 7.71 (2H, d, J = 7.1 Hz, H13), 7.44-7.39 (3H, m, H5, H15), 7.35-7.28 (4H, m, H1, H2, H3, 
H14), 4.87 (1H, d, J = 7.1 Hz, H7), 4.29-4.22 (3H, m, H10, H11); δC (101 MHz, DMSO-d6): 171.4 
(C8), 155.6 (C9), 144.4 (C12), 144.2 (C17), 141.2 (C6), 133.0 (C4), 130.1 (C2), 128.1 (C5), 127.5 
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(C1 or C3), 127.3 (C1 or C3), 127.0 (C15), 126.3 (C16), 125.7 (C14), 120.6 (C13), 66.1 (C10), 49.1 
(C7), 47.1 (C11); νmax: 3387 (OH, br), 1666 (C=O, m); [αD]20 + 79.00 (c = 0.22, MeOH); HRMS 
(ESI+): m/z found [M+H]+ 408.0997, C23H19O4N135Cl1 required 408.0990 (Δ -1.8 ppm). 
2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-2-(4-chlorophenyl)acetic acid (9) 
 
Prepared following general method 7 using NaHCO3 (1.80 g, 21.5 mmol), H2O (120 mL), MeCN 
(120 mL), 4-chloro-DL-phenylglycine (1.00 g, 5.39 mmol) and N-(9-
fluorenylmethoxycarbonyloxy)succinimide (2.00 g, 5.93 mmol). The mixture was stirred at rt for 
48 hours. After the work-up, the crude product was purified by flash chromatography on silica 
gel (0 to 20% MeOH in CH2Cl2) to yield 9 as a white solid (2.20 g, 5.39 mmol, quantitative). 
Rf = 0.47 (20% MeOH/CH2Cl2); Mp = 213.0-216.7 °C; δH (400 MHz, DMSO-d6): 7.89 (2H, d, J = 7.4 
Hz, H13), 7.72-7.70 (2H, m, H10), 7.41-7.29 (8H, m, H1, H2, H11, H12), 4.89 (1H, d, J = 6.8 Hz, 
H8), 4.28-4.22 (3H, m, H7, H15); δC (101 MHz, DMSO-d6): 171.7 (C5), 155.8 (C6), 144.4 (C9), 
144.2 (C14), 141.2 (C4), 129.5 (C1 or C2), 128.3 (C1 or C2), 128.0 (C13), 127.6 (C11 or C12), 
125.7 (C3), 125.7 (C11 or C12), 120.5 (C10), 66.0 (C7), 59.2 (C15), 47.2 (C8); νmax: 3303 (OH, br), 
1677 (C=O, m); HRMS (ESI+): m/z found [M+Na]+ 430.0817, C23H18O4N35Cl23Na required 
430.0817(Δ 0.2 ppm). 
Fmoc-Azido ornithine (12) 
 
HCl in (4 M in 1,4-dioxane, 14 mL) was added to a solution of Fmoc-Orn(Boc)-OH (2.00g, 4.39 
mmol) in 1,4-dioxane (14 mL). After stirring at rt for 16 h, the solvent was removed under a 
stream of N2 and the resulting residue was suspended in Et2O (70 mL). The solid was filtered 
and washed with Et2O (70 mL) to give the Fmoc-Orn-OH HCl as a white solid (1.70 g, 99%). 
Fmoc-Orn-OH HCl (2.96 g, 7.54 mmol) was dissolved in a biphasic mixture of H2O (44 mL), 
MeOH (87 mL) and CH2Cl2 (72 mL). CuSO4·5H2O (14.5 mg, 0.0580 mmol) and imidazole-1-
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sulfonyl azide hydrogen sulfate 6 (5.80 g, 22.7 mmol) were added. The mixture was adjusted to 
pH 9 with K2CO3 aqueous solution. After stirring vigorously for 18 hours, the organic solvents 
were removed under reduced pressure. The remaining aqueous phase was washed with Et2O (2 
x 50 mL), acidified to pH 2 with concentrated HCl and extracted with Et2O (3 x 50 mL). The 
organic extracts were dried (MgSO4) and concentrated under reduced pressure. The oily residue 
was dissolved in EtOAc and the solvent removed under a stream of N2 to give 12 as a white solid 
(2.25 g, 5.91 mmol, 78%). 
δH (400 MHz, DMSO-d6): 7.79 (2H, d, J = 7.6 Hz, H10), 7.62-7.60 (2H, m, H13), 7.43 (2H, app t, J = 
7.5 Hz, H11), 7.33 (2H, app tt, J = 7.4, 1.1 Hz, H12), 5.39 (1H, d, J = 8.1 Hz, CONH), 4.60-4.45 (3H, 
m, H1, H7), 4.23 (1H, t, J = 6.7 Hz, H8), 3.35-3.16 (2H, m, H5), 2.07-1.46 (4H, m, H3, H4); δC (126 
MHz, DMSO-d6): 175.6 (C2), 156.1 (C6), 143.7 (C14), 141.3 (C9), 127.8 (C11), 127.1 (C12), 125.0 
(C13), 120.1 (C10), 67.2 (C7), 53.2 (C8), 50.8 (C1), 47.2 (C5), 29.6 (C4), 29.5 (C3); [α]D20 -2.02 (c 
= 1.0, MeOH). 
Characterisation data in accordance with literature.251 
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6.1.1.3. Constraints 
1,2-Diethynylbenzene (C4) 
 
1,2-dibromobenzene (200 mg, 0.850 mmol), Pd(PPh3)2Cl2 (23.8 mg, 0.0340 mmol), CuI (6.50 mg, 
0.0340 mmol), PPh3 (18.0 mg, 0.0680 mmol) were dissolved in DIPEA (283 μL) and anhydrous 
toluene (1.41 mL). The mixture was stirred at rt for 5 minutes and TMS-acetylene was added. 
The mixture was refluxed under N2 for 16 hours. The solution was cooled down to 0 °C and KOH 
(6N in MeOH, 1.30 mL, 3.40 mmol) was added and the mixture was stirred at rt for 6 hours. The 
reaction was quenched with saturated NH4Cl and the volatiles removed under a stream of N2. 
The aqueous phase was acidified to pH 5 and extracted with CH2Cl2 (3 x 5 mL). The combined 
organic layers were dried (MgSO4), filtered, and the solvent evaporated under reduced pressure. 
The crude mixture was purified by flash chromatography on silica gel (100 % PE 30-40). To 
yield C4 as a 42% w/v solution in PE 30-40 (107 mg, 0.850 mmol, quantitative). 
Rf = 0.4 (100% hexane);
 
δH (400 MHz, CDCl3): 7.55-7.53 (2H, m, H2), 7.34-7.32 (2H, m, H1), 3.35 
(2H, s, H5); δC (101 MHz, CDCl3): 132.6 (C2), 128.5 (C1), 125.1 (C3), 81.8 (C4), 81.1 (C5); νmax: 
3287 (C≡C), 756 (C=C), 731 (C=C);
 
HRMS (ASAP): m/z found [M]+
 
126.0465, C10H6
 
required 
126.0470 (Δ -4.0 ppm). 
Methyl 3,5-bis((trimethylsylil)ethynyl)benzoate (C5-1) 
 
 
Trimethylsilyacetylene (6.00 mL, 42.2 mmol) was added to a stirring mixture of methyl 3,5-
dibromobenzoate (900 mg, 3.10 mmol), Pd2(dba)3 (54.0 mg, 0.0590 mmol), CuI (11.4 mg, 
0.00600 mmol) and PPh3 (77.4 mg, 0.290 mmol) in dry triethylamine (15.0 mL). The reaction 
mixture was refluxed for 16 hours under N2. The solvent was removed under reduced pressure, 
the residue was diluted with EtOAc and washed with H2O. The organic phase was dried (MgSO4) 
and the crude residue was purified by flash chromatography on silica gel (0-5% EtOAc in PE 40-
60) to give C5-1 as a yellow oil (693 mg, 2.11 mmol, 68%). 
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Rf = 0.4 (5% EtOAc/PE 40-60); Mp = 73-75 °C; δH (400 MHz, CDCl3): 8.07 (2H, app d, J = 1.4 Hz, 
H1), 7.74 (1H, app t, J = 1.4 Hz, H2), 3.93 (3H, s, H9), 0.26 (18H, s, H6); δC (101 MHz, CDCl3): 
165.7 (C8), 139.0 (C2), 132.6 (C1), 130.5 (C3), 123.9 (C7), 102.9 (C4), 96.1 (C5), 52.4 (C9), -0.2 
(C6); νmax: 2956 (C≡C, m), 2157 (C≡C-H, m), 1729 (C=O, s); HRMS (ESI+): m/z found [M+H]+
 
329.1378, C18H25O3Si2 required 329.1388 (Δ 3.0 ppm). 
Characterisation data in accordance with literature.219 
3,5-Diethylbenzoic acid (C5) 
 
Prepared following general method 8 using aqueous 6 M KOH (3.00 mL, 17.9 mmol), C5-1 (590 
mg, 1.79 mmol), MeOH (4.00 mL). After the work-up, C5 was obtained as an orange solid (300 
mg, 1.76 mmol, 98%). 
Rf = 0.40 (20% MeOH/CH2Cl2); δH (400 MHz, CD3OD): 8.05 (2H, app d, J = 1.32 Hz, H1), 7.73 (1H, 
app s, H2), 3.66 (2H, s, H5); δC (101 MHz, CD3OD): 166.4 (C7), 138.5 (C2), 132.6 (C1), 131.6 (C3), 
123.3 (C6), 81.0 (C4), 79.2 (C5); νmax: 3282 (C≡C, s), 1682 (C=O, s); HRMS (ESI+): m/z found 
[M+H]+
 
171.0444, C11H7O2
 
required 171.0441 (Δ 1.9 ppm). 
Characterisation data in accordance with literature.220 
1,5-bis(Trimethylsilyl)penta-1,4-diyn-3-ol (C6-1) 
 
Prepared following general method 9 using nBuLi (1.6 M in hexane, 3.15 mL, 0.100 mmol), 
trimethylsilylacetylene (0.700 mL, 0.100 mmol), THF (15.0 mL), 3-(trimethylsilyl)-
propriolaldehyde (0.500 mL, 0.610 mmol). After the work up, the crude residue was purified by 
preparative TLC (5% EtOAc in toluene) to give C6-1 as an orange oil (136 mg, 0.610 mmol, 
quantitative). 
Rf = 0.3 (100% hexane); δH (400 MHz, CDCl3): 5.10 (1H, s, H1), 3.49 (1H, br s, OH), 0.20 (18H, s, 
H4); δC (101 MHz, CDCl3): 101.8 (C2), 89.4 (C3), 52.8 (C1), -0.4 (C4); νmax: 3295 (O-H, br, w), 
2961 (C≡C-H, m); HRMS (ESI+): m/z found [M+H]+
 
225.1121, C11H21Si2
 
required 225.1131 (Δ -
4.4 ppm). 
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3-(4-Bromophenyl)-1,5-bis(trimethylsilyl)penta-1,4-diyn-3-ol (C6-6) 
 
Prepared following general method 9 using trimethylsilylacetylene (0.950 mL, 7.00 mmol) in 
THF (5.50 mL), nBuLi (1.6 M in hexane, 4.30 mL, 7.00 mmol), ethyl 4-bromo benzoate (300 μL, 
2.30 mmol) in THF (2.00 mL). After the work-up, the crude residue was purified by column 
chromatography on silica gel (100% hexane) to yield C6-6 as a white solid (800 mg, 2.13 mmol, 
93%).  
Rf = 0.2 (100% hexane); Mp = 87.0-88.5°C; δH (400 MHz, CDCl3): 7.67 (2H, d, J = 8.6 Hz, H2), 7.53 
(2H, d, J = 8.6 Hz, H3), 2.97 (1H, br s, OH), 0.23 (18H, s, H8); δC (101 MHz, CDCl3): 140.7 (C1), 
131.5 (C2), 127.8 (C3), 122.8 (C4), 104.1 (C6), 90.5 (C7), 65.0 (C5), -0.4 (C8); νmax: 2960 (C≡C, 
m), 838 (C=C, s), 760 (C=C, s); HRMS (ESI+): m/z found [M+Na]+ 401.0367, C17H23ON79BrNa
 
required 401.0363 (Δ 0.9 ppm). 
3-(4-Bromophenyl)penta-1,4-diyn-3-ol (C6-7) 
 
Prepared following general method 8 using aqueous 6 M KOH (0.500 mL, 2.40 mmol), C6-6 (100 
mg, 0.260 mmol) and MeOH (0.500 mL). After the work-up, the crude material was purified by 
flash chromatography on silica gel (0 to 10% EtOAc in hexane) to yield C6-7 as a yellow oil (33.0 
mg, 0.140 mmol, 54%). 
Rf = 0.11 (10% EtOAc/Hexane); δH (400 MHz, CDCl3): 7.69 (2H, d, J = 8.6 Hz, H2), 7.55 (2H, d, J = 
8.6 Hz, H3), 3.04 (1H, br s, OH), 2.82 (2H, s, H7); δC (101 MHz, CDCl3): 139.8 (C1), 131.7 (C2), 
127.6 (C3), 123.2 (C4), 83.0 (C6), 74.0 (C7), 64.2 (C5); νmax: 3283 (C≡C, s), 944 (C=C, s), 826 
(C=C, s); HRMS (ESI+): m/z found [M-H]-
 
232.9602, C11H6O79Br
 
required 232.9602 (Δ 0.0 ppm). 
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4-(3-Hydroxy-1,5-bis(trimethylsilyl)penta-1,4-diyn-3-yl)benzoic acid (C6-9) 
 
Prepared following general method 9 using trimethylsilylacetylene (5.00 mL, 34.7 mmol) in THF 
(50.0 mL), nBuLi (1.6 M in hexane, 25 mL, 36.0 mmol) and methyl-4-carboxybenzoate (2.50 g, 
13.8 mmol) in THF (10.0 mL). After the work-up, the crude residue was purified by flash 
chromatography on silica gel (100% CH2Cl2) to yield C6-9 as an off white solid (2.20 g, 6.38 
mmol, 46%). 
Rf = 0.02 (0.5% MeOH/CH2Cl2); Mp = 199.8-200.6 °C δH (400 MHz, CD3OD): 8.05 (2H, d, J = 8.4 
Hz, H3), 7.84 (2H, d, J = 8.4 Hz, H4), 0.22 (18H, s, H9); δC (101 MHz, CD3OD): 168.0 (C1), 147.4 
(C2), 130.4 (C5), 129.3 (C3), 125.6 (C4), 105.1 (C7), 88.6 (C8), 64.3 (C6), -1.7 (C9); νmax: 3340 (O-
H, br, w), 1683 (C=O, m); HRMS (ESI+): m/z found [M+H]+
 
345.1336, C18H25O3Si2 required 
345.1342 (Δ -1.7 ppm). 
4-(3-Hydroxypenta-1,4-diyn-3-yl)benzoic acid (C6) 
 
Prepared following general method 8 using aqueous 6 M KOH (5.00 mL, 29.0 mmol), C6-9 (1.00 
g, 2.84 mmol) and MeOH (6.00 mL). After the work-up, C6 was yielded as a yellow solid (350 mg, 
1.75 mmol, 62%). 
Rf = 0.4 (20% CH2Cl2/MeOH); Mp = 154.4-155.6 °C; δH (400 MHz, CD3OD): 8.07 (2H, d, J = 8.4 Hz, 
H3), 7.88 (2H, d, J = 8.4 Hz, H4), 3.22 (2H, s, H8); δC (101 MHz, CD3OD): 167.9 (C1), 147.2 (C2), 
130.5 (C5), 129.3 (C3), 125.6 (C4), 83.6 (C7), 73.2 (C8), 63.5 (C6); νmax: 3275 (C≡C, m), 1658 
(C=O, s); HRMS (ESI+): m/z found [M+Na]+ 223.0369, C12H8O3Na
 
required 223.0366 (Δ 1.7 ppm). 
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3,6-Dibromo-9H-carbazole (C8-1) 
 
A solution of N-bromosuccinimide (1.17 g, 6.60 mmol) in DMF (66.0 mL) was added dropwise to 
an ice-cold suspension of carbazole (500 mg, 3.00 mmol) in toluene (2.50 mL). The reaction 
mixture was warmed to rt, stirred for 30 minutes then poured onto H2O (100 mL). The 
precipitate formed was then washed with H2O (20 mL) and cold MeOH (20 mL). The crude 
product was triturated in cold MeOH/hexanes (1:1) to give the desired product as an off-white 
solid (673 mg, 2.10 mmol, 69%). 
Rf = 0.30 (30% CH2Cl2/PE 40-60); Mp = 250-256 °C (lit. 210-211 °C); δH (400 MHz, DMSO-d6): 
11.57 (1H, s, H7), 8.44 (2H, app. d, J = 1.44 Hz, H3), 7.55-7.47 (4H, m, H5, H6); δC (101 MHz, 
DMSO): 139.3 (C1), 129.2 (C3), 123.8 (C5), 123.8 (C4), 113.7 (C6), 111.4 (C2); νmax: 3420 (N-H, 
s), 800 (C-Br, s); HRMS (ESI+): m/z found [M+H]+ 323.9012, C12H8N79Br2 required 323.9024 (Δ -
3.7 ppm).  
Characterisation data in accordance with literature.252,253 
3,6-Diethynyl-9H-carbazole (C8) 
 
A suspension of C8-1 (5.00 g, 15.5 mmol), Pd(PPh3)2Cl2 (500 mg, 0.775 mmol), CuI (100 mg, 
0.465 mmol), ethynyltrimethylsilane (10.0 mL, 69.8 mmol), and PPh3 (100 mg, 0.388 mmol) in 
NEt3 (160 mL) was refluxed for 48 hours. The reaction mixture was filtered through Celite, 
washed with H2O (50 mL), brine (50 mL) and dried (MgSO4). The mixture was concentrated 
under reduced pressure and the residue resuspended in 500 mL of MeOH. K2CO3 (14.1 g, 101 
mmol) was added and the suspension stirred at rt for 18 hours. The reaction mixture was 
evaporated under reduced pressure and the residue was purified by flash column 
chromatography on silica gel (30% CH2Cl2/PE 40-60) to yield the desired product as a dark 
orange solid (2.69 g, 12.5 mmol, 81%).  
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Rf = 0.28 (20% EtOAc/hexanes); Mp = 210 °C decomp. (lit. Mp = 212-213 °C); δH (400 MHz, 
DMSO-d6): 11.71 (1H, s, H1), 8.37 (2H, s, H6), 7.50 (4H, app. s, H3, H4), 4.04 (2H, s, H9); δC (101 
MHz, DMSO-d6): 140.5 (C2), 130.2 (C4), 125.2 (C6), 122.4 (C7), 112.6 (C5), 112.0 (C3), 85.3 (C9), 
78.9 (C8); νmax: 3404 (NH s), 3269 (C≡C-H, m), 2103 (C≡C, s), HRMS (ESI): m/z found [M+H]+ 
216.0818, C16H10N required 216.0813 (Δ 2.3 ppm). 
Data in accordance with the literature.244 
6-(3,6-Diethynyl-9H-carbazol-9-yl)hexanoic acid (C9) 
 
Prepared following a literature procedure.254 To a solution of 3,6-diethynyl-9H-carbazole (1.00 
g, 2.78 mmol) in DMF (5.60 mL) was added powdered KOH (1.23 g, 22.0 mmol). The reaction 
mixture was stirred at rt for 20 minutes. After this time 6-bromohexanoic acid (1.08 g, 5.56 
mmol) was added and the reaction was irradiated at 37 kHz ultrasonic waves at 35 °C for 2 
hours. The reaction was acidified to pH 5 with conc HCl, portioned with Et2O and H2O and the 
organic phase washed with brine. The organic extract was dried (MgSO4) and the solvent 
removed under reduced pressure. The crude product was purified by flash chromatography on 
silica gel (0-50% EtOAc/hexane) to yield C9 as a gummy yellow oil (880 mg, 1.86 mmol, 67%). 
Rf = 0.20 (20% EtOAc/hexane); δH (400 MHz, CDCl3): 8.22 (2H, d, J = 1.0 Hz, H13), 7.61 (2H, dd, J 
= 8.4, 1.00 Hz, H9), 7.32 (2H, J = 8.4 Hz, H8), 4.27 (2H, t, J = 9.4 Hz, H6), 3.11 (2H, s, H12), 2.34 
(2H, t, J = 7.4 Hz, H2), 1.88 (2H, app quint., J = 7.4 Hz, H5), 1.68 (2H, app quint., J = 6.8, H3), 1.46-
1.39 (2H, m, H4); δC (101 MHz, CDCl3): 179.6 (C1), 140.6 (C7), 130.2 (C13), 124.8 (C9), 122.3 
(C14), 112.8 (C10), 108.9 (C8), 84.7 (C11), 75.6 (C12), 43.0 (C6), 33.7 (C2), 28.6 (C5), 26.6 (C4), 
24.3 (C3); νmax: 3260 (C≡C, m), 1698 (C=O, s); HRMS (ESI+): m/z found [M+H]+ 330.1491, 
C22H20O2N
 
required 330.1494 (Δ -0.9 ppm). 
 
 
 
 
 
 Chapter 6: Chemistry Experimental   
168 
6.1.2. Peptides 
General method 10: Manual peptide synthesis 
Manual peptide synthesis was performed on Merck LL MHBA Rink amide resin (0.33 mmol/g, 1 
equiv). Couplings were carried out by adding HATU (4 equiv) to a solution of the Fmoc-
protected amino acid (4 equiv) in DMF (~0.4 M). After 10 seconds, DIPEA (8 equiv) was added 
to the mixture. This pre-activated mixture was then added to the resin in DMF and shaken for 3 
minutes. The coupling time was extended in the case of N-terminal capping with C5 and C9 (1 
hour), for coupling of Arg and unnatural amino acids (30 minutes). The side chain protecting 
groups used were: tBu for Asp, Glu, Ser, Thr, Tyr; Boc for Lys, Trp; Pbf for Arg; Trt for Asn, Gln, 
His. Fmoc-Lys(ddve)-OH was used for conjugation of FITC with Lys. Fmoc-Gly(Dmb)-OH was 
used for the synthesis of peptide P7. 
Fmoc deprotection was carried out with 20% piperidine in DMF (3 x 3 minutes). 
N-terminal capping with FITC and Ac2O (2 equiv) was achieved using DIPEA (4 equiv) in CH2Cl2 
overnight (FITC) or for 1 hour (Ac2O).  
On-resin attachment of FITC via Lys was achieved by orthogonal deprotection of the Lys(ddve) 
with 5% NH2NH2 in DMF (2 x 10 minutes) followed by conjugation with FITC (2 equiv) in the 
presence of DIPEA (4 equiv) overnight. 
Completion of amide couplings and Fmoc deprotection was determined by a chloranil test, in 
which acetaldehyde (200 μL) and a saturated solution of chloranil in toluene (50 μL) were added 
to a small amount of resin swelled in CH2Cl2. After 10 seconds shaking at rt, no change in colour 
indicated complete coupling, whilst green colouration of the resin indicated presence of a free 
amine. Any incomplete couplings was submitted to a second round of coupling.  
Side chain deprotection and cleavage from the resin was achieved with TFA containing 2.5% 
TIPS and 2.5% H2O for 3 hours at rt or 1 hour at 42 °C. In case of methionine and cysteine-
containing peptides, cleavage was achieved with TFA containing 5% EDT, 5% H2O and 2.5% 
TIPS. After cleavage, the mixture was filtered through a sintered funnel, the beads washed with 
MeOH and the filtrate was concentrated under a stream of N2. The crude residue was triturated 
with cold Et2O before purification by preparative HPLC.  
General method 11: Automated Fmoc solid-phase peptide synthesis 
Automated peptide synthesis was carried out on a CEM Liberty Automated Microwave Peptide 
Synthesiser using Merck LL MHBA Rink Amide resin (0.33 mmol/g, 1 equiv). All peptide 
couplings were performed with Fmoc-protected amino acids (5 equiv), Oxyma pure (10 equiv) 
and DIC (5 equiv) in DMF. Arg was coupled using double couplings for 15 min each without 
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microwave irradiation. All other amino acids were coupled with 25 W power at 75 °C over 15 
min.  
Fmoc deprotection was achieved with a solution of 20% piperidine in DMF, using 45 W power at 
75 °C over 3 min. N-terminal capping, cleavage and HPLC purification of peptides were carried 
out as previously described for manual SPPS (general method 10). 
General method 12: Peptide stapling via Copper-catalysed azido-alkyne click (CuAAC).38 
A solution of diazido peptide (1 equiv) and dialkynyl linker (1 equiv) in 1:1 tBuOH/H2O (0.8 
mL/mg peptide) was degassed with N2 for 15 min, followed by the addition of CuSO4 · 5H2O (1 
equiv), THPTA (1 equiv), and sodium ascorbate (3 equiv). Peptides bearing sulfur atoms 
required CuSO4 · 5H2O (2 equiv), THPTA (2 equiv), and sodium ascorbate (6 equiv). All the 
reactions were stirred under N2 and monitored by LCMS. When no starting material could be 
detected by LCMS, the reaction mixture was diluted with H2O and lyophilised prior to 
purification. The absence of azido peak on IR (~ 2100 cm-1) was checked for all the purified, 
dried peptide. 
General method 13: Peptide macrocyclisation via disulphide bridge formation.215 
To a solution of the linear peptide in aqueous AcOH (50%) was added 2 mM I2 in MeOH 
dropwise. After 5 minutes the reaction was quenched by adding ascorbic acid (1 M). The crude 
mixture was directly purified on preparative HPLC. 
General method 14: Peptide macrocyclisation via ring-closing metathesis (RCM).46 
RCM of the peptides was carried out on resin. After N-terminus capping, the resin was de-
swollen in MeOH, then washed with CH2Cl2 and resuspended in the minimum amount of CH2Cl2. 
Grubb’s II catalyst (20 mol%) was dissolved in CH2Cl2 and added to the resin under bubbling N2. 
The reaction was agitated for 2 hours. The resin was then washed with CH2Cl2 and the process 
repeated. The peptide was then cleaved from the resin and purified as described above (general 
method 10).  
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6.1.2.1. Conversion of CuAAC macrocyclisation reactions 
The conversions of the peptides that underwent macrocyclisation via CuAAC 2C PS refer to LCMS 
conversion of the crude material (Table 18). All the reactions were quenched when no starting 
material could be detected. 
Table 18 - LCMS conversion of peptides that underwent CuAAC cyclisation. CK2 peptides are shown in the left column, 
BH3 peptides in the right column. 
Peptide Conversion (%)  Peptide Conversion (%) 
P0-C1 82  P9-C5 58 
P1-C2 65  P9-C7 81 
P1-C3 62  P9-F4C5 59 
P1-C4 79  P9-F5C5 87 
P1-C5 92  P11-F4C5 NA 
P1-C6-7 52  P14-C8 NA 
P1-C6 85  P15-C8 90 
FITC-P1-C5 56  P16-C8 60 
P1-F1C5 79  P17-C5 92 
P1-F2C5 54  P18-C5 68 
P1-F3C5 87  P19-C5 97 
P2’-C5 67  P17-F1C5 92 
P2’’-C5 NA  P18-F1C5 77 
P3-C5 53  P19-F1C5 72 
P4-C5 60  FITC-Ahx-P9-F4C4 74 
P5’-C5 53  FITC-Ahx-P9-F5C5 90 
P5’’-C5 47  FITC-Ahx-P11-F4C4 79 
P6-C5 88    
P7-C5 83    
P7-F1C5 60    
P7-F2C5 72    
P8-F1C5 72    
NA = not available due to complicated chromatogram. 
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6.1.2.2. LCMS and purity of CK2 peptides 
CK2 peptides sequence, mass observed on LCMS, purity and retention time (Rt) by analytical 
HPLC are shown in Table 19. 
Table 19- Sequence, mass, purity and retention time of CK2 peptides 
Peptide Sequence Mass 
m/z 
found 
m/z 
calcul. 
Species Purity 
Rt* 
(min) 
Pc GCRLYGFKIHGCG(S-S) 1448.7 1449.5 1449.7 M+H 87% 7.26 
Pc linear GCRLYGFKIHGCG 1450.7 1451.49 1451.7 M+H 99% 9.62 
Short Pc linear CRLYGFIHGC 1336.6 1337.3 1337.7 M+H 90% 9.92 
Short Pc CRLYGFKIHGC (S-S) 1334.6 1335.4 1335.6 M+H 84% 14.32 
P0 XRLYGFKIHX 1297.7 1298.9 1298.7 M+H > 99% 10.16 
P0-C1 XC1RLYGFKIHXC1  1376.7 1377.5 1377.7 M+H 97% 6.96 
P1 GXRLYGFKIHXGG 1468.7 1470 1469.8 M+H 91% 7.29 
P1-C2 GXC2RLYGFKIHXC2GG 1594.8 1595.61 1595.8 M+H 91% 7.78 
P1-C3 GXC3RLYGFKIHXC3GG  1532.8 1533.6 1533.8 M+H 97% 6.98 
P1-C4 GXC4RLYGFKIHXC4GG 1423.7 1424.5 1424.7 M+H 97% 7.85 
P1-C5 GXC5RLYGFKIHXC5GG 1638.9 1639.4 1639.9 M+H 89% 7.46 
P1-C6-7 GXC6-7RLYGFKIHXC6-7GG 1702.7 568.6 568.3 M+3H > 99% 7.74 
P1-C6 GXC6RLYGFKIHXC6GG  1671.0 836.2 836.2 M+2H 92% 7.14 
FITC-P1 FITC-Ahx-GXRLYGFKIHXGG 1929.7 644.6 644.3 M+3H 62% 8.96 
FITC-P1-C5 FITC-Ahx-GX C5RLYGFKIHX C5GG 1709.7 1710.1 1710.7 M+H 94% 7.89 
P1-F1C5 GX F1C5RLYGFKIHX F1C5GG 2334.3 1168.1 1168.1 M+2H >99% 6.96 
P1-F2C5 GXF2C5RLYGFKIHXF2C5GG 2851.4 1427.3 1426.7 M+2H 98% 7.69 
P1-F3C5 GXF3C5RLYGFKIHXF3C5GG 1191.1 1192.7 1192.1 M+2H 89% 8.44 
P2’ GXRLYG(L-3-Cl-F)KIHXGG 1502.7 752.3 752.4 M+2H 74% 7.57 
P2’’ GXRLYG(3-Cl F)KIHXGG 1502.7 752.3 752.4 M+2H 91% 7.50 
P2’-C5 GXC5RLYG(L-3-Cl F)KIHXC5GG 1674.7 1675 1675.7 M+H 90% 7.46 
P2’’-C5 GXC5RLYG(D-3-Cl F)KIHXC5GG 1674.7 1675.5 1675.7 M+H 85% 7.24 
P3 GXRLYG(4-Cl-F)KIHXGG 1502.7 752.3 752.4 M+2H 87% 7.71 
P3-C5 GXC5RLYG(4-Cl-F)KIHXC5GG 1677.8 1676.9 1676.8 M-H 92% 7.33 
P4 GXRLYG(3-Cl phegly)KIHXGG 1490.7 1491.1 1491.7 M+H >99% 7.56 
P4-C5 GXC5RLYG(3-Clphegly)KIHXC5GG 1659.8 1659.6 1658.4 M-H 92% 8.26 
P5 GXRLYG(4-Cl phegly)KIHXGG 1490.7 1491.2 1491.7 M+H >99% 7.61 
P5’-C5 GXC5RLYG(4-Cl phegly)KIHXC5GG 1659.8 1661.3 1660.8 M+H 92% 7.25 
P5’’-C5 GXC5RLYG(4-Cl phegly)KIHXC5GG 1659.8 1661.3 1660.8 M+H 97% 7.38 
P6 GXRLPGFKIHXGG 1403.7 1402.1 1402.7 M-H 89% 7.15 
P6-C5 GXC5RLPGFKIHXC5GG 1573.6 1574.7 1573.7 M+H 98% 6.95 
P7 GXRLYGFKWHXGG 1543.7 1544 1544.7 M+H 95% 7.48 
P7-C5 GXC5RLYGFKWHXC5GG 1713.6 1714.7 1714.6 M+H >99% 7.29 
P7-F1C5 GXF1C5RLYGFKWHXF1C5GG 2407.3 1205 1204.5 M +2H >99% 7.22 
P7-F2C5 GXF2C5RLYGFKWHXF2C5GG 2929.5 1462.2 1463.7 M+2H 95% 7.62 
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P8-F1C5 GX F1C5RLYGFKIHX F1C5GG 2146.1 1074.2 1074.1 M+2H 86% 6.27 
e1F2β MSGDEMIFDPTMS(K)8PNH2 1311.7 1312.9 1312.7 M+2H 90% 6.85 
*rt (retention time) on a 5 to 95 % B over 15 minutes run on analytical HPLC. X = Aza-alanine. All the peptides feature an 
amide at the C-terminus and an acetyl capping at the N-terminus 
6.1.2.3. LCMS and purity of CPPs 
CPPs sequence, mass observed on LCMS, purity and retention time (Rt) by analytical HPLC are 
shown in Table 20. 
Table 20-Sequence, mass, purity and retention time of cell-penetrating peptides. 
Peptide Sequence Mass 
m/z 
found 
m/z 
calcul. 
Species Purity 
Rt* 
(min) 
F1C5 C5-(Ahx)2+[(D)R]3 863.5 864.9 864.5 M+H 99% 7.47 
F2C5 C5-Ahx2[(D)R]3K-FITC 1381.7 1382.4 1382.7 M+H 83% 9.18 
F3C5 C5-(Ahx)2+K+FITC 911.3 912.4 911.3 M+H 97% 7.18 
F4C4 C5-RRR 637.4 638.7 638.4 M+H 93% 6.6 
F5C5 C5-(Ahx)2-PKKKRKV 1259.8 1261.2 1260.9 M+H 99% 7.3 
*rt (retention time) on a 5 to 95 % B over 15 minutes run on analytical HPLC. 
6.1.2.4. LCMS and purity of BH3 peptides 
BH3 peptides sequence, mass observed on LCMS, purity and retention time (Rt) by analytical 
HPLC are shown in Table 21. 
Table 21-Sequence, mass, purity and retention time of BH3 peptides. 
Peptide Sequence Mass 
m/z 
found 
m/z 
calcul. 
Species Purity 
Rt* 
(min) 
P9 IWIAQELRXF5C5IGDXF5C5FNAYYARR 2677.4 1339.7 1337.6 M+2H 94% 13.7 
P9-C5 IWIAQELRXC5IGDXC5FNAYYARR 2846.4 1424.9 1424.2 M+2H 93% 9.92 
P9-F4C5 IWIAQELRXF4C5IGDXF4C5FNAYYARR 3315.2 1658.1 1658.1 M+2H 96% 14.32 
P9-F5C5 IWIAQELRXF5C5IGDXF5C5FNAYYARR 3940.0 1314.1 1314.3 M+3H > 99% 8.49 
P9-C7 IWIAQELRXC7IGDXC7FNAYYARR 2975.2 1487.6 1487.6 M+2H 99% 10.09 
FITC-P9 FITC-Ahx-IWIAQELRXIGDXFNAYYARR 3136.5 1046.6 1046.2 M+3H >99% 11.73 
FITC-P9-F4C5 FITC-Ahx-IWIAQELRXF4C5IGDXF4C5FNAYYARR 3773.8 1887.3 1887.9 M+2H 83% 9.96 
FITC-P9-F5C5 FITC-Ahx-IWIAQELRXF5C5IGDXF5C5FNAYYARR 4397.3 1465.3 1466.4 M+3H >99% 9.82 
FITC-P9-C7 FITC-Ahx-IWIAQELRXC7IGDXC7FNAYYARR 3228.6 1075.7 1075.5 M-3H 89% 12.14 
P10 IWIAQELRRIGDEFNAYYARR 2682.1 1341.6 1341.2 M +2H 95% 6.16a  
FITC-P10 FITC-Ahx-IWIAQELRRIGDEFNAYYARR 3141.5 1629.86 1629.2 (M+TFA) 88% 9.9 
P11-F4C5 IWIAQELDXF4C5IGDXF4C5FNAYYARR 3272.7 1638.4 1638.3 M+2H 98% 8.98 
FITC-P11 FITC-Ahx-IWIAQELDXIGDXFNAYYARR 3095.4 1548.7 1548.7 M+2H 97% 12.27 
FITC-P11-F4C5 FITC-Ahx-IWIAQELDXF4C5IGDXF4C5FNAYYARR 3731.8 1866.9 1866.4 M+2H 90% 10.11 
SAHBa IWIAQELRXAHIGDXAHFNAYYARR 2646.4 1324.24 1324.2 M+2H 91% 11.13 
FITC-SAHBa FITC-Ahx-IWIAQELRXAHIGDXAHFNAYYARR 3106.5 1554.8 1554.2 M+2H 93% 11.91 
P12 RYGRELRRMSDEFVDSF 2204.6 2205.7 2205.7 M+H 87% 7.81 
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P13 IIRNIARHLAQVGDSMDRS 2192.2 1098 1098.1 M+2H 96% 8.66 
P14 IAXELRRIGDEFNXYAA 2151.1 2152.4 2152.4 M+H 86% 9.21 
P14-C8 IAXC8ELRRIGDEFNXC8YAA 2366.1 1182.6 1182.2 M-2H 92% 9.95 
P15 XYGRELRRMSDXFVDSF 2199.6 2200.5 2200.6 M+H 75% 8.79 
P15-C8 XC8YGRELRRMSDXC8FVDSF 2414.0 2415.2 2415 M+H 75% 9.59 
P16 IIRNIAXHLAQVGDSMDXS 2160.4 2161.8 2161.4 M+H 85% 9.68 
P16-C8 IIRNIAXC8HLAQVGDSMDXC8S 2375.5 1189.2 1188.7 M+2H 90% 9.45 
P17 IAQXLRRIGDXFNAYAA 2092.1 1047.7 1047 M+2H 75% 10.65 
P17-C5 IAQXC5LRRIGDXC5FNAYAA 2262.1 2263.8 2263.1 M+H 88% 10.1 
P17-F1C5 IAQXF1C5LRRIGDXF1C5FNAYAA 2955.6 1479.2 1478.8 M+2H 88% 9.42 
P18 YGRXLRRMSDXFVDSF 2069.0 1035.6 1035.5 M+2H 80% 9.2 
P18-C5 YGRXC5LRRMSDXC5FVDSF 2240.7 1120.0 1120.0 M+2H 85% 8.74 
P18-F1C5 YGRXF1C5LRRMSDX F1C5FVDSF 2933.0 1468.4 1466.5 M+2H >99% 8.59 
P19 IIRXIARHLAXVGDSMDRS 2230.2 1117.1 1116.1 M+2H 75% 9.3 
P19-C5 IIRXC5IARHLAXC5VGDSMDRS 2400.2 1202.3 1201.1 M+2H 98% 9.52 
P19-F1C5 IIRXF1C5IARHLAXF1C5VGDSMDRS 3097.0 1548.8 1548.5 M+2H 90% 9.09 
*Unless otherwise specified, rt (retention time) refers to a 5 to 95 % B over 15 minutes run on analytical HPLC.  
a rt on a 30 to 100% solvent B over 15 minutes. 
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With the exclusion of the docking studies, all the experiments described in this dissertation were 
performed by Dr Yaw Sing Tan, A*STAR, Singapore. 
7.1. Docking studies for CK2 fragments 
All the docking studies herein reported were performed using Glide of the suite Maestro, 
produced by Schrodinger.255–257 The protein was prepared starting from the PDB file of the X-ray 
structures generated by Dr Paul Brear (Department of Biochemistry, Hyvӧnen Group) and using 
the PrepWinz feature of Maestro. To keep the conformation of the protein as close as possible to 
the X-ray structures, no modifications such as ‘cap termini’, ‘filling loops’ or ‘side chain’, ‘original 
hydrogen deletion’ were performed. Only the orientation of the water molecules was sampled, 
and the ionisation state of the protein was calculated at pH 7 ± 2. Ligands were prepared with 
the LigPrep functionality, using OPLS_2005 as the force field. All other parameters were left as 
default. Conformational search of the ligands was performed after ligand preparation. The 
parent ligand of the crystal structure was used as the template for the grid generation and 
positional constraints were given to the benzylamine nitrogen of the ligand. All other 
parameters were left as default. Ligand input partial charges were used and, in addition to 
default parameters, the planarity of conjugated pi groups was enhanced. For the conformer 
generation, enhanced sampling was used, and the energy window for ring sampling was 
increased to 3.5 kcal mol-1.  
7.2. Computational chemistry for CK2 peptides  
7.2.1 Molecular dynamics 
Chains A and D from the crystal structure of human CK2α in complex with a CK2β-derived cyclic 
peptide called Pc (1-GCRLYGFKIHGCG-13) (PDB: 4IB5)215 were used as the initial structures for 
molecular dynamics (MD) simulations. The unresolved CK2α residue Met1 was added using 
PyMOL. CK2α was capped at its C-terminus by N-methyl while Pc was capped by acetyl and 
amide groups. Crystallographic water molecules were retained. PDB2PQR258 was then used to 
determine the protonation states of residues. Using the LEaP program in the AMBER 14259 
package, each complex was solvated with TIP3P260 water molecules in a periodic truncated 
octahedron box such that its walls were at least 10 Å away from the complex, followed by 
neutralisation of the system with either sodium or chloride ions. 
Energy minimisations and MD simulations were carried out by the PMEMD module of AMBER 
14, using the ff14SB261 force field for protein residues and the generalised AMBER force field 
(GAFF)262 for the stapled residues. Atomic charges for the stapled residues were derived using 
the R.E.D. Server,263 which fits restrained electrostatic potential (RESP) charges264 to a molecular 
electrostatic potential (MEP) computed by the Gaussian 09 program265 at the HF/6-31G* theory 
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level. A total of three independent explicit-solvent MD simulations using different initial atomic 
velocities were carried out. The SHAKE algorithm266 was applied to constrain all bonds involving 
hydrogen atoms, allowing for a time step of 2 fs. A cutoff distance of 9 Å was implemented for 
nonbonded interactions. The particle mesh Ewald method267 was used to treat electrostatic 
interactions with a grid spacing of 1.0 Å and the order of B-spline interpolation set to 4. Energy 
minimisation was performed for 500 steps with the steepest descent algorithm, followed by 
another 500 steps with the conjugate gradient algorithm. The system was then heated gradually 
to 300 K over 50 ps at constant volume before equilibration at a constant pressure of 1 atm for 
another 50 ps. During the minimisation and equilibration, weak harmonic positional restraints 
with a force constant of 2.0 kcal mol-1 Å-2 were imposed on the non-hydrogen atoms of the 
solute. These restraints were removed in a subsequent equilibration run (2 ns) and the 
production run (100 ns), which were carried out at 300 K and 1 atm. The Langevin thermostat268 
was used to maintain the temperature with a collision frequency of 2 ps-1. Pressure was 
maintained by a Berendsen barostat269 with a pressure relaxation time of 2 ps.  
7.2.2 Ligand mapping simulations 
Ten different distributions of chlorobenzenes around apo CK2α were created using Packmol.270 
The LEaP module in the AMBER 14 package was then used to solvate each system with TIP3P 
water molecules in a periodic truncated octahedron box, such that its walls were at least 10 Å 
away from the protein, resulting in a final chlorobenzene concentration of ~0.15 M. 
Minimisation, equilibration and production (20 ns) MD simulations were carried out as 
described above for the CK2α complexes, for a cumulative sampling time of 200 ns. The GAFF6 
force field was used to describe the chlorobenzenes during the simulations. Atomic charges for 
chlorobenzene were used as previously described.271 
The 10 individual runs were combined into a single trajectory for analysis. Chlorobenzene 
occupancy grids were generated using the cpptraj module of AMBER 14 to bin both carbon and 
chlorine atoms of chlorobenzenes into 1 Å × 1 Å × 1 Å grid cells. The cutoff isocontour value used 
for visualisation of chlorobenzene carbon and chlorine atom occupancies is five times the 
threshold bulk value, which is defined as the highest isovalue at which the respective atoms are 
detected in the bulk solvent. In order to compare the overlap of the chlorobenzene occupancy 
maps with known CK2α ligands, the respective ligand-bound CK2α structures were aligned 
using PyMOL272 to the average protein structure sampled during the LMMD simulations. 
7.2.3 Binding free energy decomposition  
The contribution of each Pc peptide residue to the binding free energy of the complex was 
computed by applying the free energy decomposition method273 on 200 equally-spaced 
structures extracted from the last 40 ns of the MD simulations of the CK2α–Pc complex. Binding 
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free energies were calculated in AMBER 14259 using the molecular mechanics/generalised Born 
surface area (MM/GBSA) method.274 The molecular mechanical energies and polar contribution 
to solvation free energy were computed by the sander module and pbsa program using the 
modified GB model described by Onufriev et al.275 respectively. The nonpolar contribution to 
solvation free energy was estimated from the solvent accessible surface area (SASA) using the 
ICOSA method.276 
7.2.4 Computational alanine scanning (CAS) 
Computational alanine scanning was carried out on 200 equally-spaced structures extracted 
from the last 40 ns of the MD simulations of the CK2α–Pc complex. The difference in the binding 
free energy (ΔΔGbind) of the wild-type and alanine mutants was calculated using the MM/GBSA 
method 18 with modules in AMBER 14.259 Molecular mechanical energies were calculated with 
the sander module. The polar contribution to the solvation free energy was calculated by the 
pbsa module277 using the modified GB model described by Onufriev et al.275 while the nonpolar 
contribution was estimated from the SASA using the linear combinations of pairwise overlaps 
method,278 with γ set to 0.0072 kcal mol-1 Å-2 and β to zero.278 The entropy term was not 
considered due to the high computational cost and the assumption that the entropy of the 
mutant does not differ considerably from that of the wild-type.279 
7.2.5 Binding free energy calculations 
Binding free energies for the CK2α complexes were calculated using the molecular 
mechanics/generalised Born surface area (MM/GBSA) method274 implemented in AMBER 14.259 
Two hundred equally-spaced snapshot structures were extracted from the last 40 ns of each of 
the trajectories, and their molecular mechanical energies calculated with the sander module. The 
polar contribution to the solvation free energy was calculated by the pbsa277 module using the 
modified generalised Born (GB) model described by Onufriev et al.275 while the nonpolar 
contribution was estimated from the solvent accessible surface area using the molsurf280 
program with γ = 0.0072 kcal Å-2 and β set to zero. Entropies were estimated by normal mode 
analysis281 using the nmode program. Due to its computational expense, only 50 equally-spaced 
snapshots from the last 40 ns of the trajectories were used for entropy calculations. 
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7.3. Computational chemistry for BH3 peptides  
7.3.1 Preparation of structures 
The structure of Bcl-xL (∆45-84) in complex with Bim BH3 (residues 141-166) (PDB: 4QVF)246 
was used as the initial structure for MDs. Bim BH3 was truncated to residues 146-166. The 
unresolved Bim residues 165 and 166 were then added using PyMOL to give peptide P9-C2 Bcl-
xL was capped at its N- and C-termini by acetyl and N-methyl groups respectively while peptide 
P9-C2 was capped at its N- and C-termini by acetyl and amide groups respectively. Peptide P9-
C2 was modified into the stapled peptide by replacing residues 154 and 158 with a two-
component triazole staple formed by a double-click reaction between two azido-ornithine 
residues and 1,3-diethylnylbenzene. PDB2PQR258 was used to determine the protonation states 
of residues. Each Bcl-xL complex was solvated with TIP3P water molecules260 in a periodic 
truncated octahedron box, such that its walls were at least 9 Å away from the complex, and 
neutralised with sodium ions. 
7.3.2 Molecular dynamics 
Energy minimisations and MD simulations were performed with the sander and PMEMD 
modules of AMBER 14259 respectively. Three independent MD simulations were carried out on 
each of the Bcl-xL complexes using the ff14SB261 and GAFF. Atomic charges for the stapled 
residues were derived using the R.E.D. Server,263 which fits RESP charges264 to a MEP computed 
by the Gaussian 09 program265 at the HF/6-31G* theory level. All bonds involving hydrogen 
atoms were constrained by the SHAKE algorithm,266 allowing for a time step of 2 fs. Nonbonded 
interactions were truncated at 9 Å, while the particle mesh Ewald method267 was used to 
account for long range electrostatic interactions under periodic boundary conditions. Weak 
harmonic positional restraints with a force constant of 2.0 kcal mol-1 Å-2 were placed on the 
protein and peptide non-hydrogen atoms during the minimisation and equilibration steps. 
Energy minimisation was carried out using the steepest descent algorithm for 500 steps, 
followed by the conjugate gradient algorithm for another 500 steps. The systems were then 
heated gradually to 300 K over 50 ps at constant volume before equilibration at a constant 
pressure of 1 atm for another 50 ps. Subsequent unrestrained equilibration (2 ns) and 
production (100 ns) runs were carried out at 300 K using a Langevin thermostat268 with a 
collision frequency of 2 ps-1, and 1 atm using a Berendsen barostat269 with a pressure relaxation 
time of 2 ps.  
7.3.3 Binding free energy calculations 
Binding free energies for the Bcl-xL complexes were calculated using the molecular 
mechanics/generalised Born surface area (MM/GBSA) method274 implemented in AMBER 14.259 
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Two hundred equally-spaced snapshot structures were extracted from the last 40 ns of each of 
the trajectories, and their molecular mechanical energies calculated with the sander module. The 
polar contribution to the solvation free energy was calculated by the pbsa program277 using the 
modified GB model described by Onufriev et al.275 while the nonpolar contribution was 
estimated from the solvent accessible surface area using the molsurf program280 with γ = 0.0072 
kcal Å-2 and β set to zero. Entropies were estimated by normal mode analysis281 using the 
nmode program. Due to its computational expense, only 50 equally-spaced snapshots from the 
last 40 ns of the trajectories were used for entropy calculations.  
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8.1. Biophysics experimental for CK2 fragments and peptides 
8.1.1. Protein expression and purification 
8.1.1.1. CK2α 
Three constructs of CK2α were used in this study. For kinase activity assays and competition 
experiments, CK2α_WT was used (residues 2-329). For ITC CK2α_KA construct was used whilst 
CK2α_FP10 was used for crystallisation purposes. CK2α_KA (residues 2-329) contained four 
mutations designed to aid crystallisation by reducing the overall charge of the protein; R21S, 
K74A, K75A and K76A. CK2α_FP 10 contained one mutation (R21S) and an N-terminal extension 
GSMDIEFDDDADDDGSGSGSGSGS aimed at mimicking a substrate peptide for CK2α. CK2α_FP10 
was cloned into pHAT4 vector and CK2α_KA was cloned into pHAT2 vector to give constructs 
with cleavable His6-tags. Recombinant plasmids containing one of the three constructs 
(CK2α_WT/ CK2α_KA/ CK2α_FP10) were introduced into Escherichia coli BL21(DE3) for protein 
production. Single colonies of the cells were grown in 6 x 1L of 2 x TY with 100 μg/mL ampicillin 
at 37°C. Isopropylthio-β-D-galactopyranoside (IPTG) was added to a final concentration of 0.4 
mM to induce expression when the optical density at 600 nm reached 0.6. The cells were 
incubated overnight at 25°C then harvested by centrifugation at 4,000 g for 20 minutes. The 
same extraction and purification procedure were used for all three constructs, with the 
exception that CK2α_KA used 350 mM NaCl in the buffer, whereas, CK2α_WT and CK2α_FP10 
required 500 mM NaCl. The cell pellets were suspended in 20 mM Tris, 350/500 mM NaCl, pH 
8.0) and lysed using a high-pressure homogeniser. Protease inhibitor cocktail tablets (one tablet 
per 50 mL extract; Roche Diagnostics) and DNase I were then added. The crude cell extract was 
then centrifuged at 10,000 g for 45 minutes, the supernatant was filtered with a 0.22 μm filter. 
The soluble supernatant was applied on a Ni Sepharose Fast Flow6 column at pH 8.0, washed 
and eluted in 20 mM Tris pH 8.0, 350/500 mM NaCl, 200 mM imidazole. After overnight dialysis 
into 20 mM Tris, pH 8.0, 350/500 mM NaCl the N-terminal His6-Tag was cleaved overnight by 
TEV protease and passed through a second metal affinity column to remove uncleaved protein 
and the protease. The cleaved protein was further purified on a Sepharose Q HP anion-exchange 
column and the main peak fraction from this column was further purified by gel filtration on a 
Superdex 75 16/60 HiPrep column equilibrated with Tris 20 mM, pH 8.0, 350/500 mM NaCl. 
Pure protein was concentrated to 15 mg/mL and flash frozen in liquid N2. 
8.1.1.2. CK2β 
pGEX-CK2β construct (1-198) obtained from Victor Bolanos-Garcia (Prof. Tom Blundell’s lab) was 
introduced into Escherichia coli BL21 (DE3) for protein production. Single colonies of the cells 
were grown in 6x1 L of 2 x TY with 100 μg/mL ampicillin at 37 °C. Isopropyl thio-β-D-
galactopyranoside (IPTG) was added to a final concentration of 0.4 mM to induce expression when 
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the optical density at 600 nm reached 0.6. The cells were incubated overnight at 25 °C then 
harvested by centrifugation at 4,000 g for 20 minutes. The cell pellets were suspended in 20 mM 
Tris, 500 mM NaCl, pH 8.5) and lysed using a high-pressure homogeniser. 
Protease inhibitor cocktail tablets (one tablet per 50 mL extract; Roche Diagnostics) and DNase I 
were then added. The crude cell extract was then centrifuged at 10,000 g for 45 minutes, the 
supernatant was filtered with a 0.22 μm filter. The soluble supernatant was applied on a 
Glutathione Sepharose column and washed with 5 column volumes of loading buffer (20 mM Tris, 
500 mM NaCl, pH 8.5) followed by washing with 10 column volumes of cleavage buffer (20 mM 
Tris 500 mM NaCl, 1mM DTT, 1mM EDTA, pH 8.5). 100µL of the precision protease was loaded 
onto the column and incubated for 5 hours at 4°C and eluted in the cleavage buffer. The cleaved 
protein was further purified on a Sepharose Q HP anion-exchange column (gradient 0-500 mM 
NaCl) and the main peak fraction from this column was further purified by gel filtration on a 
Superdex 75 16/60 HiPrep column equilibrated with Tris 20 mM, pH 8.5, 500 mM NaCl. Pure 
protein was concentrated to 15 mg/mL and flash frozen in liquid N2. 
8.1.2. Fluorescent Polarisation 
Approximate % inhibition of the holoenzyme assembly was determined using a PHERAstar FS 
plate reader (BMG labtech). The fluorescein probe was measured using 485 nm excitation and 
530 nm emission. The fluorescein probe was covalently linked to the N-terminal of the linear 
CK2β-based peptide RLYGFKIHPMAYQLQ (CK2β_pep). Inhibition was measured using 15 µM 
and 0 µM of the test compounds at a constant concentration of 3% DMSO. The experiments were 
performed in a 384 well plate with final concentrations of 450 nM CK2α_KA, 7.4 nM CK2β_pep, 
350 mM NaCl, 20 mM MES pH 6.5. The plates were read after a 30 min incubation period. The 
experiment was ran in triplicates. 
8.1.3. Isothermal Calorimetry Titration 
Direct binding assay 
All ITC experiments were performed at 25 °C using a MicroCal ITC-200 (GE Healthcare). 
CK2α_KA (20 mg/mL, 20 mM tris pH 8.0, 500 mM NaCl) was diluted in Tris buffer (200 mM, NaCl 
300 mM, 10% DMSO) and concentrated to 20-50 μM. Compounds in 100× stock solutions were 
diluted into the same buffer. In a typical experiment CK2α (25 μM) was loaded into the sample 
cell and 19 injections (2 μL each) with a 2 second duration were performed at 150 second 
intervals. The syringe was loaded with 200-250 μM peptides or with 0.4-2 mM fragments and 
rotated at 750 rpm. Control titrations were performed, and the data fitting was performed with 
a single site binding model using Origin software. 
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Competition assay 
Experiments were performed at 25 °C using a MicroCal ITC-200 (GE Healthcare). CK2α (0.2 
mg/mL, 20 mM Tris pH 8.0, 500 mM NaCl) was diluted in Tris buffer (200 mM, NaCl 300 mM, 
10% DMSO) and concentrated to 4-6 μM. CK2β (9.3 mg/mL, 20 mM Tris pH 8.5, 500 mM NaCl) 
was diluted in Tris buffer (200 mM, NaCl, 300 mM, 10% DMSO) and concentrated to 40 μM. In a 
typical experiment, CK2α was loaded into the sample cell and 19 injections (2 μL each) with a 2 
second duration were performed at 150 second intervals. The syringe was loaded with CK2β and 
rotated at 750 rpm. The same experiment was repeated in the presence of the peptides: 
compounds in 10 mM DMSO stock solutions were diluted to 1 mM and added to the solutions of 
CK2α and CK2β (prepared as described above) to a final concentration of 100 μM. Control 
titrations were performed, and the data fitting was performed with a single site binding model 
using Origin software. 
8.1.4.  Kinase assay 
The kinase assays were performed using the ADP-Glo™ kinase assay kit (Promega). 50 nM 
CK2α_WT was incubated in the kinase reaction buffer (40 mM Tris pH 7.5, 200 mM NaCl, 20 mM 
MgCl2, 0.1 mg/mL BSA, 25 μM ATP, 50 μM substrate peptide (RRRADDSDDDD, Enzo Life Sciences 
Inc. or eIF2β peptide, MSGDEMIFDPTMSKKKKKKKKP), 5% (v/v) DMSO) in the presence of 
different concentrations of the inhibitor at 25 °C for 120 min. In the kinase assay using eIF2β 
substrate 50 nM CK2β_WT was added to the reaction mixture. 5 μL aliquots of the kinase 
reaction were quenched with 5 μL of ADP-glo™ solution. After 45 min 10 μL of the kinase 
detection reagent was added and maintained at 25 °C for 20 minutes. The luminescence was 
recorded using a PHERAstar FS plate reader (BMG LABTECH) with an integration time of 1 s. 
Percentage inhibition was calculated relative to a DMSO control and a baseline measurement 
without substrate. All measurements were performed in duplicates. The IC50 curves were fitted 
using GraphPad Prism software.  
8.1.5.  X-ray crystallography 
X-ray crystallography was performed by Dr Paul Brear, Department of Biochemistry, University 
of Cambridge.  
For fragment crystallisation the following conditions were used: CK2α_KA at 5 mg/mL in 20 mM 
Tris, pH 8.0, 350 mM NaCl, 1 mM DTT, and 25 mM ATP was crystallised with 112.5 mM MES pH 
6.5, 35% glycerol ethoxylate and 180 mM ammonium acetate in a 1:1 ratio with a total volume of 
2 μL by the hanging drop vapour-diffusion method. The fragments were soaked as singletons at 
2-100 mM into these crystals for 15–20 h in 107 mM MES pH 6.5, 35% glycerol ethoxylate and 
1.04 M ammonium acetate after which the crystals were cryo-cooled in liquid nitrogen for data 
collection. CK2α_FP10 at 10 mg/mL in 20 mM Tris, pH 8.0, 500 mM NaCl, 4 mM DTT, 13 mM 
 Chapter 8: Biophysics Experimental   
184 
ATP, 2 mM phytic acid was crystallised with 107 mM MES, pH 6.5, 29% glycerol ethoxylate, 1.04 
M ammonium acetate in a 1:1 ratio with a total volume of 2 μL by the hanging drop vapour-
diffusion method. The fragments were soaked into the crystals of CK2α_FP10 for 15–20 h at 100 
mM in 107 mM MES pH 6.5, 29% glycerol ethoxylate and 1.04 M ammonium acetate.  
Co-crystals of CK2α and P1-C5 were generated by screening CK2α_FP10 at 10 mg/mL in 20 mM 
Tris, pH 8.0, 500 mM NaCl and 500 μM peptide with the JCSG+ screen (molecular dimensions). 
Drops were set up at 0.2 μL protein solution 0.2 μL screen using the sitting drop vapour-
diffusion method. Crystals were observed in a number of conditions in the JCSG+ screen. The 
condition that yielded the crystals from which the final data set was collected grew in 0.1 M 
Hepes pH 7.5, 10%(w/v) PEG 8K, 8% v/v Ethylene glycol. The crystals were cryo-cooled in 
liquid nitrogen in the same solution for data collection.  
Crystals of P2’-C5 and P7-C5 were generated using matrix seeding from the co-crystals grown of 
P1-C5. Seeds of CK2α were generated using Micro seed beads (Molecular Dimensions). Co-
crystals of CK2α and P2’-C5 or P7-C5 were generated by screening CK2α_FP10 at 10 mg/mL in 
20 mM Tris, pH 8.0, 500 mM NaCl and 500 μM peptide with the JCSG+ screen (Molecular 
Dimensions) and the seed stocks obtained from P1-C5. Drops were set up at 0.2 μL protein 
solution + 0.2 μL screen +0.01 μL seed stock using the sitting drop vapour-diffusion method. 
Crystals were observed in a number of conditions in the JCSG+ screen. The condition that yielded 
the crystals from which the final data set was collected grew in 0.16 M calcium acetate, 0.08 M 
sodium cacodylate, 14.4% PEG 8K, 20% glycerol.  
The crystals were cryo-cooled in liquid nitrogen in the same solution for data collection. The 
crystals were cryo-cooled in liquid nitrogen in the same solution for data collection.  
X-ray diffraction data was collected at the Diamond synchrotron radiation source, then 
processed using the pipedream package by Global Phasing Ltd; structures were solved by using 
programs from the CCP4 package. Models were iteratively refined and rebuilt by using 
AutoBuster and Coot programs. Ligand coordinates and restraints were generated from their 
SMILES strings using the Grade software package. 
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8.2. Biophysics experimental for BH3 peptides 
8.2.1.  Protein expression and purification of Bcl-xL 
Bcl-xL protein was expressed and purified by Jha Rupam at AstraZeneca. The His6-TEV-Bcl-xL 
construct was expressed in Escherichia coli (BL21 Gold DE3) by induction with 0.2 mM IPTG for 
16 h at 18 °C and purified by affinity purification followed by gel filtration. The pellets from 3 L 
culture were thawed and resuspended in lysis buffer (50 mM Hepes, pH 8.0, 500 mM NaCl, 20 
mM imidazole, 5% glycerol, 1 mM TCEP) supplemented with protease inhibitors 
(Complete‐EDTA Free, Roche Applied Science), Benzonase, and 2.5 mg/mL lysozyme. The lysate 
was clarified by centrifugation (15000 rpm, 60 min, 4 °C) and incubated with 8 mL of Talon 
Supeflow resin (Clontech) for 1 hour whilst rotating. The lysate was then passed through an 
Econocolumn (BioRad) and washed with 200 mL of lysis buffer. The protein was eluted by 
elution buffer (50 mM Hepes pH 8, 500 mM NaCl, 250 mM imidazole, 1 mM TCEP, 5% glycerol), 
and dialysed overnight against 5 L of dialysis buffer (50 mM Hepes pH 8, 300 mM NaCl, 1 mM 
TCEP). The dialysed protein was concentrated to 4 mL volume using centrifugal 10K MWCO 
concentrator (Millipore). The concentrated protein was loaded on to HiLoad 16/60 Superdex 75 
PG (GE Healthcare) pre-equilibrated in the storage buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 1 
mM TCEP). The fractions containing Bcl-xL protein from this size exclusion chromatography step 
were analysed on SDS-PAGE, pooled, snap frozen, and stored at -80 °C. 
8.2.2.  Surface plasmon resonance (SPR)  
Biacore™ T200 (GE Healthcare) was used to conduct all experiments reported herein. Sensor 
surface preparation and all interaction analyses experiments were performed at 25 °C utilising a 
data collection rate of 10 Hz. Reagents were purchased from GE Healthcare. Running buffer 
containing 10 mM Hepes, pH 7.4, 150 mM sodium chloride, 1 mM DTT, 1% DMSO and 0.05% 
polysorbate 20 were utilised throughout surface preparation and all interaction analysis 
experiments. Histidine tagged Bcl-xL protein was diluted to 5 μg/mL and captured onto Sensor 
chip NTA via the following sequence of injections to achieve a target Bcl-xL surface density of 
700 R.U. (response units). The carboxymethyl dextran surface of Sensor chip NTA was activated 
by injection of an aqueous solution containing 50 mM N-hydroxysuccinimide (NHS) and 200 mM 
N-ethyl-N’-(dimethylaminopropyl) carbodiimide (EDC). 500 μM nickel sulfate (NiSO4) was 
subsequently injected for one minute and utilised to capture Bcl-xL from a 5 μg/mL solution 
injected for one minute. A further one-minute injection of 1 M ethanolamine, pH 8.5 was 
performed to deactivate any unreacted carboxymethylesters.282 The flow-rate for all injections 
during surface derivatisation was 10 µL/min. A blank flow-cell was similarly treated with the 
exception of injection of Bcl-xL and served as a reference surface in the direct binding interaction 
analyses. Interaction analyses were performed by first equilibrating each sample within a 7-
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point 2-fold peptide dilution series in the range 33.3 nM to 1.03 nM for 30 minutes during 
instrument start-up procedures. nM peptide concentrations were used to accommodate 
potential solubility issues for the panel screening assay. Running buffer samples (0 nM peptide) 
were injected following each cycle and later used to facilitate double-referencing procedures 
during data analysis. Each peptide sample was injected over each peptide surface 90 seconds at 
a flow-rate of 80 μL/min to monitor peptide association, and peptide dissociation was 
subsequently monitored for 300 seconds. Data analyses were carried out using Biacore™ T200 
evaluation software v2.0 to validate assay quality, perform double-referencing (blank buffer 
sample and reference surface data subtraction) and evaluate steady state affinity plots. Briefly, 
equilibrium R.U. levels (Req) were collected 5 seconds before the end of the sample injection. R.U. 
levels at this time-point were plotted versus sample concentration and the resultant binding 
isotherm fitted using the following steady state equation:  
Req = Conc*Rmax/(Conc+Kd) 
Req refers to the equilibrium binding response (R.U.), Rmax is the total surface binding capacity 
(R.U.) and Kd is the apparent equilibrium dissociation constant, a parameter subsequently 
utilised to provide a relative ranking for the peptides studied in the current panel. 
8.2.3.  Circular dichroism experiments  
CD spectra of selected peptides were recorded on on an Applied Photo-physics Chirascan 
circular dichroism spectro-polarimeter (P9-C5 and P10) or on an AVIV 410 circular dichroism 
spectro polarimeter using a 1 mm path length quartz cuvette. CD measurements were 
performed at 298 K over a range of 185-260 nm using a response time of 0.5 s, 1 nm pitch and 
0.5 nm bandwidth. The recorded spectra represent a smoothed average of three scans, zero-
corrected at 260 nm and normalised against the solvent used (Mean Residue Ellipticity θMRE is 
quoted in deg·cm2·dmol−1·residue-1 and defined as the ratio between the Molar Ellipticity and 
the number of residues in the peptide). Peptides were dissolved in a 1:1 mixture of MQ water 
and MeCN to a final concentration of 50-100 μM. 
Percentage helicity was calculated based on mean residue ellipticity at 222 nm compared to the 
theoretical maximum helicity:  
𝑚𝑎𝑥𝑖𝑚𝑢𝑚 𝑀𝑅𝐸222 = 40000 × [1−(2.5/𝑛)] 
where n is the number of amide bonds, as previously reported.290 
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9.1. Biology experimental for CK2 peptides 
9.1.1.    Serum stability test 
500 μL of PBS buffer supplemented with 20% (v/v) of human serum was allocated into an 
Eppendorf tube and temperature kept at 37 °C for 15 minutes before commencing the 
experiment. 5 µL of the peptide from 10 mM stock solution in DMSO was added. Caffeine was 
added as an internal standard (10 μL of a 15 mg/mL solution in MQ water). At specific intervals, 
50 µL of the reaction mixture was taken and quenched with 100 µL of a 1:1 mixture of 96% 
Ethanol:DMSO. The suspension was spun at 13400 g for 10 minutes. 100 μL of the supernatant 
was analysed using C-18 HPLC with an eluting gradient 5-95% MeCN (0.05% TFA) in water 
(0.05% TFA) over 15 minutes (90 μL injection volume). Percentage of intact starting peptide 
was monitored over 24 h (calculated as the ratio of the area of the peak corresponding to the 
intact peptide to the area of the peak of caffeine). The experiment was performed in duplicates. 
9.1.2.    Tissue culture 
All cell lines used were supplied by AstraZeneca cell bank as mycoplasma free. U2OS bone 
osteosarcoma and HCT116 colon carcinoma cells were maintained in RPMI-1640 (1x, Sigma 
Aldrich, R0883) supplemented with 2 mM L-glutamine (Gibco, 25030-149) and fetal bovine 
serum (FBS, Gibco Life Technologies, 10270-106) at a final concentration of 10%. All cells were 
grown at 37°C / 5% CO2 in a humidified environment and all the assays were performed using 
these culturing conditions.  
9.1.3. Proliferation assay 
HCT116 cells were seeded at 2000 cells per well into two flat-bottomed tissue 384-well plates 
(PerkinElmer CellCarrier Ultra™) in a volume of 40 μL of growth medium. After 24 hours, the 
peptides dissolved in DMSO (10 mM) were added to the cells (to final concentrations of 100, 75, 
50, 32, 25, 16, 10, 7.7, 5, 3.2, 0 μM) using HP Tecan dispenser and DMSO normalised to a final 
concentration of 1% (v/v). Cells were then incubated in the presence of the compounds for 4 
days and the rate of growth monitored with IncuCyte Zoom™ (plate day 4). To one plate (day 0), 
5 μL of Saponin (2.5% w/v in 5 mM EDTA in Tris buffer) and 10 μL of Sytox green™ reagent (2 
μM Tris buffer containing 5 mM EDTA) were added after dosing. The plate was left in the dark at 
rt for 4 hours before imaging with Thermo Scientific™ CellInsight™ CX5 High Content Screening 
(HCS) Platform using a 10X lent. The same procedure was repeated for plate day 4 after 4 days of 
incubation. 
Percentage of growth inhibition was calculated relative to DMSO controls, normalised against 
day 0 and GI50 values were calculated using Graphpad Prism. The results are the average of at 
least 4 independent repeats. 
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9.1.4.    Viability assay 
HCT116 cells were seeded at 5000 cells per well into a flat-bottomed tissue 384-well plate 
(PerkinElmer CellCarrier Ultra™) in a volume of 40 μL of growth medium. After 24 hours, the 
compounds (10 mM stock in DMSO) were added to the cells (to final concentrations of 100, 75, 
50, 32, 25, 16, 10, 7.7, 5, 3.2, 0 μM) using HP Tecan dispenser and DMSO normalised to a final 
concentration of 1% (v/v). After 4 hours, 20 μL of CytoTox-Glo™ Cytotoxicity Assay Reagent 
(Promega) were added to all well. After 15 minutes at room temperature, luminescence was 
read on a multimode plate reader (EnVision™, PerkinElmer). 40 µL of Lysis Reagent (prepared 
using 33 μL Digitonin in 5 mL of assay buffer) were added to all the wells, mixed, and incubated 
at room temperature for 15 minutes to cause lysis of all the cells. Luminescence of total dead 
cells was measured and used as normalisation. The results are the average of at least three 
independent repeats. 
9.1.5.    Co-localisation experiments 
Confocal imaging of fixed U2OS cells was conducted using a Yokogawa Cell Voyager CV8000™ 
confocal microscope with a 40X water immersion objective. Images were acquired with 
excitation at 488, 561 and 405 nm and emissions detected with a 525/50, 600/37, 445/460 nm 
BP filter for the green, red and blue channel respectively.  
The following primary antibodies were used: 
 
Antibody Supplier and catalogue number Working concentration 
EEA1 Abcam, ab2900 1:4000 
Rab7 Abcam, ab50533 1:4000 
LAMP1 Cell Signalling, 9091 1:4000 
TGN46 Abcam, ab50595 1:750 
ZFPL1 Sigma, HPA014909 1:500 
Calnexin Invitrogen, PA5-34665 1:750 
 
Secondary antibodies goat anti-rabbit IgG (H+L) AlexaFluor 568 and goat anti-mouse IgG (H+L) 
AlexaFluor 568 were used at a working concentration of 1:500. Hoechst nuclei stain was used to 
a working concentration of 1:5000. FITC-labelled peptides were used to 1.25 μM final 
concentration. 
U2OS cells were seeded at 2500 cell per well into a flat-bottomed tissue 384-well plate 
(PerkinElmer CellCarrier Ultra™) in a volume of 40 μL of growth medium and cultured for 24 h 
before commencing the experiment. After 24 hours, FITC-labelled compounds dissolved in 
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DMSO (1 mM) were added to the cells using HP Tecan™ dispenser and DMSO normalised to a 
final concentration of 0.3% (v/v). Cells were fixed after 360, 180, 120, 60, 30, 15, and 5-minute 
incubation using 40 μL of 8% PFA (final PFA concentration 4%). Cells were fixed for 15 minutes, 
washed with PBS (3x) and blocked with 3% BSA + 0.1 % Triton X-1000 for 5 minutes. The 
blocking solution was then removed and 40 μL of the primary antibodies in BSA added. The 
plate was stored in the dark, at 4 °C overnight. The primary antibodies were washed with PBS 
(3x) and 40 μL of the secondary antibodies and Hoechst nuclei stain in BSA added. The plate was 
kept at 4 °C for 1 hour, washed with PBS (3x) and imaged as described above. Images were 
analysed using Fiji (ImageJ) software. 
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9.2. Biology experimental for BH3 peptides 
Ethical approval was obtained from the Faculty Research Ethics Committee at Anglia Ruskin 
University, Cambridge, UK where the experiments were carried out. Unless otherwise stated, the 
experiments were performed on no fewer than three separate occasions using platelets from 
different donors. Data were analysed using AccuriC6 BD Software and GraphPad Prism.  
9.2.1.    Preparation of washed platelet suspension  
Human blood was collected from healthy volunteers, who had not taken medication for two 
weeks, following informed consent in accordance with the Declaration of Helsinki. Blood was 
collected into 11 mM sodium citrate and washed platelets were prepared as follows: Platelet-
rich plasma (PRP) was obtained by centrifugation (240 g, 15 min). Prostaglandin E1 (PGE1, 2 
µM) was added to prevent premature platelet activation, and the plasma was centrifuged at 640 
g for 15 min. Platelets were suspended in calcium free Tyrode‘s buffer (CFT buffer, containing: 
140 mM NaCl, 5 mM KCl, 10 mM Hepes, 5 mM Glucose, 0.42 mM NaH2PO4, 12 mM NaHCO3, 
titrated to pH 7.4 with NaOH) to a final concentration of 2x108 platelet/mL and rested at 37 °C 
for 1 hour prior to experimentation. 
9.2.2.    Flow cytometry 
Treated washed platelet suspensions (1x107/mL) were analysed by flow cytometry using a C6 
Accuri Flow Cytometer (Beckton Dickinson, UK), in the presence or absence of Annexin-V-PE 
(BD Biosciences, UK), anti-PAC-1 (BD Biosciences, UK), anti-CD62P (BD Pharmingen, UK), or 
anti-CD63 (BD Pharmingen, UK). Peptides were used to a final concentration of 10 µM (from 1 
mM DMSO stock solutions). At least 10,000 events were acquired per experiment. In all the 
experiments, the entire platelet population was primarily gated by FSC. Untreated platelets (no 
fluorescent markers, no compounds) were analysed by flow cytometer on the laser of interest 
and the measurement used as zero. The shift of the peak of treated platelets towards the right 
was normalised against untreated platelets (Figure 72). 
 
Figure 72 – Example of flow cytometry data normalisation. a) The fluorescence associated with untreated platelets is 
used to set the threshold for future measurements. b) After treatment, the platelet population that gives a shift towards 
the right of the threshold in the fluorescent signal is considered as positive platelets. 
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9.2.2.1. Peptide uptake experiments in a washed platelet suspension  
250 μL of washed platelet suspension was incubated with 2.5 μL of the fluorescently labelled 
peptide. The suspension was kept in the dark at 37 °C and measurements taken at the designed 
time points (1, 2, 3 hours). For real time measurements, the peptides were added to the 250 μL 
of washed platelet suspension after events had been recorded for 1 minute and then event were 
monitored for a further 4 minutes.  
9.2.2.2.      Peptide uptake experiments in platelet reach plasma (PRP)  
The PRP was rested for 30 minutes prior experimentation. 120 μL of PRP was added to 1.2 μL of 
the fluorescently labelled peptide (1 mM DMSO stock) and incubated in the dark at 37 °C for 1 h 
prior analysis by flow cytometry. 
9.2.2.3.      PS exposure and activation markers 
PS exposure was assessed after incubation of 50 µL of washed platelet suspensions at 37 °C in 
445 µL of Tyrode’s solution (pH 7.4) with the peptide (5 μL of 1 mM stock solution in DMSO). At 
the designed time point 25 µL of the suspension was added to 25 µL of Annexin V (10% Annexin 
V in Tyrode‘s solution) under the protection from direct light and analysed by flow cytometry. 
Platelet activation markers (PAC-1, CD62P and CD63 binding) were assessed after incubation of 
3 µL of washed platelet suspensions at 37 °C in 105 μL of CFT buffer (pH 7.4) with 1.2 µL of the 
desired antibody and 1.1 μL peptide (1 mM DMSO stock). The suspensions were analysed by 
flow cytometry. 
9.2.3. Light Transmission Aggregometry 
Platelet aggregation was monitored using an AggRam™ aggregometer (Helena Biosciences, UK). 
250 μL of washed platelet suspensions (1x108/mL) were stimulated with 10 μM peptide under 
stirring conditions at 37 °C for 15 minutes and the percentage aggregation was acquired from 
the aggregation traces using proprietary software (Helena Biosciences, UK).  
9.2.4.    Confocal microscopy of live platelets 
Peptides were used to a final concentration of 10 µM. Confocal imaging of live washed platelet 
suspensions (2x108/mL) were conducted using a Ziess 510 confocal microscope with a Plan-
APOCHROMAT 63x/1.4NA oil immersion objective, and a confocal aperture of 60 µm. Images of 
TAMRA-labelled model peptide stained platelets were acquired after 1-hour incubation using 
with excitation at 565 nm and emission was detected with a 560-615 nm BP filter. Images of 
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FITC-peptide stained platelets were acquired after 15-minute incubation38 using excitation at 
488 nm and emission was detected with a 505-550 nm BP filter. 
9.2.5.    Serum stability test 
One mL of RPMI-1640 media supplemented with 25% (v/v) of human serum was allocated into 
an Eppendorf tube and temperature kept at 37 °C for 15 minutes before commencing the 
experiment. 40 µL of 10 mM peptide in DMSO were added to make a final peptide concentration 
of 100 μg/mL. At specific intervals, 100 µL of the reaction mixture was taken and quenched with 
200 µL of a 1:1 mixture of 96% Ethanol:DMSO. The suspension was cooled to 4 °C for 15 minutes 
and then spun at 13400 g for 4 minutes.283 Caffeine (0.5 µL of 7 mg/mL solution in MQ water) 
was then added to 100 µL of the supernatant and used as a reference. The supernatant was 
analysed using C-18 HPLC with an eluting gradient 5-95% MeCN (0.05% TFA) in water (0.05% 
TFA) over 15 minutes. Percentage of intact starting peptide was monitored over time (calculated 
as the ratio of the area of the peak corresponding to the intact peptide to the area of the peak of 
caffeine). The results are the average of three independent repeats.
                                                          
38 Difference in incubation times are due to the fact that the model peptides do not activate platelets while the BH3 peptides do. 
Therefore, to avoid complication in the imaging due to platelet aggregation or activation images were acquired after 15 minutes 
incubation. 
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A.2. HPLC traces of selected compounds 
CK2 peptides 
Pc linear 
 
 
Pc cyclic 
 
 
  
Pc cyclic short 
 
 
P0-C1 
 
 
 
P1-C2 
 
 
 
P1-C3 
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P1-C4 
 
P1-C5 
 
P1-C6 
 
FITC-P1-C5 
 
P1-F1C5 
 
P1-F2C5 
 
P1-F3C5 
 
P2’-C5 
 
P2’’-C5 
 
P3-C5 
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P4-C5 
 
P5’-C5 
 
P5’’-C5 
 
P6-C5 
 
 
P7 
 
P7-C5 
 
P7-F1C5 
 
P7-F2C5 
 
P8-F1C5 
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BH3 peptides  
P9-C5 
 
P9-C7 
 
P9-F4C5 
 
P9-F5C5 
 
 
P10 
 
FITC-P10 
 
SAHBa 
 
FITC-SAHBa 
 
FITC-P9-F4C5 
 
FITC-P9-F5C5 
 
 
 
 
 
 
 
 269 
 
FITC-P9-C7 
 
P11-F4C5 
 
FITC-P11-F4C5 
 
P12 
 
P13 
 
P14-C8 
 
P15-C8 
 
P16-C8 
 
P17-C5 
 
P18-C5 
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P19-C5  
 
P17-F1C5 
 
P18-F1C5 
 
P19-F1C5 
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A.3. Structures of additional fragments docked 
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A.4. Selected ITC binding curves 
 
 
  
P1-C5  
Kd = 460 nM 
Pc 
Kd = 1 μM 
 
P1-C6  
Kd = 58 μM 
P2’-C5 
Kd = 2 μM 
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P3-C5 
Kd = 56 μM 
 
P2’’-C5 
P1-F1C5 
Kd = 800 nM 
 
P8-F1C5 
 274 
 
  
 
 
CK2β 
Kd = 9 nM 
 
CK2β with P1-C5 
CK2β with P7-C5 
 
P7 
Kd = 44 μM 
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Thermodynamic data 
Peptide KD μM ΔH cal/mol ΔS cal/mol/deg Stoichiometry 
Pc 1 -1.483E4 ± 487.7 -22.7 1.15 ± 0.0256 
P1-C5 0.46 -1.305E4 ± 155.5 -14.8 1.04 ± 0.00824 
P1-C6 58 -1.452E4 ± 2.06 E4 -29.3 1.45 ± 1.25 
P2’-C5 2 -2.035E4 ± 818.0 -42.3 0.807 ± 0.0239 
P3-C5 56 -2.244E4 ± 5273 -55.8 1.00 ± 0 
P1-F1C5 0.8 -1.373E4 ± 94.70 -18.6 1.10 ± 0.00559 
CK2β 0.01 -1.231E4 ± 301.7 -4.23 1.68 ± 0.0212 
P7-C5 0.15 -1.992E4 ± 125.6 -35.7 0.989 ± 0.00421 
P7 44 -4.372E4 ± 4711 -126 1.00 ± 0 
P7-F1C5 0.34 -2.712E4 ± 826.6 -61.4 0.864 ± 0.0188 
 
 
 
P7-F1C5  
Kd = 170 nM 
 
P7-C5 
Kd = 150 nM 
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A.5. Unsuccessful crystallisation attempts of CK2 peptides and CK2α 
Crystallisation 
technique 
Protein construct Conditions Results 
Soaking WT, K74A 
No ATP 
10 µM peptide 
Conditions from 
Brear et al.198 
Crystals of the 
protein 
Soaking WT, K74A 
No ATP 
100 µM peptide 
Conditions from 
Brear et al.198 
Crystals of the 
protein 
Soaking WT, K74A 
No ATP 
1 mM peptides 
Conditions from 
Brear et al.198 
Crystals of the 
protein 
Co-
crystallisation 
WT, K74A 
Conditions from 
Raaf et al.215  
No crystals 
Co-
crystallisation 
WT, K74A 
No ATP 
JCSG+™ screen  
100 µM peptide 
No crystals 
Co-
crystallisation 
WT, K74A 
ATP 
JCSG+™ screen 
10 to 100 µM 
peptide 
No crystals 
Co-
crystallisation 
K74A 
No ATP 
JCSG+™ screen 
10 to 100 µM 
peptide 
No crystals 
Co-
crystallisation 
FP_10, K74A, WT 
ATP 
JCSG+™ screen 
50 µM peptide 
No crystals 
Co-
crystallisation 
FP_10,K74A, WT 
ATP 
Proplex™ screen 
1 mM peptide 
No crystals 
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